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Diagnosis and treatment of melanoma patients 
with lymph node metastases 
1. Accurate stadiering van patienten met een klinisch stadium IIIB melanoom is van 
belang om die patienten te identificeren die voor in opzet curatieve chirurgische 
behandeling in aanmerking komen. 
2. 18F-FDG-PET(/CT) is de onderzoeksmodaliteit om hoogrisico melanoom patienten 
te screenen op metastasen door de combinatie van hoge FDG opname in de 
melanoom metastase en het onvoorspelbare patroon van metastasering (dit 
proefschrift). 
3. Wanneer 18F-FDG-PET-CT niet beschikbaar is voor het stadieren van een klinisch 
stadium I11B melanoom patient is een CT scan een goed alternatief (dit proefschrift). 
4. De klinische bruikbaarheid van de Standardized Uptake Value bij 18F-FDG­
PET blijft een probleem zolang de standaardisatie regels voor PET niet volledig 
geimplementeerd zijn (dit proefschrift). 
5. De belasting die wordt ervaren door de patienten tijdens 18F-FDG-PET en CT scans 
is gering. (dit proefschrift). 
6. Het toevoegen van 18F-FDG-PET-CT aan het diagnostische traject van melanoom 
patienten stadium IIIB is mogelijk met minder dan 15% verhoging van de kosten 
voor dit deel van de diagnose-behandel combinatie (dit proefschrift). 
7. De huidige ontwikkelingen in de behandeling van melanoom metastasen zal de 
impact van de diagnostische modaliteiten vergroten. 
8. De incidentie van het melanoom bij ouderen neemt sneller toe dan bij jongeren 
terwijl de prognose achter blijft. 
9. De excisie marge van melanomen is na zes gerandomiseerde onderzoeken en een 
Cochrane analyse nog steeds niet gedefinieerd en het wordt nu tijd voor een goed 
opgezette 'melanoma margin trial'. 
10. Het gedrag van het melanoom is onvoorstelbaar en onvoorspelbaar. 
11. Een gedachte kan niet ontwaken zonder anderen te wekken (M. von Ebner­
Eschenbach) 
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General introduction and 
outline of the thesis 

MELANOMA 
The incidence of melanoma has increased dramatically in Caucasian populations in all 
parts of the world. It is one of the tumours with the most rapidly increasing incidence 
among all malignancies. Since the mid 1960s, melanoma incidence has risen by 3-8% 
in most people of European background, with the greatest increase in elderly men. 1 In 
the European Community the incidence is 17,000/year and annually 5,000 patients die 
of melanoma.2 For the Netherlands, the incidence for invasive and in situ melanoma has 
increased from 9.3/100 000 in 1990 to 28.1/100 000 in 2008 for males (crude incidence) 
and from 15. 3/100 000 in 1990 to 35.2/100 000 in 2008 for females. 3 Predictions of 
melanoma incidence show a doubling in the total number of melanoma patients by 
the year 2015 in the Netherlands, with the largest increase in males.4 There is strong 
evidence that increased exposure to the ultraviolet solar radiation is the main cause of the 
rising incidence, with severe sunburn in early life correlating best with melanoma risk_5-7 
Consequently, efforts to reduce the incidence of melanoma have focused on identifying 
and screening people at high risk and on promoting sun protection.8 The 10-year survival 
rates for stage I are 79%-88%, for stage II 32%-64%, for stage Ill 15%-63% and for 
stage IV 3%-16% depending on the number and site of distant metastases (Table 1&2).9 
The 5-year survival has steadily improved over the recent decades but melanoma causes 
disproportionate mortality in those of young and middle age, such that an average of 
18.6 years of potential life are lost for each melanoma death in the USA, one of the 
highest rates for adult-onset cancer.10 
Wide local excision with proper resection margins according to the thickness of the lesion 
remains the treatment for localized melanoma.13 Sentinel Lymph Node Biopsy (SLNB) is 
the most optimal staging procedure for stage I and II melanoma and is indicated for 
patients with melanoma thicker than 1 mm.14 The additional benefit of completion lymph 
node dissection (CLND) and the survival benefits of the SLNB are still under study.15· 16 
However, the 4th interim analysis of the Multicenter Selective Lymphadenectomy Trial 
(MSLT-1) showed an improved disease specific survival of the procedure for extremity 
melanomas with a Breslow thickness of 1.2-3.5 mm.17 
Probably as result of increased awareness melanoma is diagnosed at an earlier stage of 
disease. Nevertheless, a proportion of the patients present or recur with lymph node 
or distant metastases. Patients with lymph node metastases (stage 111), synchronous or 
metachronous, are candidates for a so called therapeutic lymph node dissection if no 
distant metastases are present (Figure 1). A randomised clinical trial showed that adjuvant 
radiotherapy improved regional control in melanoma patients at high risk of regional 
relapse after lymphadenectomy without affecting survival.18 For patients with distant 
metastases (stage IV) no trials of any specific single or combination cytostatic agents or 
vaccination have shown a convincing survival benefit, although promising results have 
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No distant metastasis 
Distant skin, subcutaneous or nodal 
metastases 
Lung metastasis 
All other visceral metastasis 
Any distant metastasis 
Ulceration status/ mitoses 
T1 a: without ulceration and mitoses < 1/mm2 
T1 b: with ulceration and mitoses 2'.: 1/mm2 
T2a: without ulceration 
T2b: with ulceration 
T3a: without ulceration 
T3b: with ulceration 
T4a: without ulceration 
T4b: with ulceration 
Nodal metastatic burden 
N 1 a: micrometastasis* 
N 1 b: macrometastasis* * 
N2a: micrometastasis* 
N2b: macrometastasis** 
N2c: In-transit metastases/satellites without 
metastatic nodes. 
4+ metastatic nodes, or matted nodes, or in­







LDH=Lactate dehydrogenase. *Micrometastases are diagnosed with sentinel lymph node biopsy. 
**Macrometastases are defined as clinically detectable nodal metastases (pathologically confirmed). 
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Figure 1: Draining lymph node fields (Source: Dutch Cancer Society) 
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Table 2: Anatomic stage groupings for melanoma (AJCC 2009) 12 
Clinical staging 
0 Tis NO MO 0 
IA T1a NO MO IA 
1B T1b NO MO 1B 
T2a NO MO 
IIA T2b NO MO IIA 
T3a NO MO 
118 T3b NO MO 118 
T4a NO MO 
IIC T4b NO MO IIC 
Ill AnyT N1-3 MO IIIA 
1118 
IIIC 
IV AnyT Any N M1 IV 
Pathological staging 
Tis NO MO 
T1a NO MO 
T1b NO MO 
T2a NO MO 
T2b NO MO 
T3a NO MO 
T3b NO MO 
T4a NO MO 
T4b NO MO 
T1-4a N1a MO 
T1-4a N2a MO 
T1-4b N1a MO 
T1-4b N2a MO 
T1-4a N1b MO 
T1-4a N2b MO 
T1-4a/b N2c MO 
T 1-4b N1b MO 
T 1-4b N2b MO 
AnyT N3 MO 
AnyT Any N M1 
shown a survival benefit with BRAF inhibitors.19 Besides, surgical resection, which can be 
performed if there are only a few resectable distant metastases, seems to have a survival 
benefit. One of the studies achieved a 5-years survival of 40% by metastasectomy. 20 
This was also documented in the Canvaxin trial as presented by Morton et al at the 550 
meeting 2011 in San Antonio. 
The detection of distant metastases in clinically stage Ill melanoma patients is important 
for several reasons: 
- Firstly, to identify those patients who may benefit from a surgical procedure, while 
avoiding these potentially harmful surgical procedures that does not improve survival 
for patients with multiple distant metastases. 
- Secondly, accurate staging is important to improve the efficiency of clinical trials, for 
example patients with a limited number of distant metastases. 
- Thirdly, to provide patients with detailed information about their prognosis. 
IMAGING TECHNIQUES 
Few established guidelines for melanoma define the appropriate diagnostic tests for the 
initial evaluation and subsequent follow-up. Standard imaging techniques as chest X-ray, 
ultrasound, CT (chest or abdomen) and MRI (brain) can be used to evaluate the presence 
of distant metastases in melanoma patients. 
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Positron Emission Tomography 
Compared to most normal tissues, cancer cells have an increased glucose metabolism, 
which seems to correlate with the aggressiveness of tumour growth. Positron 
Emission Tomography (PET) with 18-F-Fluoro-DeoxyGlucose (18F-FDG) depicts this 
metabolic activity and has become an important modality in diagnosing and staging 
of (cancer) patients. 18-F-FDG is a radio-labelled glucose analogue (labelled with the 
positron emitter 18-F) that is taken up by cells through the glucose transporters. 21 It 
is subsequently phosphorylated intracellularly by hexokinase and trapped in the cells. 
18F-FDG distribution within the body is thus a measure of glucose metabolism, which 
is increased in malignant cells. Melanomas are typically FDG-avid and together with the 
erratic pattern of spread, high-risk patients are good candidates to screen with FDG-PET(/ 
CT) for distant metastases. 
The Standardized Uptake Value (SUV), which represents the accumulation of the used 
tracer in the tumor or metastases, is a useful index in different cancers and could be used 
to predict the prognosis. 22 •23 Several studies in different tumors (breast, head and neck, 
pancreatic cancer, lung cancer) have shown that a high 18F-FDG uptake was associated 
with a lower Disease Free Survival (DFS) or Overall Survival (OS). However, other studies 
reported no significant association with survival. 
SUMMARY 
Melanoma causes more than 75% of all deaths related to skin cancer, and its incidence 
dramatically increased in Caucasian populations and is predicted to increase in the 
coming years. Melanoma has the well-known feature to spread to unusual sites and 
multiple distant metastases are usually a contraindication for surgery. Consequently, 
accurate staging is extremely important for clinical decision making to identify those 
patients who may benefit from surgery while avoiding unnecessary, potentially harmful 
surgery that does not improve survival and finally to inform patients with respect to 
prognosis. Melanomas typically are quite FDG-avid and together with the erratic pattern 
of spread, the disease is candidate for screening distant metastases in high-risk patients 
with whole body FDG-PET. Studies suggest that FDG-PET may indeed be more accurate 
than standard staging procedures to detect melanoma metastases, particularly in patients 
with regional spread (American Joint Committee on Cancer (AJCC) stage Ill). 
OUTLINE OF THE THESIS 
The studies in this thesis discuss the value of FDG-PET and CT in the staging of melanoma 
patients and (the consequences for) treatment of clinically stage 111 patients. 
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Part I discusses all stages of melanoma and the use of FDG-PET in these patients. 
In chapter 2 the value of FDG-PET (and the new combined modality of FDG-PET and 
CT) in staging and follow-up of melanoma patients is described. The additional value of 
FDG-PET above the conventional staging modalities are explored as well as the limitations 
of FDG-PET. Chapter 3 describes a retrospective study of 257 melanoma patients and 
discusses how patients' treatment changed after evaluation with FDG-PET, and reports 
unexpected findings with FDG-PET. Chapter 4 covers the value of the standardized 
uptake value (SUV) measured in a retrospective design. As identification of additional 
prognostic factors may allow the development of individualized strategies, this study was 
undertaken to evaluate the potential role of the standard uptake value (SUV) in predicting 
disease-free and overall survival in melanoma patients with lymph node metastases. 
Part II consists of 4 chapters concerning the prospective OMSPECT study. In this 
prospective multicenter study we assessed the optimal staging of melanoma patients by 
a head-to-head comparison of FDG-PET and CT. In Chapter 5 the burden (embarrassment, 
anxiety and discomfort) of the diagnostic tests X-ray, CT and PET experienced by 
melanoma patients with lymph node metastases are described. Melanoma patients with 
lymph node metastases have to deal with diagnostic tests to exclude the presence of 
distant metastases; results of the tests could have major implications for their prognosis 
and treatment. There are, however, few studies concerning the patients' psychological 
issues and perception of diagnostic tests. Chapter 6 shows the main results from the 
OMSPECT study. The results of this prospective multicenter study in which a head-to­
head comparison of FDG-PET and CT in staging of melanoma patients with palpable 
lymph node metastases was performed is described in terms of diagnostic accuracy and 
impact on treatment. Chapter 7 concerns the value of SUV measured in the prospective 
OMSPECT study for patients of the UMCG to determine whether SUV is of prognostic 
value for the disease free survival or disease specific survival in melanoma patients with 
palpable lymph node metastases. Finally, in Chapter 8 costs for the FDG-PET and CT 
given certain scenarios are calculated. Besides, a proposal for a guideline in the use of 
FDG-PET for melanoma patients is presented. 
Part Ill focuses on the treatment of melanoma patients with lymph node metastases. 
Adjuvant radiation treatment following lymph node dissection in the melanoma patient 
has been suggested and investigated in an attempt to gain regional control and improve 
survival. Chapter 9 is a review that discusses treatment, loco-regional control, disease­
free and survival rates and complications after lymph node dissection. 
At the end of the thesis new research developments in the field of melanoma are 
discussed and a summary in English and Dutch of the work is presented. 
13 
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Chapter 
FDG-PET in melanoma patients 
E. Bastiaannet1 , H.J. Hoekstra1 , O.S. Hoekstra2 
1 University Medical Centre Groningen, 2VU University Medical Centre 
Amsterdam The Netherlands. 
A Textbook for Clinicians and Imaging Physicians, Methods in Molecular Biology 
ABSTRACT 
This chapter discusses the value of FDG-PET and combined FDG-PET/CT in staging and 
follow-up of melanoma patients. For melanoma patients, the presence or absence of 
regional lymph node metastases is one of the most important prognostic factors; the 
recent development of SLNB offers a highly sensitive staging method. FDG-PET has 
shown a limited sensitivity to detect microscopic lymph node metastases in this selected 
group of patients with stage I and II melanoma. However, for the detection of distant 
metastases, FDG-PET is frequently used. Although there is no consensus, some surgeons 
pursue surgical excision of metastatic disease if only one or a few sites of disease are 
apparent. Precise identification of the location and number of metastatic lesions could 
therefore be important for surgical planning. Even though patients with metastatic 
melanoma generally have a poor prognosis (5-years survival 3-16%) there is still a need 
for accurate staging. Firstly, to identify those patients who may benefit from a surgical 
procedure, while avoiding these potentially harmful surgical procedures for patients 
with multiple distant metastases. Secondly, accurate staging is important to improve the 
efficiency of clinical trials and thirdly, to provide patients with detailed information about 
their prognosis. Taken the published literature together and reasoning that FDG-PET/CT 
is the current standard in PET imaging, there may be a case for the combined PET/CT in 
the setting of metastatic melanoma. However, further research is needed as the benefit 
of the combined FDG-PET/CT versus FDG-PET alone seems to be less than reported for 
other tumor entities, which may be due to the high avidity of melanoma for FDG, so 
that many of the metastases are detected with FDG-PET and the additional CT does not 
increase the sensitivity. 
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INTRODUCTI ON 
The incidence of melanoma, which causes a large proportion of all deaths related to skin 
cancer, has increased dramatically in Caucasian populations in all parts of the world. It 
is one of the tumors with the most rapidly increasing incidence among all malignancies. 
Particularly among whites in areas of high sun exposure, the incidence has steadily 
increased in the last decades.1 For the USA, it is estimated that one in 82 women and 
one in 58 men will develop melanoma during their lifetime. 2 This accounts for more 
than 55,000 new cases per year and approximately 7600 deaths; it is also the most 
common cancer among women 20 to 29 years of age.2-4 In the European Community 
the incidence is 17,000 / yr and annually 5000 patients die of melanoma.5 Predictions of 
melanoma incidence show an increase of 99% in the total number of melanoma patients 
by the year 2015 in the Netherlands, with the largest increase for males. 6 Word-wide, the 
incidence of melanoma is highest in Australia and New-Zealand. There is strong evidence 
that increased exposure to the ultraviolet solar radiation is the main cause of the rising 
incidence, with severe sunburn in early life correlating best with melanoma risk_7-9 The 
ultraviolet radiation promotes malignant change in the skin by 1) direct mutagenic effects 
on DNA, 2) promoting reactive oxygen species of melanin that cause the DNA damage 
and suppress apoptosis, 3) reducing the cutaneous immune defense and 4) stimulating 
the cellular constituents of the skin to produce growth factors.7• 1 0  Other risk factors for 
the development of melanoma include familial melanoma (HR 3-70), multiple atypical 
naevi (HR 11), freckling (HR 2.5), skin type I (HR 1.7), and history of severe sunburn 
(HR 2.5).7 Consequently, efforts to reduce the incidence of melanoma have focused on 
identifying and screening people at high risk and on promoting sun protection.1 1  
The most important factor for successful management of melanoma is early diagnosis, 
allowing treatment to be undertaken at a stage when cure is still achievable.7 Wide local 
excision with proper resection margins according to the thickness of the lesion remains 
the treatment for localized melanoma (stage I and I I ). Sentinel Lymph Node Biopsy 
(SLNB), as a staging procedure, can be considered for patients with melanoma thicker 
than 1 mm. 1 1  The additional benefit of complete lymph node dissection (CLND) and the 
survival benefits of the SLNB are still under study, although an interim analysis did show 
a survival benefit. 1 2 • 1 3  Patients with lymph node metastases (stage 111), synchronous or 
metachronous, are candidates for a lymph node dissection if no distant metastases are 
present. For patients with distant metastases (stage IV) no trials of any specific drug 
or a combination of drugs have shown a convincing survival benefit.1 1 •14 However, 
surgical resection, which can be performed if there are only a few resectable distant 
metastases, seems to have a survival benefit: a 5-years survival of 40% can be achieved 
by metastasectomy. 1 5  Probably as result of increased awareness, melanoma is diagnosed 
at an earlier stage of disease. Nevertheless, some patients still present or recur with lymph 
node or distant metastases. The 10-year survival rates for stage I are 79%-88%, for stage 
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II 32%-64%, for stage I ll 1 5%-63% and for stage IV 3%-16% depending on the number 
and site of distant metastases.1 Prognostic factors for recurrence and survival are Breslow 
thickness of the primary melanoma, ulceration, mitotic index, gender, localization and 
nodal status. 1 6• 1 7  Besides, in patients with lymph node metastases, the number and size 
of metastatic nodes and extranodal growth are of prognostic importance.1 6•1 8•1 9  
Melanomas are typically FDG-avid; and together with the erratic pattern of spread, 
high risk patients are good candidates to screen with FDG-PET(/CT) for distant 
metastases. Several studies have suggested that FDG-PET is more sensitive and specific 
for the detection of melanoma metastases than conventional diagnostic tests. 20-22 Even 
though whole-body PET does not provide the same anatomical detail as CT or MRI ,  it 
can easily cover the entire body and target-background contrasts are usually high, to 
allow for relatively easy identification of suspected sites. Furthermore, semi-quantitative 
measurement of glucose metabolism (by calculating standard uptake values) might have 
prognostic relevance to predict disease specific survival .  23 Disadvantages of PET include 
its limited ability to detect brain metastases and lesions �5 mm, its limited availability and 
high cost compared to CT . 24-27 
This chapter will discuss the value of FDG-PET and combined FDG-PET/CT in staging and 
follow-up of melanoma patients. The additional value of FDG-PET above the conventional 
staging modalities will be discussed as well as the limitations of FDG-PET. Finally, we will 
propose a guideline for the use of FDG-PET in clinical practice for melanoma patients. 
FDG-PET acqu is it ion and criter i a 
The typical scan trajectory for most oncology FDG-PET or PET/CT studies comprises 
skull base to mid femur. Since melanoma may metastasize to virtually any organ, it is 
one of the indications to perform a true whole-body FDG-PET scan (scan from the skull 
vertex to the feet). However, this requires extending the scan by an additional six to 
seven bed positions at 3-5 minutes per position, nearly doubling the emission scanning 
time (although nowadays 1-2 minutes per position with a higher dose of FOG is also 
performed). 28 With the use of PET/CT the additional radiation exposure by the CT scan 
is not negligible, particularly in patients for whom the scan is performed for surveillance 
purposes. 28 Niederkohr et al assessed the addition benefit of scanning the lower 
extremities and skull in PET/CT evaluation of metastatic melanoma in 173 patients. 28 
Unanticipated metastatic melanoma in the lower extremities outside the routine imaging 
field of view were identified in 8 scans (2.7% of all scans) and two scans (0.7% of all 
scans) identified unanticipated metastatic lesions in the brain or scalp on PET/CT. 28 The 
authors suggest that three categories of patients should have a true whole body scan: 
1) primary melanoma in the head or neck region or at the lower extremities; 2) known 
or suspected metastases in the head or neck region, or lower extremities and 3) clinical 
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suspicion of aggressive or widespread disease. 28 In another study of 153 patients with 
suspected or recurrent melanoma29 , the authors recommend a true whole-body scan for 
patients with previous melanoma manifestations to the legs. 
Definitions of PET positivity are variable in the literature and often, criteria are not 
specified. In the studies where PET positivity criteria are mentioned different criteria 
prevail, usually a definition where PET positivity is 'any tracer uptake exceeding normal 
uptake'. Standardization of these criteria, and extending them with criteria of combined 
PET and CT interpretations would facilitate meta-analysis, and this should be part of 
further research. 
FDG-PET in the stag ing of melanoma 
A retrospective review of 257 melanoma patients in three university centers in the 
Netherlands showed that most scans were requested for staging, and mainly to detect 
distant metastases in stage 111 patients. 30 At initial presentation, most patients with 
melanoma have disease confined to the skin, and extensive staging procedures are 
inappropriate because of the extremely low detection rate of distant metastases.31 As 
is the case with all diagnostic tests, high rates of false positivity are to be expected in 
settings with low prevalence. 
FDG- PET to detect reg ional lymph node 
metastases 
The presence or absence of regional lymph node metastases is an important prognostic 
factor for patients with melanoma and the recent development of SLNB offers a 
highly sensitive staging method. FDG-PET has shown a limited sensitivity to detect 
microscopic lymph node metastases in this selected group of patients with stage I and 
I I  melanoma. 32-37 The average sensitivity of FDG-PET for subclinical nodal disease in 
stage I and 11 melanoma was 14%-17%, whereas sentinel node biopsy reached 86%-94% 
sensitivity. 34 ,3 5 , 37 Recent studies in 2006 and 2007 confirmed that PET has no place 
in the initial work-up of patients without any clinical evidence of regional lymph node 
metastases.3 8• 39 The low yield in nodal staging is readily explained since sizes of tumor 
deposits within non-enlarged, i.e. clinically normal lymph nodes are too small to be 
identified with FDG-PET (30 mm). 3 6· 37 Therefore, sentinel lymph node biopsy remains 
the technique of choice for initial nodal staging in patients without clinically apparent 
lymph node metastases. Not surprisingly, the accuracy of FDG-PET to detect lymph 
node metastases is higher in patients with clinically suspicious or palpable lymph nodes: 
Blessing et al reported a sensitivity of 74% at a specificity of 93% in such patients40 . 
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However, the clinical relevance of these findings in lymph node stations is limited since 
biopsies usually are quite effective to solve the clinical problem.41 
Crippa et aI42 studied the relation between size and sensitivity: sensitivity was only 23% 
for lymph nodes less than 5 mm, but increased to 83% and 100% for lymph nodes with 
a size of 6-10 mm and greater than 10 mm, respectively. Even though performance of 
PET is partly related to scanner performance and image reconstruction algorithms, these 
clinical data are in line with the predictions based upon histomorphometric analysis and 
in vitro PET data as shown by Mijnhout et al.43 
FOG-PET to detect distant metastases 
Although there is no consensus, some surgeons pursue surgical excision of metastatic 
disease if only one or a few sites of disease are apparent.15· 22 Precise identification of 
the location and number of metastatic lesions could therefore be important for surgical 
planning. As mentioned before, the 'not guideline-driven' clinical indication for FOG-PET 
is to detect distant metastases in high risk melanoma patients. There is an apparent 
paradox that even though patients with metastatic melanoma generally have a poor 
prognosis (5-years survival 3-16%), there still is a need for accurate staging. Firstly, to 
identify those patients who may benefit from a surgical procedure, while avoiding these 
potential ly harmful surgical procedures for patients with multiple distant metastases.41 
Patients with lymph node metastases (without distant metastases) can benefit from 
a lymph node dissection, while patients in whom distant metastases are found could 
benefit from other individualized treatment including surgery, immunotherapy and 
chemotherapy. Secondly, accurate staging is important to improve the efficiency of 
clinical trials, for example patients with a limited number of distant metastases. Thirdly, 
to provide patients with detailed information about their prognosis.41 
Several studies found FOG-PET to be highly sensitive to detect distant metastases. In 
a systematic review and meta-analysis of all literature before July 1999, Mijnhout and 
co-authors found a pooled sensitivity of 79% (95%CI 66%-93%) and a specificity of 
86% (95%CI 78%-95%) for the detection of melanoma metastases (lymph nodes and 
distant) in all stages of disease.33 Schwimmer et al found a range of overall sensitivity 
and specificity of 92% (95%CI 88.4-95.8) and 90% (95%CI 83. 3-96.1), respectively, for 
the detection of recurrent melanoma reported in literature from 1980-1999.44 Finally, 
the review of Prichard (literature between 1980-2000) found ranges of sensitivity from 
74%-100% and specificity from 67%-100% in the detection of distant metastases.45 
However, one of the problems in determining accuracy is the definition of the reference 
test: e.g. the appropriate time of follow-up in the case of a negative scan and the 
gold standard to confirm metastases if pathological confirmation is not possible. 
Two studies assessed the accuracy of FOG-PET to detect distant metastases in exclusively 
stage Ill patients, where FOG-PET seems to have the most value. The largest study of 251 
patients with palpable lymph node metastases found that 27.1 % of the patients were 
upstaged to stage IV as result of the FOG-PET scan.46 FOG-PET scan was significantly 
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better for identifying bone and subcutaneous metastases than CT. Overall, FDG-PET 
depicted more metastases than CT (p=0.017), and in 34 patients (13.5%) FDG-PET had 
an additional value in the management of these patients above spiral CT. Tyler et al 
examined 95 patients with clinically evident lymph node and/or in-transit metastases. 
FDG-PET changed the management of 15% (95%CI 9.5-23.1) of the patients, as compared 
to 19.1% (95%CI 14.7-24.4) in the study of Bastiaannet et al.47 Both studies found a 
high sensitivity (87. 3% and 86.1%) and positive predictive value (78.6% and 85.0%) for 
the detection of distant metastases in stage 111 patients, however direct comparison is 
difficult as one analysis was patient-based47A8 
Taken the published literature together and reasoning that FDG-PET/CT is the current 
standard in PET imaging, there may be a case for the combined PET/CT in the setting of 
metastatic melanoma. Reinhardt et al recently reported a significant increase in sensitivity 
and accuracy with FOG-PET/CT for M-stage assessment of 250 melanoma patients (all 
stages) in comparison to FDG-PET alone and CT alone, although not better than PET 
alone for N-stage assessment.49 In a retrospective study, Lagaru et al also concluded 
that the best performance of the combined FDG-PET/CT scanner was in patients with 
advanced stage of disease; overall ,  the addition of CT increases the specificity of PET/ 
CT over PET alone, and added diagnostic data for small lesions, such as small pulmonary 
metastases. 50 However, it has been shown that CT can also miss small lesions in liver and 
lung.46·51  Finally, Mottaghy et al performed a retrospective study of 127 scans in patients 
with all stages of melanoma: PET alone, side-by-side PET and CT and integrated PET/CT 
were independently and separately interpreted. 27 With histological proof or follow-up as 
gold standard, PET, side-by-side PET and CT and PET/CT had a sensitivity of 86%, 89% 
and 91%, at similar specificity (94%), no difference in PPV (96%) and a NPV of 80%, 83% 
and 87%, respectively (lesion based). The benefit seems less than reported for other 
tumor entities, which may be due to the high avidity of melanoma for FDG, so that many 
of the metastases are detected with FDG-PET and the additional CT does not increase 
the sensitivity. 
Other modalities for staging melanoma in comparison with FDG-PET(/CT) 
The diagnostic accuracy of imaging tools to detect distant metastases of melanoma 
depends on the method of examination , the technique used, the organ and the size of 
the tumor. 52 Several studies compared FDG-PET with other diagnostic tools. Gulec et al 
studied 49 patients with metastatic melanoma; patients first underwent conventional 
imaging with CT and MRI after which a treatment plan was formulated, followed by 
a FDG-PET scan .53 The FDG-PET scan identified more metastatic sites in 55% of the 
patients and led to treatment changes in 49%; FDG-PET was more accurate to depict 
the extent of disease in patients with metastatic melanoma. A recent study of Brady et 
al studied the clinical utility of FDG-PET if it was used in addition to standard imaging 
in patients with preoperative stage l i e, Ill and IV melanoma. 2 1  Imaging findings led to 
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a change in clinical management in 36 of the 1 03 patients ( 35%); in 32 (89%) of these 
patients the information was accurate. However, as the authors note in the discussion, a 
possible bias in this study was introduced as approximately one third of the patients who 
were referred for resection had a CT scan before referral; so patients with unresectable 
metastases would not have been referred. Two studies have compared staging with 
FDG-PET and CT in all stages of melanoma patients; both found FDG-PET to be superior 
in terms of sensitivity and specificity to CT in all stages of melanoma. 54•55 I n  contrast 
to the previous publications, Krug et al were not convinced of the diagnostic value of 
FDG-PET as a potential routine clinical procedure.52 They conclude that FDG-PET is 
inferior to CT (patient based) for the detection of lung and liver metastases, and should 
therefore not be used alone to exclude metastasis. Direct comparison of FDG-PET and 
CT in stage I ll patients showed correct upstaging in 27. 1% by FDG-PET and in 24. 3% 
with CT (p=0.1 78).46 FDG-PET detected more metastatic sites ( 141 vs. 1 12, p=0.01 7), 
significantly more bone and skin metastases. Treatment changed in 1 9. 1%; in 79.2% as 
result of both scans, 1 6.6% exclusively FDG-PET and 4.2% exclusively CT. 
Change in treatment as result of the FDG-PET 
scan 
Results of the FDG-PET scan can lead to a change in treatment, especially in stage 111 
or IV melanoma patients. Several studies assessed this change in treatment (Table 1 ). 
Overall, in all stages of melanoma FDG-PET lead to a change in treatment in 1 7-48% 
of the patients. Three studies included stage I IC- IV patients and found a change in 
treatment from 34%-49%; a single study in exclusively stage I l l  patients found a change 
Table I :  Change in treatment as result of FDG-PET in melanoma patients in different stages of d isease 
Authors Year Stage Tests before FDG-PET N Change in 
treatment 
Damian et aI1 
Stas et al2 
Wong et aI3 
Reinhardt et al4 
Bastiaannet et aI5 
Brady et a l6 
Gulec et al7 
Harris et a l8 
Bastiaannet et al9 
Mijnhout et aI 1 0  
1996 A l l  stages 
2002 Al l stages 
2002 All stages 
2006 All stages 
2006 All stages 
2006 l ie, I l l  and IV 
2003 1 1 1  or IV 
2005 92% I l l  or IV 
2008 I l l  
2002 Recurrent disease 
None 1 00 
Chest X-ray, liver US, blood 84 
analysis, CT. Subgroup: 




D ifferent modalities 
CT scan 
CT and MR I  
CT 
Chest X-ray 




















in treatment in 19.1% of the patients. Mijnhout et al studied the change in treatment in 
patients with recurrent melanoma and found a change in 1 7% of the patient as result of 
the FDG-PET scan. 
Unexpected findings other than melanoma 
FDG-PET has the potential to detect other unexpected (pre)malignant lesions besides 
melanoma which can lead to a change in treatment. A study with 257 melanoma patients 
found unexpected, clinically relevant, pathology mainly of the colon and rectum in 4. 3% 
(n=1 1) of the patients. 20 Additionally, another study depicted 58 (3%) abnormalities 
(malignant or premalignant) in 1750 FDG-PET scans (all malignancies), which were not 
clinically apparent and needed treatment and follow-up. 60 Also, in two studies with the 
combined whole-body PET/CT scanner new, unexpected FDG-avid primary malignant 
tumors were detected in 1.2% and 1.7%, respectively, of the patients with known 
malignancies.61 •62 
Response assessment with FDG- PET 
There is very little literature concerning the value of FDG-PET i n  the evaluation of 
response to treatment in patients with melanoma. Mercier studied three patients whom 
underwent FDG-PET before and one month after isolated limb perfusion.63 A reduction 
in the number of visualized limb lesions was seen,  but also a diffusely enhanced uptake 
throughout the perfused limb, probably as result of post-treatment inflammation. 
Hofman et al performed a pilot study (7 patients) to evaluate the value of FDG-PET/CT to 
assess the early response to chemotherapy in metastatic melanoma. 64 The study showed 
the potential use of FDG-PET and FDG-PET/CT to assess the response to chemotherapy 
in patients with distant metastases as distant metastases were accurately depicted by 
PET. According to the authors metabolic imaging may improve the palliation of patients 
receiving chemotherapy for metastatic melanoma by identifying patients unlikely to 
respond and thereby avoiding ineffective further chemotherapy. 64 The largest study 
so far with 41 patients treated for melanoma metastases, showed PET/CT suitable for 
response assessment in patients with proven melanoma metastases. 65 In all patients, 
therapy response was assessed using visual criteria and change of DeltaSUV(max) or 
total lesion glycolysis; correlations between these and S-100 were both excellent showing 
that the PET/CT findings did correlate with response. A study that evaluates the effect 
of treatment with bevacizumab with PET is currently conducted in the Netherlands. 
However, other and larger prospective studies need to be performed. 
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FDG-PET in the follow-up  of melanoma 
patients 
There is no universally accepted consensus advocating the routine use of FDG-PET in 
the follow-up of melanoma.66 ·67 Most recurrences are actually detected by the patient 
and the most essential component of surveillance to detect recurrences or new primary 
melanoma is the history and physical examination.68•69 A recent study assessed the 
methods to detect recurrent disease after SLNB.70 Of the 1062 patients, 1 98 had a 
recurrence: established by symptoms and self-detection in 1 09 patients (55%), physician 
detection in 89 (45%), nearly half of which by a scheduled radiographic test (chest X-ray 
16%, CT 29%, PET 1 %). A Finnish study studied the impact of FDG-PET to detect clinically 
silent metastases in the follow-up of patients with high risk melanoma.66 FDG-PET was 
performed (together wit CT and physical examination) in 30 asymptomatic patients 
(stage IIB- I I IC) and was able to detect six of the seven recurrences . The authors conclude 
that FDG-PET could be a valuable modality in the follow-up of high risk melanoma 
to diagnose recurrences and to select patients who are suitable for metastasectomy. 
However, at this moment, there is no place for FDG-PET in the follow-up of melanoma 
patients outside a clinical study. 
Standard ized Uptake Value 
The Standardized Uptake Value (SUV), which represents the FDG accumulation in the 
tumor or metastasis, could be a useful index in different cancers. It could be used to 
predict the prognosis, as metabolic activity correlates with tumor proliferation; and tumor 
proliferation is related to the clinical behavior.7 1 •7 2  Several studies in different tumors 
(breast, head and neck, pancreatic cancer, lung cancer) have shown that a high FDG 
uptake was associated with a lower Disease Free Survival (DFS) or Overall Survival (OS).73-
77 However, there are also studies published where the SUV value had no significant 
association with survival.78·79 As far as the authors know, only one study has been 
published in patients with cutaneous melanoma. 23 This retrospective study included 38 
stage I l l  melanoma patients and showed that DFS was prolonged in melanoma patients 
with a low SUVmean in the lymph nodes (p=0.009) compared to patients with a high 
SUVmean. Results of the Dutch prospective study are pending, however preliminary 
results show again that DFS was increased in patients with a low SUV in the lymph 
nodes. 80 There are many factors that may influence the FDG uptake: glucose and insulin 
levels, patient size, and the interval between FDG injection and image acquisition.8 1  
SUV estimates suffer from poor reproducibility between centers because of the lack of 
standardization in acquisition and processing protocols in the past.8 1  This makes the 
SUV cutoff value only applicable in the centre where the study was performed while 
multi-centre trials need standardization of acquisition, reconstruction and data analysis. 
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Recently, standardization of scanner calibration, acquisition and analysis protocols was 
achieved for different institutes in the Netherlands (see Chapter Boellaard et al) . 8 1  
Hopefully; this standardization will also be performed in other countries, so  SUV values 
will be easily compared. 
As a result of the current methodological heterogeneity, there is no consensus on the 
optimal SUV threshold to distinguish between malignant or benign tissues, and no cut-off 
value has been established to define subgroups of different prognosis.82 Additional 
prospective studies need to be performed to determine these values. The SUV value 
could be used, additional to the number of positive nodes, tumor size and extranodal 
growth, to decide for adjuvant radiotherapy. However, to be a practical prognostic factor 
in routine practice, a single SUV threshold allowing distinguishing between long and 
short survival patients remains to be validated and agreed upon.83 
L im itations and p itfalls 
There are several limitations and pitfalls with the use of FDG-PET in melanoma patients; 
first, due to physiological uptake of FDG in the brain, cerebral metastases are difficult to 
detect. Besides, FDG-PET has a low ability to detect pulmonary metastases, which has 
been attributed to lowering of target-non target contrast due to blurring by respiratory 
movement, partial volume effects (function of scanner quality, biological contrast and 
image reconstruction techniques), scatter from other organs in basal lung fields, and 
different levels of background activity in normal lung tissue.84 However, a recent study 
also showed that lung metastases detected with FDG-PET were not detected with CT.46 
The review of Prichard et al showed a high sensitivity of FDG-PET to detect metastases 
in the mediastinum, abdomen and lymph nodes (abdominal and peripheral).45 Besides, 
sensitivity of FDG-PET to detect lung metastases was 70% with a specificity of 100%.45 
Ghanem et al compared MRI and FDG-PET to detect liver metastases in 35 patients; 
sensitivity was higher for MRI (100%) compared to FDG-PET (47%). However, sensitivity 
was higher (71%) if only lesions >1 cm were assessted.85 A recent study comparing 
FDG-PET and CT discussed that in retrospect several of the bone metastases were seen 
in a second reading of the CT, suggesting that the bone structures were not routinely 
evaluated (enough) with CT.46 
It is unlikely that a generalizable, quantitatively correct added value of FDG-PET will 
become available in this setting. Total body CT generates huge amounts of data (300-400 
images) to be reviewed with several windows-settings. Moreover, the erratic spreading 
pattern of melanoma requires scrutinous survey of all tissues. This may just be too much 
for what a human brain can consistently manage. In our experience, reviewing the CT 
after PET usually identifies the anatomical substrate for the PET findings at CT in normal­
sized structures or retrospectively abnormal ones. This is the strength of combined PET/ 
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CT as a "one stop-shop" procedure in these patients, together usually providing the basis 
for management decisions. G u ide l i ne  and recommendations for the use of FDG-PET(/CT) i n  me lanoma 
Most studies assess the sensitivity and specificity of FOG-PET which is level 2 in the 
proposed hierarchical model of efficacy for diagnostic tests. 86,87 To justify FOG-PET in 
the clinical practice, the technique should also be valuable in diagnostic work-up (level 
3) and have a beneficial effect on the patients' management plan (level 4). This is true 
for stage 1 11 and IV melanoma patients. Next, level 5 studies should measure or compute 
the effect of the information on patient outcomes, which has not been performed 
for melanoma patients. Finally, at level 6, costs and benefits of a diagnostic imaging 
technology for society in general can be examined. It is unlikely that such data will be 
provided within the next few years, if at all. 
Patient with melanoma (primary or recurrent) 
1stage 1 1 1  
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Tailored tr atm nt 
M1  disease 
Confirm with histology, 












CT if PET is not 
available 
Tailored treatment. PET if 
metastasectomy is 
considered 
Figure 1: Proposed guideline for the use of FDG-PET or FDG-PET /CT in melanoma patients for the different 
stages of disease. 
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Since there are currently no standardized or universally agreed guidelines regarding the 
stage-specific use of imaging modalities available for clinicians caring for patients with 
melanoma68 , we provide a proposal for such guideline of FDG-PET and FDG-PET/CT in 
melanoma patients (Fig 1). In stage I and II, and SNB positive patients, FDG-PET has no 
additional value. However, for patients with palpable, proven lymph node metastases 
with no suspicion for lung metastases on chest X-Ray, FDG-PET(/CT) does have additional 
value vs. CT alone in terms of treatment planning.46 Also, for stage IV melanoma patients 
FDG-PET may be of importance to localize the distant metastases if surgical treatment is 
considered. Verification of PET and CT findings remains necessary in patients to prevent 
that potentially beneficial surgery for localized disease is withheld. 
a b 
Figure 2: a) FDG-PET scan of a female melanoma patient with lymph node metastases at the g roin 1 1  years 
after the primary melanoma at the leg (Breslow thickness 1 .3 mm). The abdominal lesion turned out to be 
an adenoma. 
b) FDG-PET scan of a male patient with lymph node metastases at the axi l la one year after the primary 
melanoma at the trunk (Breslow 5.0 mm). FDG-PET depicted a midthoracic bone metastasis not seen at CT. 
The metastasis was confirmed with MRI .  
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ABSTRACT 
Background. Several studies have shown adequate sensitivity and specificity of FDG-PET 
for the detection of melanoma metastases. However, only few have addressed the 
impact on treatment. In this retrospective study the impact on treatment of FDG-PET in 
melanoma patients was determined in three Dutch university medical centres. 
Methods. The medical records of 257 patients were reviewed. The indications for 
FDG-PET and findings were recorded. Unexpected findings of suspected (pre)malignant 
tumours other than melanoma were assessed. Treatment plans before and after FDG-PET 
were recorded from reports of the patient visits and were analysed to evaluate change 
in disease management. 
Results. Most scans were requested for staging (overall 71.2%), mainly to detect distant 
metastases in stage I ll patients. Overall 56 patients (21.8%) were upstaged as a result 
of the PET scan. In 44 patients (17.1%) treatment was changed, usually from surgery 
to systemic treatment in stage Ill patients. In 4.3% of the patients unexpected, mainly 
colorectal, tumours were detected. 
Conclusion. FDG-PET is most valuable in patients with stage 1 1 1  melanoma to detect 
distant metastases and to identify those patients who are candidates for surgery and/ 
or systemic treatment. In 37% of the stage Ill patients, surgical treatment changed as a 
result of the PET scan. Unexpected FDG-PET findings should not be disregarded, as (pre) 
malignant clinical relevant, tumours may be identified. 
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INTRODUCTI ON 
Melanoma causes more than 75% of all skin cancer deaths. Particularly among whites 
in areas of high sun exposure, the incidence has steadily risen in the last decades.1 In 
individual patients, the development of metastases from melanoma is unpredictable, but 
prognosis is linked directly to the stage of disease at presentation. 2 •3 The 5-year survival 
for stage Ill melanoma patients (lymph node metastases) differences considerably from 
the 5-year survival for stage IV melanoma patients (distant metastases): 47% and 10%, 
respectively. If patients are staged correctly as stage Ill patients, a curative intended 
lymph node dissection can improve their survival. 
Conventional staging in melanoma patients compromises physical examination, LDH and 
chest X-ray. Based on the staging results and the clinical symptoms found after physical 
examination, appropriate additional staging with CT or ultrasound can be requested. 
Accurate staging of melanoma patients is necessary for appropriate management.4 In 
primary melanoma, the presence of nodal metastases is an indication for lymph node 
dissection. In recurrent or metastatic melanoma, accurate staging is needed to decide for 
surgical or systemic therapy. 
Compared to normal tissues, cancer cells have an increased glucose metabolism which 
correlates with the aggressiveness of tumour growth. 5-7 Positron emission tomography 
(PET) with 18Fluoro-deoxyglucose (FDG) depicts this metabolic activity and has become 
an important modality in diagnosing and staging of cancer patients. Safar, and not 
unexpectedly micrometastases in normal sized lymph nodes are beyond the detection 
limit of any imaging technique, including FDG-PET.8-1 1  However, FDG-PET has high 
sensitivity and specificity to detect melanoma metastases in patients with palpable 
lymphadenopathy.4•12 Furthermore, FDG-PET shows a higher sensitivity and specificity 
for the detection of distant metastases at certain sites (soft tissue, small-bowel and 
lymph node) than other modalities.4 
Few studies have addressed the impact of FDG-PET on the (surgical) treatment of 
melanoma patients. The initial evaluation of diagnostic tests is usually limited to the 
assessment of diagnostic performance in terms of sensitivity and specificity, level 2 
in the proposed hierarchical model of efficacy for diagnostic tests. 1 3• 1 4  To justify the 
introduction of FDG-PET in clinical practice, the technique should also be valuable in 
diagnostic workup (level 3) and have a beneficial effect on the patients management plan 
(level 4). Next, level 5 studies should measure or compute the effect of the information 
on patient outcomes. Finally, at level 6, costs and benefits of a diagnostic imaging 
technology for society in general can be examined. Diagnostic imaging should provide 
images of the best technical quality and should provide accurate diagnoses.1 4  However, 
diagnostic imaging is part of a larger system, the effective and efficient treatment of 
patients. Therefore, an adequate clinical evaluation of the added value of FDG-PET, which 
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provides guidelines, is needed before widespread uncontrolled introduction of FDG-PET 
into clinical practice takes place.1 5 This retrospective, multicenter study was designed to 
determine the value of FDG-PET scan and to provide insight on the impact on surgical 
management of melanoma patients. 
PAT I ENTS AN D M ETH O DS 
Patients 
The medical records of all patients with primary or recurrent melanoma between 
1992 and 2004, referred for FDG-PET to one of the three university medical centres in 
Amsterdam (VU Medical Centre), Nijmegen (University Medical Centre St. Radboud) or 
Groningen (University Medical Centre) were reviewed. Inclusion criteria were availability 
of clinical data and an adequate medical follow-up and availability of an FDG-PET report 
with the clinical question regarding the PET scan and an answer of the nuclear medicine 
physician. Based on the results of FDG-PET, patients were divided in five groups suspected 
of melanoma: no suspected melanoma at time of FDG-PET (normal FDG-PET scan), 
primary or recurrent melanoma (stage I or II), regional metastases (stage Ill), solitary 
distant metastasis (stage IV), and multiple distant metastases (stage IV). The same five 
groups were created based on the pathology or clinical follow-up. Patient characteristics 
(gender, date of birth, date of diagnosis of melanoma, localisation of tumour) were 
recorded. 
FOG-PET 
In Amsterdam and Nijmegen, FDG was obtained from Mallinckrodt Medical, Petten, The 
Netherlands. In Groningen, FDG was synthesised on site according to Hamacher by an 
automated synthesis module. 1 6 Prior to PET imaging, patients were instructed to fast 
for at least 6 hours.17• 18 They were also instructed to drink one litre of water prior to 
imaging, to stimulate FDG excretion from the renal calyces and subsequent voiding. FDG 
was injected through a venous canulla in the forearm of the patient. Whole-body imaging 
was performed in the two or three dimensional mode, with emission scans of 4 to 10 
min per bed position, starting 1 hour after the injection of FDG. In Amsterdam a Siemens 
ECAT EXACT H R+ scanner (Siemens/CTI Inc., Knoxville, TN) was used. In Nijmegen, a 
dedicated, rotating half-ring PET scanner ( ECAT-ART, Siemens/CTI) was used for data 
acquisition in the period 1998 to 2001, thereafter an ECAT EXACT H R+ (Siemens/CTI). 
In Groningen, an ECAT 951/31 or an ECAT H R+ scanner (Siemens/CTI) were used since 
1 992 for data acquisition. In all centres, FDG-PET readings were done using a computer 
display. All clinical information was available when reading the FDG-PET scans. This 
analysis was based on the reports provided to the clinician. 
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Data analysis 
The results of FDG-PET were compared to the results of pathology or a follow-up of 
more than six months (gold standard). Sensitivity ((TP/TP+FN) x1 00%) and specificity 
((TN/TN+FP) x1 00%) of FDG-PET for the detection of melanoma were calculated (patient 
level). If FDG-PET showed multiple metastases and pathology or follow-up proved only 
one metastasis, the scan was scored as false positive. If FDG-PET showed a solitary 
distant metastasis and pathology or follow-up showed multiple metastases, the scan 
was scored false negative. If FDG-PET showed multiple lesions and pathology or follow­
up proved two or more, the scan was scored as true positive. The reason for FOG-PET 
requests were recorded: more accurate staging, more accurate diagnosis, monitoring 
disease (follow-up) or therapy, detection of the primary melanoma, a combination or not 
clear. After recording the indications for FDG-PET, the FDG-PET report was reviewed to 
verify if the clinical questions were answered. In each category, the number of positive or 
negative and true or false scans compared to the pathology or follow-up was recorded. 
Unexpected findings of (pre)malignant tumours other than melanoma were described. 
Treatment was recorded from the reports of the patient visits before and after the PET 
scan. The intended and performed treatment (surgery, systemic treatment, radiotherapy 
or no treatment) before and after the PET scan was compared to assess if FDG-PET 
led to any change in treatment. If there was a change in treatment as a result of other 
reasons than the FDG-PET scan, this was recorded as change in treatment, not as result 
of FDG-PET. Patients were considered to be upstaged (unexpected lesions found) or 
downstaged (expected lesions not found). I n  accordance with the proposal from UCLA 
School of Medicine, Los Angeles, patients were classified into intermodality changes 
(from one modality to another, i.e. from surgery to systemic treatment) and intramodality 
changes (change within a modality, i.e. additional surgery).1 •19-2 1 
RESU LTS 
I n  this study 257 PET scans and medical records of melanoma patients were reviewed: 
1 1 5 from the University Medical Centre Nijmegen, 1 01 from the VU Medical Centre 
Amsterdam and 41 from the University Medical Centre Groningen . Females and males 
were equally represented ( 125 versus 1 32). Median age at the time of the FDG-PET scan 
was 54 years (range 1 4  to 84 years). In descending order, the primary melanoma was 
located on the trunk (38.5%), lower extremities (35.4%), in the head and neck region 
( 1 1 .7%) and the upper extremities (6.2%). Eight percent of the patients presented with 
melanoma metastases of an unknown primary. Median follow-up time was 33.8 months 
(range 0.5-146). In 1 65 patients (64.2%) pathological confirmation was recorded, in 92 
patients (35.8%) clinical follow-up served as gold standard. 
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Patients were divided into five groups based on the FDG-PET results. In this subanalysis 
37 procedures could not be used as the FDG-PET report was not clear (unclear 
abnormality, recommendation of a CT or X-ray, interfering uptake in the muscles, uptake 
in the operation field or no FDG uptake in the known melanoma metastases). The same 
five categories were created based on the pathology and/or follow-up (gold standard). 
Patients were considered positive or negative for melanoma metastases. Table 1 shows 
that 62 scans were true negative, 112 were true positive, 21  were false negative and 25 
false positive. Overall sensitivity for the detection of melanoma or melanoma metastases 
(patient-based) was 84.2%(95% Cl: 78.0%-90.4%) and specificity 71. 3%(95% Cl : 61.8%-
80.8%). Positive Likelihood Ratio was 2.9 (95% Cl: 2.1-4.1) and Negative Likelihood Ratio 
was 0.2 (95% Cl: 0.1-0. 3). Positive predictive value in stage 1/11 was 0.5(95% Cl : 0.4-0.7) 
and in stage I l l and IV 0.9 (95% Cl: 0.9-1.0). 
Table 1 Comparison of stages according to PET results and pathology or fol low-up 
Pathology or follow-up Total 
No mela- Pr imary/ Regional Sol itary M u ltiple 
noma recurrent meta-stases d istant d ista nt 
tumour  m etastases metastases 




Primary/recurrent 3 1 9  2 4  ( 1 0 .9%) 
tumour 
p Regiona l  metastases 5 2 39 47 (2 1 .4%) 
E Solitary distant 3 3 6 24 37 ( 1 6 .8%) 
metastases 
T Mu ltip le  d istant 3 30  33 ( 1 5 .0%) 
metastases 
Total 73 (33.2%) 30 ( 1 3 .6%) 57 (25.9%) 29 ( 1 3 . 2%) 31 (1 4 . 1%) 220 ( 1 00%) 
Table 2 shows the indication for the PET and the result of these scans (positive/negative 
and correct/incorrect). Most scans were requested for staging (71.2%), mainly to detect 
or exclude distant metastases. Approximately 15% of the scans were requested for more 
accurate diagnosis in case of a positive CT, clinical symptoms or palpable lesions. Most of 
the scans were positive for melanoma metastases rather than negative and correct when 
compared with pathology or follow-up. 
As shown in Table 3, unexpected foci suspected of other primary tumours were reported 
in 11 (4. 3%) patients. Almost all abnormalities were located in the colorectal region, 
except for one patient who had a confirmed hypofyse adenoma. 
As shown in Table 4, treatment was changed in 44 patients ( 17.1 %) as a result of FDG-PET. 
In this group 57% of the patients had regional metastases in which the FDG-PET had 
to detect or exclude distant metastases. In 56 patients (21.8%) unknown lesions were 
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Table 2 Clinica l question and ratio scans positive/negative, correct/incorrect 
Clinical question Number of scans Positive/ Negative Correct/ Incorrect 
Ratio {n=257) Ratio 
Staging 
Diagnosis 
Monitor d isease 
Finding primary melanoma 
Diagnosis and staging 
Monitor therapy 
Finding primary and stag ing 
Not clear 
1 83 (71 . 2%) 
38 ( 14.8%) 
1 5  (5 .8%) 
7 (2.7%) 
6 (2 .3%) 
4 (1 .6%) 
2 (0.8%) 
2 (0.8%) 
NA: ratio not calculated due to a small patient group. 
Table 3 Unexpected findings of other cancers than melanoma 
Unexpected findings 
Polyp colon or rectum 
Colorectal cancer 
Hypofyse adenoma 
No further diagnostics (colon and intestinal) 
1 .6 
2 .2  


















detected. These patients were considered 'upstaged' as a result of FDG-PET, in 46 
patients this proved to be correct. In 26(46%) of these patients the treatment did not 
change as a result of the upstaging. In 37% of the stage Ill patients surgical treatment 
was changed. In 11 (4. 3%) patients expected lesions were not detected (CT was false 
positive, palpable lymph nodes were not detected or based on clinical symptoms). 
In 6 patients treatment changed within a modality: in 2 patients the radiotherapy 
changed from intended curative to palliative treatment, 3 patients received less surgery 
or palliative surgery instead of surgery with curative intent and one patient received 
Table 4 Change in treatment and number of patients upstaged or downstaged. Patients with a change in 
treatment divided into stages (pre-test) and positive, negative, true or false PET scan 




Expected lesions not found 
2 1 3  
44 
56 
1 1  
N=257 true or false 
82.9% 




I l l  




TP :  5, TN: 1 
TP: 1 8, FP: 2, TN: 2, FN: 3 
TP: 1 0, FP: 1 ,  FN: 2 
TP: true positive, FP: false positive, TN: true negative, FN: false negative. 
additional surgery (recurrence and metastasis). Table 5 shows the intermodality change 
in 15.6% of the patients. Most patients changed from surgery to systemic treatment, 6 
patients changed from surgery to no treatment (observation) and 5 from no treatment 
to systemic treatment. 
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Table 5 l ntermodality change. Change in treatment before and after the FDG-PET scan 





Surgery and systemic 
Surgery and rad iotherapy 
Not clear 
Tota l  
DISCUSSION 
Performed treatment 








24 (9 .3%) 
3 
2 




56 (21 .8%) 
in our analysis, 21.8% of the patients were upstaged as a result of FDG-PET. In 17.1% the 
treatment was changed, in most cases from surgery to systemic treatment. Most patients 
had known locoregional metastases and were correctly upstaged to stage IV (distant 
metastases). In 4. 3% of the patients unexpected pathology of the colon and rectum was 
found. 
Diagnostic tests may positively influence survival if they improve treatment planning. 1 5  
A study of the UCLA School o f  Medicine in Los Angeles found a change in clinical 
management in 47% of the melanoma patients. 1 However, a responder bias may have 
confounded their data. They hypothesised that if all non-responders felt that FDG-PET 
did not contribute to patient management, FDG-PET would have resulted in a change 
in management in 18% of the melanoma patients, which is consistent with the present 
data. Gulec et al described that PET identified more metastatic disease in 27 of 49 (55%) 
melanoma patients with known or suspected metastatic disease. 22 The results of PET 
led to treatment changes in 24 patients (49%), in 50% of these patients the planned 
operative procedure was cancelled. A Dutch study assessed the reproducibility and 
clinical impact of PET in 58 patients with (suspected) recurrent melanoma.1 5  Diagnostic 
understanding and therapy choice were prospectively evaluated before, directly after, 
and 6 months after the PET scan. According to the attending physicians PET was very 
important compared with other factors, leading to a beneficial change in therapy in 17% 
(95%CI 10-29%) and contributed to a change in therapy, but other factors were at least 
equally important in 23% (95%CI  14-35%). In a study of Damian et al PET influenced 
management in 22% of the patients, which is similar to our results. 23 Wong et al indicated 
that whole body FDG-PET changed the clinical stage in 29% of the patients; which is 
consistent with our study in which 26. 1 %  of the patients were upstaged or downstaged. 1 
The FDG-PET findings resulted in inter-modality changes in 29% of the patients and intra­
modality changes in 18%, in our study the inter-modality and intra-modality changes 
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Surgery and Surgery and radio-
systemic treatment therapy 
2 
1 (0.4%) 2 (0 .8%) 
Systemic and 
rad io-therapy 




Tota l  
1 72 (66.9%) 
1 3  (5. 1 %) 
6 (2 .3%) 
56 (21 .8%) 
(0.4%) 
3 ( 1 . 2%) 
6 2 .3%) 
257 -1 00% 
were 15.6% and 2. 3%, respectively. These lower percentages are probably caused by 26 
patients (10%) in whom the stage was changed as a result of FDG-PET, but no change in 
treatment did occur, while in the study by Wong et al 24% of the patients did not change 
in clinical stage, but did have a change in treatment. 
In our study we found an overall sensitivity of 84.2% and specificity of 71. 3% for the 
detection of melanoma and melanoma metastases for FDG-PET. Sensitivity could be 
underestimated in this study due to the inclusion of a small proportion of sentinel node 
patients in which FDG-PET was negative. On the other hand, sensitivity and specificity 
could be overestimated if the nuclear physician had the benefit of having a CT imaging 
prior to the PET scan. This was however the case in only 5% of the patients in this study. 
FDG-PET imaging has evolved in the last years; the data in this study show an increase 
of sensitivity in the last years. The review of Prichard et al found an overall sensitivity of 
74%-100% and specificity of 67%-100%.24 Mijnhout et al found a pooled sensitivity 
of 78% and a pooled specificity of 88% in the detection of melanoma metastases 
(lymph nodes and distant). 25 Clinical trials demonstrated the superiority of FDG-PET over 
conventional imaging in the detection of regional and mediastinal lymph nodes, cervical 
and abdominal metastases and soft tissue metastases. 26-28 A study in stage I l l  melanoma 
patients by Tyler et al concludes that FDG-PET can be helpful in managing patients with 
lymph node metastases in whom further surgery is contemplated. 29 Although false­
positive scans are not uncommon, FDG-PET did change the management in 15% of the 
patients. Another study of stage Il l and IV melanoma patients by Valk et al avoided 
surgery in 36% of their 35 patients as a result of FDG-PET. 30 
The development of sentinel lymph node mapping in the staging of melanoma offers 
a highly sensitive procedure with a very low false-negative rate.8•3 1 •3 2  The studies of 
Acland et al and Havenga et al were designed to compare the sensitivity and specificity 
of PET scanning with SNB in the detection of micrometastatic disease in the regional 
nodes.8• 1 0  Their data clearly demonstrates that FDG-PET is not sufficiently sensitive to 
detect very small deposits within clinical normal lymph nodes. 
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However, combined with the ability to scan the complete patient in one time, it is 
reasonable to suggest that FDG-PET should be the first modality to be applied whenever 
staging for distant metastases is needed for clinical decision making in melanoma 
patients.4 The staging of melanoma patients with clinically palpable metastases to the 
lymph nodes is especially important to determine presence and localisation of distant 
metastases. A recent review concludes that FDG-PET identifies the location and number 
of metastatic lesions in stage Ill and IV disease and is therefore important for surgical 
planning.33 The combined use of FDG-PET scanning and conventional imaging with CT 
and/or MRI imaging may be an accurate strategy to help identify sites of metastasis 
in patients with stage IV melanoma who are being considered for complete surgical 
resection according to a recent prospective study. 34 
FDG-PET has the potential to detect other cancers besides melanoma and in this study 
cancers other than melanoma were unexpectedly detected in 1 1  patients. Eight of these 
patients had (pre)malignant findings of colorectal origin. The identification of unexpected 
foci of hypermetabolism at whole-body FDG-PET may indicate the presence of tumours 
that are unrelated to the neoplasm for which the patient was scanned.3 5 A majority 
of the 58 abnormalities ( 3%) found in a study of 1 ,750 FDG-PET scans, were either 
malignant or premalignant tumours, which were not clinically apparent and needed 
treatment and follow-up.3 5 
The pattern of distant metastases in melanoma patients is highly unpredictable.36· 37 
Attempting to survey the entire body with a series of conventional diagnostics is not 
cost-effective or practical. 38 Whether PET and CT should be regarded as complementary 
and in which order they should be performed is currently the subject of a prospective 
multicenter study in The Netherlands (OMSPECT study). A retrospective cohort study 
of Swetter et al showed PET to be more sensitive and specific than CT for detection of 
melanoma metastasis.39 In conclusion, FDG-PET has the highest value in staging patients 
with loco-regional metastases to detect or exclude distant metastases, surgical treatment 
changed in 37% of the patients. Due to its high diagnostic accuracy and its whole body 
imaging technique, FDG-PET can reliably identify those patients who would qualify for 
and might benefit from surgery. 1 Whole-body FDG-PET may identify unexpected foci 
of hypermetabolism within the colorectal region, which may have clinical relevance. 
Findings of this study emphasise the (added) value of FDG-PET as a whole-body imaging 
technique that provided important clinical information, especially in patients eligible for 
resection of metastatic disease. 
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ABSTRACT 
Background. The incidence of malignant melanoma has increased. Identification of 
additional prognostic factors may allow the development of individualized strategies. 
This multivariate analyses was undertaken to evaluate the potential role of the standard 
uptake value (SUV) in predicting disease-free and overall survival in melanoma patients 
with lymph node metastases. 
Methods. All melanoma patients with palpable lymph node metastases who where 
referred for a FDG-PET scan were eligible. The SUV in the lymph node metastasis was 
calculated. Data was analyzed (Kaplan-Meier) and differences in cumulative survival 
and disease-free rate were assessed (log-rank test). Univariate and multivariate analysis 
(Cox proportional hazard model) were performed to determine independent prognostic 
factors. 
Results. There was no statistical difference in survival for the 38 patients with high or 
low SUVmean (p=0.1 1 ). However, a significant difference was found in disease-free 
survival (p=0.03). Ulceration of the primary melanoma (p=0.023) was an independent 
predictor of survival. For the disease-free survival, multivariate Cox regression showed 
adjuvant radiation (p=0.001 ), localization of the primary melanoma (p=0.01 7) and a high 
SUVmean (p=0.009) as independent prognostic factors. 
Conclusion. Disease-free survival of melanoma patients was prolonged in those with a 
low SUVmean value (p=0.03) in their lymph node metastasis, as compared to those 
with a high SUVmean. However, this difference was not found for overall survival. In 
multivariate analysis high SUVmean was an independent prognostic factor (p=0.009) 
for disease-free survival. If these results are confirmed by prospective research, adjuvant 
radiation treatment should be considered for patients with high FDG uptake in melanoma 
lymph node metastases. 
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INTRODUCTION 
Cutaneous melanoma is among the malignant tumors with the most rapidly increasing 
incidence rates in Caucasian populations.1 In 2000 the incidence in The Netherlands was 
14 per 100.000 which is a rise of 38% compared to 1990, which represents the highest 
increase of the 10 most common cancers in The Netherlands. As a result of increased 
awareness and surveillance, melanoma is now diagnosed at an earlier stage of disease. 
Nevertheless, some patients with melanoma still present or recur with loco-regional 
metastases (Stage Ill A.J.C.c.). Surgical excision of the primary tumor and a therapeutic 
lymph node dissection remains the standard of care for these patients. 
Many melanoma patients with lymph node metastases die as a consequence of distant 
metastases, usual ly in less than three years despite lymph node dissection with a curative 
intent. Loco-regional recurrences (stage Ill) are often difficult to treat and treatment 
may result in a substantial morbidity, such as ulceration and disfigurement. The number 
of node metastases, the size of metastatic nodes, extracapsular extension, number 
of involved nodal basins and ulceration of the primary tumor are the most significant 
prognostic factors in stage Ill melanoma patients.2-9 However, patients with the same 
clinicopathological parameters can still have a different outcome of treatment, regional 
control and survival. Identification of additional prognostic factors may allow the 
development of individualized strategies that may lead to improved results. 
Positron Emission Tomography (PET) allows an assessment of tumor physiology by 
determining the uptake of radiolabeled tracers.1 0  18F-Fluorodeoxyglucose (FDG) is a 
radiolabeled glucose analogue that is taken up by cells through the glucose transporter. 
It is subsequently phosphorylated intracellular by hexokinase and trapped in the cells. 
FDG distribution within the body is thus a measure of glucose metabolism, which is 
increased in cancer cells.11  Several studies have shown the value of FDG-PET in melanoma 
patients. A systematic review and meta-analysis revealed that FDG-PET is accurate for 
the detection of distant and regional lymph node metastases.1 2 For regional staging, 
subgroup analysis showed a better accuracy of FDG-PET in stage Ill melanoma compared 
with stage I and I I  disease. 
To assess the degree of FDG accumulation, Standardized Uptake Value (SUV) is a popular 
index in different cancers. Studies in breast cancer, head and neck carcinoma, pancreatic 
cancer, lung cancer and sarcoma show that patients with high FDG uptake had a 
significantly lower disease-free and overall survival. The SUVmean or SUVmax turned out 
to be significant prognostic factors in several univariate and multivariate analysis. 1 3-20 
However, studies have also been published where the SUV had no prognostic value with 
respect to disease-free or overall survival. 2 1 • 2 2  
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While FDG-PET has adequate sensitivity and specificity in staging melanoma, no studies 
exist focusing on the prognostic value of FDG uptake in melanoma patients. 23-27 
Using retrospective data, this analysis was undertaken to evaluate the potential role of 
the standardized uptake value (SUV) in predicting disease-free and overall survival in 
melanoma patients with lymph node metastases. 
PATI ENTS AN D M ETHODS 
Patients 
All melanoma patients with palpable lymph node metastases who where referred for 
FDG-PET to Groningen University Medical Center or Radboud University Nijmegen 
Medical Centre, from 1999 to 2004 were eligible for this study. In all patients the lymph 
node metastases had to be cytologically proven and untreated before FDG-PET. Patients 
were included in the study if FDG-PET could be evaluated with the provided software 
and if they had a lymph node dissection after the FDG-PET. The medical records of these 
patients were reviewed and the following information was retrieved: age, sex, treatment, 
FDG-PET result, interval from the occurrence of the primary melanoma, characteristics 
of the primary melanoma (localization, Breslow, ulceration) and characteristics of the 
lymph node metastases (localization, extranodal growth, number of lymph nodes). We 
recorded the number of days of follow-up, and if a patient died or recurred, the days until 
death (primary endpoint) or until recurrence (secondary endpoint). Follow-up was the 
same for all patients; Physical examine in the first year every three months, in the second 
year every 4 months, in the third to fifth year every 6 months and sixth to tenth year once 
a year, with every year a chest x-ray. PET and CT scans were only performed on clinical 
indication of metastases. Tumor recurrence events could be recurrence in the lymph 
nodes or metastatic disease and had to be cytological or histological proven. 
Positron emission tomography 
In Nijmegen, FDG was obtained commercially from Mallinckrodt Medical, Petten, The 
Netherlands. In Groningen, FDG was synthesized on site according to Hamacher by an 
automated synthesis module. 28 Prior to PET imaging, patients were instructed to fast for 
at least 6 hours after which FDG was injected intravenously. Patients were instructed to 
drink one liter of water prior to imaging, to stimulate FDG excretion. Whole-body imaging 
was performed in the two or three dimensional mode, with emission scans of 4 to 10 min 
per bed position, starting 1 hour after the injection of FOG. In Nijmegen, a dedicated, 
rotating half-ring PET scanner (ECAT-ART, Siemens/CTI) was used for data acquisition 
in the period 1999 to 2001, thereafter an ECAT EXACT (Siemens/CTI) . In Groningen, 
an ECAT 951/31 or an ECAT HR+ scanner (Siemens/CTI) were used for data acquisition. 
Data were iteratively reconstructed (ordered subsets expectation maximisation). In both 
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centers, FDG-PET was read using a computer display. All clinical information was available 
when reading the FDG-PET scans. 
Standard Uptake Value 
The SUV depends on the amount of injected radioactivity, the patient's weight, and the 
calibration factor of the camera, and is calculated according to the following formula: 
SUV = radioactivity concentration in tissue (Bq/kg) / (injected dose (Bq) / patient weight 
(kg)). 
Three-dimensional regions of interest (ROls) were placed semiautomatically using a 
dedicated software program over the tumor on multiple slices, using a threshold of 70% 
of the maximum pixel value within the tumor. The SUVmean and SUVmax in the lymph 
node metastasis were calculated; SUVmean reflects the mean value over all voxels and 
SUVmax reflects the maximum SUV value in the tumor. If there was more than one 
metastasis in the lymph node basin, the lesion with the most intense uptake was chosen. 
Data analysis 
The relationships between SUV and patient' characteristics were assessed by the Student's 
t-test or analysis of variance as appropriate. Patients were divided in two groups based 
on the SUVmean and SUVmax for the survival analysis. In the absence of an established 
cutoff point we chose the median SUVmean and median SUVmax. 
Data were analyzed using the Kaplan-Meier method and the differences in cumulative 
survival rate and disease-free rate was assessed using the log-rank test. Univariate and 
multivariate analysis (Cox proportional hazard model) were performed to determine 
independent prognostic predictors. All variables with p<0.2 in the univariate analysis were 
entered in the multivariate analysis. All p-values are 2-tailed and significant if p�0 .05. 
RESU LTS 
FDG-PET and medical records of 38 patients were reviewed. Twenty patients were male, 
18 female; mean age was 54 years (range 28-86 years). Lymph node dissection was 
performed in all patients of whom 35 showed no distant metastases on the FDG-PET 
scan. The median time from the primary melanoma to the presentation of the lymph 
node metastases was 289 days (range 0-611 7 days). The primary melanoma was located 
at the leg (47.4%), trunk (31.6%), head (7.9%), unknown primary (10.5%) and arm (2.6%). 
The lymph node metastases were located inguinal (52.6%), in the axilla (34.2%) and in 
the neck (13.2%). Median SUVmax was 6.0 (range 1.0-20.6) and median SUVmean was 
5.2 (range 0.9-16.7). The median follow-up time after FDG-PET scanning was 257 days 
(range 27-1813 days). At last follow-up, 25 patients were alive and 13 died as a result of 
melanoma metastases. In the follow-up period, 17 patients developed a recurrence. 
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Patient and melanoma characteristics and comparisons of SUVmax and SUVmean in each 
group are summarized in Table 1. There were no significant differences in SUVmax or 
SUVmean for the different characteristics. For the survival analysis, patients were divided 
into two groups based on the median value of the SUVmax or SUVmean, these groups 
showed no difference in division, the SUVmean was used for further analysis. As shown 
in Figure 1, there was no statistical difference in survival for patients with high or low 
SUVmean (p=0.11). However, as shown in Figure 2, disease-free survival was significantly 
longer for patients with a low SUVmean (p=0.03). 
Univariate survival and disease-free survival analysis for various patient characteristics is 
shown in Table 2 .  The cumulative survival rate was significantly decreased in patients 
Table 1 Standard uptake value (SUVmax and SUVmean) and patient or melanoma characteristics. 
Characteristic Patients Mean p-value Mean p-value 
n SUVmax ±SE SUVmean±SE 
Male 20 6 .2±1 .0 0 .3  5 .4±0.8 0.4 
Female 1 8  8 . 1±1 . 3  6 .7±1 . 1  
Age �58 years 1 8  7.2±1 . 1  0.9 6.0±0.9 0 .9 
Age <58 years 20 7.0±1 . 2  6 .0±1 .0 
Days from primary � 289 19 7.9±1 .0 0 .3 6.7±0.8 0.4 
Days from primary <289 1 9  6 .3±1 . 3  5 .5±1 . 1  
Primary leg 1 8  6 .7±1 . 1  0 .3  5 . 5±0.9 0.3 
Primary a rm 1 6 .8 1 3 .47 
Primary head 3 7. 1 ±1 .4 5.9±1 . 1  
P rimary trunk 1 2  6 . 1±1 . 2  5 .6±1 .0  
Unknown primary 4 9.8±4.8 8.0±3.9 
B reslow thickness �2.4 19 7.6±1 .3  0 .6 6 .3±1 .0 0.7 
Breslow thickness <2.4 1 9  6 .7±1 . 1  5 .8±0.9 
U lceration primary 6 6.7±2.0 0.9 6.6±1 .7 0.7 
No ulceration primary 27 7.0±0.8 5. 8±0.7 
Recurrence 24 7. 5±0.9 0 .5  6 .4±0.7 0.4 
No recurrence 1 4  6 . 5±1 .6 5 .4±1 .4 
Axi l la metastases 1 3  6 . 5±1 .4 0.9 5 .8±1 . 2  0 .9  
I nguinal metastases 20 7.3±1 . 2  6 . 1 ±0.9 
Neck metastases 5 7.8±2.2  6.4±1 .8  
Extranoda l  growth 1 7  7.7±1 . 5  0 .5  6.7±1 .2  0 .4 
No extranodal growth 1 9  6 .5±1 .0 5.4±0.8 
N umber lymph nodes �2 25 7.8±1 . 1  0 .3  6.6±0.9 0 .3  




























Kaplan-Meier survival estimates Figure 1: Kaplan-Meier overall 
survival for patients with a high 
SUVmean or low SUVmean. 
' )  
...... ... . 
! .......................................... ----· · · --·· · · ···-· ···· · -······· · -
2 3 4 5 
Years 
--- Low SUVmean {<=5.2 ) ················· High SUVmean {>5.2) 
....... 
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with the primary melanoma located on the head or an unknown primary (p=0.0005), 
although the numbers are too small to draw conclusions. 
The cumulative disease-free survival rate was significantly decreased for patients who 
received no adjuvant radiation (p=0.03), patients with the primary melanoma located 
on head and unknown primary (p<0.00005), although too small numbers to draw 
conclusions), and patients with a high SUVmean (p=0.03). 
Because of possible interrelation between prognostic factors, multivariate analysis 
was performed. All variables with p<0.2 in the univariate analysis were entered in the 
multivariate analysis. For survival these were localization of the primary melanoma, 
ulceration, localization of the lymph node metastases, extranodal growth and SUVmean. 
For the disease-free survival sex, time from the primary melanoma, localization primary 
melanoma, recurrence or not, extranodal growth, adjuvant radiation and SUVmean. 
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Table 2 Univariate survival analysis. 
Variable No. of Mean survival p-value Mean disease- p-value 
patients ±SE free survival ±SE 
Female 18 984±172 0 .2  830±184 0.09 
Male 20 836±88 462±127 
Age �58 1 8  71 6±168 0 .9 627±1 74 0.7 
Age <58 20 1058±229 61 7±1 50 
Adjuvant rad iation 13 748±1 45 0 .04 
No adjuvant radiation 25 322±136 
Days from primary �289 19  874±226 0 .4  857±1 72 0 .2 
Days from pr imary <289 19  897±208 504±125 
Primary leg 1 8  935±1 79 0 .0005 794±1 81 <0.0001 
Primary arm 1 1 61 56 
Primary head 3 268±74 268±74 
Primary trunk 1 2  11 72±283 606±1 72 
Unknown primary 4 269±83 139±55 
Breslow �2.4 1 9  1 1 73±249 0 .2  624±147 0 .9 
B reslow <2.4 19 61 6±159 606±177 
U lceration primary 6 863±416 0 .2 591 ±265 0 .4 
No ulceration primary 27 1 043±1 86 648±1 46 
Metastases recurrence 24 877±180 0 . 5  857±1 43 0.06 
No recurrence 14 874±236 419±130 
Axi l la metastases 13 965±257 0 .2 498±1 50 0.2 
I nguinal metastases 20 880±174 780±173 
Neck metastases 5 241 ±54 212±74 
Extranodal g rowth 1 7  708±172 0. 1  447±121 0 .2 
No extranodal g rowth 19 1 442±21 8 913±145 
Number lymph nodes �2 25 749±1 76 0.3 489±130 0.3 
Number lymph nodes <2 13 1327±271 857±175 
SUVmean ::;;5 . 24 20 1120±228 0 . 1  790±1 47 0 .03 
SUVmean >5 .24 18 7 1 5±238 377±1 42 
Multivariate Cox regression for survival showed that ulceration of the primary melanoma 
(p=0.023) was an independent predictor of survival. For the disease-free survival, 
mu ltivariate Cox regression showed adjuvant radiation (p=0.001), localization of the 
primary melanoma, although too small numbers to draw conclusions (p=0.017) and a 
high SUVmean (p=0.009) with a hazard ratio of 8.2 as independent prognostic factors. 
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D ISCUSS I ON 
The prediction of disease-free and overall survival of patients with lymph node metastases 
of melanoma is usually based on the number of lymph nodes and extranodal growth. 
However, patients with the same clinicopathological parameters can show differences 
in survival and disease-free rates. Identification of factors predictive of outcome in 
melanoma patients is of potential interest, as it may allow adjuvant radiation therapy 
tailored to the characteristics of individual patients. 
This study showed a difference for the disease-free survival (p=0.03) in patients with 
high or low SUVmean, although a statistical difference for survival was not found in 
these patients with lymph node metastases after surgery with a curative intent. Also 
high SUVmean turned out to be an independent prognostic factor (p=0.009) in the 
multivariate disease-free survival analysis. 
There are no data in the literature concerning the relationship between SUV and survival 
or disease-free survival in melanoma patients. However, in head and neck cancer patients 
treated with radiotherapy SUV was found to have potential value in predicting local 
control and disease-free survival. 29 Similar to the present study, no difference in overall 
survival was found. Consequently, high FDG uptake may be a useful parameter for 
identifying patients who may benefit of adjuvant systemic treatment. In another study of 
143 patients with previously treated head and neck squamous cell carcinoma SUV proved 
to be an independent predictor of relapse-free and overall survival in a multivariate 
proportional hazards model.30 Also, in sarcoma the multivariate analyses showed that 
the SUVmax information is a statistically significant independent predictor of sarcoma 
patient survival and disease progression. 31 One of the few prospective studies showed 
that high uptake of FDG was associated with advanced disease and poor survival in head 
and neck cancer. 32 
Studies in patients with pancreatic cancer, prostate cancer and gastric cancer have shown 
that the SUV is an important prognostic factor.33-36 A systematic review shows good 
evidence that FDG uptake on PET had independent prognostic value in newly diagnosed 
non-small-cell lung cancer.37 Two studies did not observe this prognostic value of SUV. 
In 38 patients with primary non-small cell lung cancer the tumor FDG uptake did not 
independently predict the prognosis. 38 Also, in a study of 40 patients with newly 
diagnosed cancer of the esophagus or gastro-esophageal junction, SUV was not useful 
as an independent predictor of survival.22 
FDG-PET is useful in distinguishing benign from malignant tumors in the diagnosis of 
different cancers. An accelerated rate of glucose transport and an increased rate 
of glycolysis are among the most characteristic biochemical markers of malignant 
transformation.39 FDG is such a glucose analogue that is actively taken up by Glut-1 into 
the cell and phosphorylated by hexokinase during the first step of the glycolytic pathway. 
However, FDG cannot be further processed and becomes trapped within the cell. 
55 
Two meta-analyses reported an overall sensitivity of FDG-PET in detecting melanoma 
of 92% and 79%, with a overall specificity of 90% and 86%.40,41 These overall values 
indicate the potential benefits of using FDG-PET as a diagnostic management tool. 
Furthermore, in a study in 257 melanoma patients, it was found that FDG-PET had the 
highest value in staging patients with loco-regional metastases for detection or exclusion 
of distant metastases; changing surgical treatment in 37% of the patients.42 Predicting 
response to treatment through the measurement of increased glucose metabolism, 
the uptake of FDG, may be of potential value. In the current study we analyzed FDG 
uptake in the lymph node metastases of melanoma patients. Obviously, the impact of 
these findings is limited due to the retrospective design in a limited number of patients. 
However, this study can serve as the basis for a prospective study on the value of SUV 
in the disease-free survival and overall survival of melanoma patients with lymph node 
metastases (stage Ill A . J .C.c .) .  
Despite the advantage of calculating a SUV from a non invasive pre-treatment PET 
study, SUV values are subject to many sources of variability, such as the timing of PET 
acquisition after tracer injection, patient size, RO I definition, partial volume, and image 
recontruction.43-48 Although we realize that there is variation in the scanners (2D, 
3D, partial and full ring scanner), our approach was based on the use of commercially 
available software to prevent different ways of calculating the SUVs in the two centers. 
There is currently no consensus on the optimal methodology for objective quantitative 
measurement of FDG uptake.49 Regarding the SUV, no diagnostic threshold has 
been clearly established for distinguishing uptake in malignant or benign tissues, and 
in cancer cases, no cutoff has been established for defining subgroups of different 
prognosis. Additional prospective studies need to be performed to determine these 
values. Regarding the prognostic value of FDG-PET, the main question concerns the 
possible link between FDG uptake intensity and the other known prognostic indicators. 
Current evidence suggests that intensity of FDG uptake correlates less clearly with tumor 
burden than it does with biological aggressiveness. 50 FDG uptake has been found to be 
associated with cell viability and particularly with cell proliferative activity. 5 1 -53 
In conclusion, disease-free survival in patients with high SUVmean is significantly lower 
than in patients with low SUV. However, this difference is not reflected in differences in 
overall survival. In the multivariate analysis high SUVmean proved to be an independent 
prognostic factor for disease-free survival in melanoma patients with lymph node 
metastases. If the results of this study are confirmed by prospective studies, patient with 
high FDG uptake in lymph node metastases should be considered for adjuvant radiation 
therapy after lymph node dissection. 
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ABSTRACT 
Background. Melanoma patients with lymph node metastases have to deal with 
diagnostic tests to exclude the presence of distant metastases; results of the tests could 
have major implications for their prognosis and treatment. There are, however, few 
studies concerning the patients' psychological issues and perception of diagnostic tests. 
The aim of this study was to describe the burden of diagnostic tests {X-ray, CT and PET) 
experienced by melanoma patients with lymph node metastases. 
Methods. Patients were asked to complete a questionnaire concerning satisfaction 
and burden experienced during the diagnostic tests. The levels of embarrassment, 
discomfort and anxiety for the different tests, as well as total scores for each burden 
were calculated. Logistic regression was used to examine factors associated with the 
degree of experienced burden. 
Results. Fifty-nine of the 68 patients completed the questionnaire: response rate was 
87%. The overall mean scores on satisfaction and Quality of Life were high. More than 
half of the patients experienced no burden during PET, 65% no burden during CT and 
80% no burden during chest X-ray. Patients experienced significantly more discomfort 
during the PET scan than during the CT (p=0.003). Less burden was experienced (in 
univariate analysis) by patients who were more satisfied. 
Conclusions. The overall experienced burden by patients is low and should therefore 
not interfere with primary choice for a diagnostic test based on accuracy, costs and 
percentage of patients upstaged. Attention should be paid to explaining the procedure 
and answering questions of the patients to reduce burden. 
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INTRODUCTION 
The incidence of melanoma is one of the most rapidly increasing types of cancer. 1 The 
incidence in the Netherlands in 2003 was 16.1 per 100.000; a rise of 41% compared to 
1992. Increased awareness and surveillance have resulted in earlier diagnosis of melanoma 
and, consequently, the melanoma patient is now diagnosed at an earlier stage of disease. 2 
Nevertheless, some melanoma patients still present or recur with loco-regional metastases 
(AJCC stage Ill). When no distant metastases are detected, the standard of care for 
these patients is a surgical excision of the primary tumor and a lymph node dissection. 
Several imaging techniques: X-ray of the chest, Computed Tomography (CT), and Positron 
Emission Tomography (PET), are available to detect distant metastases. Defining the 
additional value of these diagnostic tests requires an evaluation of the accuracy, the 
impact on treatment, and the costs of the tests. As the value of PET and spiral CT for 
melanoma patients clinically stage Ill is not clear, a prospective multicenter study in the 
Netherlands was undertaken .  Additionally, burden experienced by the patients could be 
an important feature in defining the value of these diagnostic tests. 
Considering the increased incidence of melanoma there are only a few studies 
concerning the psychological issues and perception of diagnostic tests related to this 
disease, often with contradicting results. Studies have reported that newly diagnosed 
melanoma patients (stage I) exhibited the same psychological distress as other cancer 
patients, despite a good prognosis. 3 .4 However, other studies found that melanoma 
patients do not differ from the general public in terms of emotional well-being and even 
that their psychological functioning was superior to that of other dermatology patients. 5 
Participants with a hereditary risk of melanoma in a melanoma prevention programme 
showed relatively low levels of psychological problems, while participants in public 
screening revealed higher levels of problems.6·7 Considerable gender differences were 
found in this last study; women were more concerned, had higher levels of anxiety, 
tiredness and psychosomatic complaints.7 A delay in diagnostics was also reported to be 
significantly more distressing for females than for males. 8 
Some studies have shown anxiety-related reactions in patients undergoing Magnetic 
Resonance Imaging (MRl).9-1 1  Patients who experience such feelings may disrupt the 
examination or move which may cause a degradation of the images. Anxiety-related 
reactions may also influence patients' perception concerning their care.12 Additionally, 
information about patients' preferences is necessary to be able to assist patients in making 
decisions about which tests to undergo, as patients may prefer an active role in test and 
treatment decision-making.1 3• 1 4  Patients with lymph node metastases have to deal with 
more diagnostic tests to prove or exclude the presence of distant metastases. The results 
of the tests could have major implications for prognosis and treatment. Therefore, the 
aim of this study was to describe and compare the perception, both satisfaction and 
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burden, of the diagnostic tests (chest X-ray, CT and PET) of melanoma patients with 
lymph node metastases. 
PATIENTS AND METHODS 
From September 2004 until November 2006, patients with clinically stage Ill melanoma 
were included in a prospective study to determine the value of PET with the tracer 
FluoroDeoxyGlucose (FOG) and CT. If patients showed no distant metastases on CT and 
PET, they were questioned about different aspects related to the diagnostic tests. They 
received a questionnaire 2 to 6 weeks after lymph node dissection .  
Diagnostic tests 
Some patients had a standard chest X-ray taken before the other diagnostic tests. All 
patients underwent at least a multidetector spiral CT and PET to prove or exclude the 
presence of distant metastases. 
Computed Tomography 
The examination was performed with a multidetector spiral CT with at least four detector 
rows. Patients had to drink 800 ml oral contrast in 4 portions before the CT examination. 
Firstly, a chest CT was performed with intravenous contrast, followed by an abdomen CT. 
If the lymph node metastases were located in the neck, CT of the neck was performed 
with intravenous contrast. Total investigation time is 5-10 minutes. The CT results were 
examined by experienced radiologists. 
Positron Emission Tomography 
After a 6 hours or overnight fasting period, patients were intravenously injected with 
220-650 MBq and prehydrated with 500-1500 ml water. The interval between the FOG 
injection and the PET scan was 60-90 min. When specially indicated, furosemide or bed 
rest was given. Patients were scanned from the midfemoral region until the skull (2D or 
3D acquisitions). Emission scan duration was 5 minutes per bed position, transmission 
imaging 3 minutes. The total duration of the procedure was approximately two and half­
hours including a scan time of approximately 1 hour. 
Questionnaire 
Patients were asked to complete a self-administrated questionnaire. The following 
sociodemographic information was gathered: date of birth, sex, marital status, education 
and occupational status. Eleven questions assessed patients' satisfaction with care and 
with all the diagnostic tests combined. A high score corresponds with high satisfaction 
(see Table 2).1 5  For each diagnostic test (chest X-ray, CT scan and PET scan), the following 
questions were asked: 1) how much embarrassment, 2) discomfort and 3) anxiety did 
you experience during the test, and 4) would you recommend the test to a friend. These 
66 
questions were also used in other studies.1 6-20 Questions concerning the burden had 
to be answered on a five-point scale, with 1 indicating 'none' , 2 'mild', 3 'moderate', 4 
'severe' and 5 indicating 'extreme' and were followed by the question of why patients 
felt that way. Lastly, patients were asked to rank the different diagnostic tests, questions 
were asked about the length of the tests, how they felt about having to travel to the 
hospital on two different days and whether they had come with their partner, family or 
friends. At the end of the questionnaire, we left space for patients' comments. 
The levels of embarrassment, discomfort and anxiety for the different tests, as well 
as total scores for each burden were calculated. Correlation was assessed between 
Qol as scored by the patient, and the preference for decision-maker. Differences in 
embarrassment, discomfort and anxiety during the tests were calculated (Wilcoxon for 
two groups and Friedman test for the three groups). Regression analysis was used to 
examine the factors that affected the degree to which patients experienced burden. 
P-values below 0.05 were considered statistically significant. 
RESU LTS 
Fifty-nine of the 68  patients completed the questionnaire; the response rate was 87%. 
Male and female patients were almost equally represented. The median age of the 
included patients was 58.6 (range 29-85) years. Most of the patients were married (69%) 
or cohabiting and almost half had finished middle/higher secondary or middle vocational 
school. Almost a third of the patients had a full-time job or was retired (Table 1 ). 
Table 1: Demographic characteristics of the patients. 
Characteristic N % 
Gender Male 33 55 .9  
Female 26 44.1  
Age ::,;45 years 1 5  25 .4  
46-64 years 29 49. 2 
2::65 years 1 5  25 .4  
Marital status Married 40 69. 0  
No relationship, l iving alone 9 1 5 . 5  
Relationship, l iving a lone 3 5 . 2  
Divorced o r  widower 6 1 1 . 3 
Highest education Primary school / Lower vocational school 20 33 .9  
Midd le/higher secondary or middle vocational school 28 47. 5 
H igher vocational school/University 1 1  1 8 .6  
Occupation Ful l-time job 1 8  30 .5  
Part-time job 1 1  1 8 .7  
Housekeeping 7 1 1 .9 
Retired 1 7  28 . 8  
Unable to work 6 1 0 . 2  
67 
The overall scores on satisfaction and Qol were high (Table 2). Satisfaction with the 
amount of information that was given to the patients received the highest score. Second 
was satisfaction concerning the doctors' willingness and patience to answer questions. 
Patients were highly satisfied if they felt that all their questions were answered and the 
procedure and reason for the test were explained. A mean score of 4.4 was reported 
concerning the satisfaction of patients with the amount of time and attention given to 
them and the satisfaction concerning the support given. Patients were also satisfied with 
the weight that was given to their opinion in the decision making. The mean score for 
the satisfaction with quickness of help was also relatively high. The lowest score was 
in the satisfaction with the amount of space patients were given to make their own 
decisions. A high mean score was reported for patients' satisfaction with the amount 
of information they received about their medical situation. The overall mean satisfaction 
with the course of the diagnostic tests was 8.0. 
Table 2: Reported scores concerning the satisfaction of the patients, qua lity of life and preference for 
decision-maker (part 2 of the questionnaire). 
Satisfaction of patients (possible range 0-5) Mean±st.dev 
Amount of i nformation g iven 
Wi l l ingness and patience of doctors in  answering your questions 
Answers to a l l  your questions 
Explanation of the procedure and the reason for the test 
Time and attention g iven to you 
The support g iven 
The weig ht of your own opinion in decisions 
Quick he lp 
To make own decisions 
Satisfaction of patients (possible range 0-10) 
The amount of medical i nformation you wou ld l i ke to have 
Overal l  satisfaction with d iagnostic tests 
Quality of life 
How would you judge your  qual ity of life? 
Decision-maker 






4.4±1 . 1  
4.3±0.6 
4 . 1±1 . 2  
3 . 5±0.8 
Mean±st.dev 
8 .9±1 .6  
8 .0±1 .6 
7. 5±1 . 5  
On ly  the doctor:  3 (5 . 1 %) 
Predominantly the doctor:  
12 (20.3%) 
The doctor and patient equal ly :  
39  (66 . 1%) 
Predominately the patient: 
5 (8. 5%) 
On ly the patient: 0 
Most patients thought the decisions about their treatment had to be made by the 
doctor and the patient collaboratively, 20% preferred the doctor to be the predominant 
decision-maker, 9% preferred the patient to be the predominant decision-maker and only 
a few patients preferred the doctor to be the sole decision-maker. The mean quality of 
life was 7.5; four patients judged their quality of life lower than 6. In this study, there 
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was a significant correlation between the reported Qol and the preference for decision­
maker: the larger the doctor's role in making the decision, the higher the patient's Qol 
(r=-0. 38; p=0.004). Additionally, older age was associated with preference for the doctor 
to make the decision (p=0.01). 
Table 3 shows the amount of embarrassment, discomfort or anxiety patients felt during 
the diagnostic tests. Of the forty patients who had a chest X-ray, 35 (87.5%) felt no 
embarrassment. Five patients (12.5%) felt mild to extreme embarrassed: two for having 
to be nude from the waist up, two because they were not sure what to do and one 
patient was anxious about the test results during the chest X-ray. No discomfort during 
the chest X-ray was reported by 36 patients (90%). Four patients (10%) felt mild to 
moderate discomfort during the chest X-ray; reasons that were mentioned were having 
to hold their breath for a longer time, being cold, feeling nervous or pain in the shoulder. 
Thirty-two patients (80%) reported no anxiety during the chest X-Ray. Eight patients 
(20%) reported anxiety about the results of the chest X-ray. 
No embarrassment during the CT scan was reported by 38 patients (65.5%). However, 
20 patients were mild to extreme embarrassed during the CT scan, mainly because they 
did not know what to do and they had trouble lying still. Discomfort during the CT scan 
was not reported by 38 patients (65.5%). Twenty patients experienced discomfort during 
the CT scan; again a larger percentage found it difficult to lay still and others felt cold. 
Forty patients (69%) experienced no anxiety during the CT scan; 18 (31%) experienced 
some kind of anxiety because they were anxious about the results or claustrophobic 
(extreme anxiety). 
Table 3: Number of patients who felt none to extreme embarrassment, discomfort and anxiety during the 
chest X-ray, PET scan and CT scan 
X-Ray N(%) CT N(%) FDG-PET N(%) 
Embarrassment None 35  (87. 5) 38 (65 .5) 36 (61 .0) 
Mild 3 (7. 5) 14 (24.1 ) 1 5  (25 .4) 
Moderate 1 (2. 5) 3 (5 .2) 4 (6 .8) 
Severe 1 (2. 5) 1 ( 1 .7) 2 (3 .4) 
Extreme 2 (3 .5)  2 (3 .4) 
Discomfort None 36 (90 .0) 38 (65.5) 25 (42.4) 
M ild 3 (7. 5) 18 (3 1 .0) 27 (45 .8) 
Moderate 1 (2. 5) 5 (5 .8) 
Severe 1 ( 1 .7) 
Extreme 1 ( 1 .8) 2 (3.4) 
Anxiety None 32 (80.0) 40 (69.0) 38 (64.4) 
Mi ld 3 (7. 5) 1 1  ( 1 9.0) 1 1  ( 18 .6) 
Moderate 3 (7. 5) 4 (6.9) 5 (8 . 5) 
Severe 2 (5 .0) 1 ( 1 .7) 4 (6.8) 
Extreme 2 (3.4) 1 ( 1 .7) 
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No embarrassment during the PET scan was reported by 36 patients (61%). Twenty­
three patients (39%) were embarrassed during the PET scan, mainly because they did 
not know what to do or they had trouble lying still. Discomfort during the PET scan was 
not reported by 25 patients (42.2%). However, 34 patients (58%) reported discomfort 
(trouble lying still, feeling cold and discomfort from having a full bladder). Thirty-eight 
patients (64.4%) felt no anxiety during the PET scan. Twenty-one patients (35%) were 
anxious during the PET scan; patients were anxious about the test results and felt 
claustrophobic. 
Overall, more than half of the patients experienced no burden during the PET scan, 
more than 65% of the patients experienced no burden during the CT and more than 
80% experienced no burden during the chest X-ray. Patients who experienced anxiety 
during one of the diagnostic tests, experienced anxiety during all tests (correlation 
CT and PET p<0.001; CT and X-ray p=0.0006; PET and X-ray p=0.003). Patients who 
experienced discomfort during the PET scan experienced discomfort during the CT scan 
(p=0.001). Additionally, patients who experienced embarrassment during the CT also felt 
embarrassed during the PET (p<0.0001) and X-ray (p=0.01). 
Patients experienced significantly more discomfort during the PET scan than during the CT 
scan (p= 0.003). Despite this burden, all patients indicated that they would recommend 
the tests to a friend if they were advised to go for one. Less burden was experienced 
by patients who felt satisfied that the procedure was explained (p<0.001), doctors 
were willing and patience (p=0.002), questions were answered (p=0.011), attention 
was given (p=0.006), enough support was given (p=0.001 ), and that enough medical 
information was given (p=0.018). Additionally, patients who were more overall satisfied 
(p=0.006) and patients who reported a higher Qol (p=0.002) also reported less burden 
in univariate analysis. Age (p=0.22), sex (p=0.07), marital status (p=0.83) and education 
(p=0.67) were not statistically significant associated with burden. In addition, time from 
lymph node dissection to filling in the questionnaire was not associated with the burden 
experienced (p=0.168). In multivariate analysis, none of the variables was significantly 
associated with burden. 
Most patients ranked the PET scan as most inconvenient, 25% thought there was no 
difference in inconvenience between the diagnostic tests. The length of the PET scan 
was experienced as rather long or very long by 51.7% of the patients, the CT scan by 
2 patients. The fact that the tests could not be performed in one day was no problem 
to 48% of the patients, a small problem to 36% and 9 patients reported it being very 
unpleasant. Having to travel to the hospital was no problem for 56% of the patients, a 
small problem for 37% and very unpleasant for 7%. Only three patients came to the test 
alone, the remaining came with their spouse (61 .4%), with family members (26.3%), or 
with spouse and family members or a friend (7.0%). 
70 
DISCUSSION 
In the last 15 years, quality of life has been identified as an important outcome for 
cancer patients. The amount of emotional distress the patient experiences is an 
important component of that quality of life.2 1  The psychosocial demands that confront 
cancer patients vary over the course of the illness, however, the time of diagnosis is 
described as particularly distressing.22-24 Additionally, younger cancer patients face more 
difficulties when they receive a cancer diagnosis than older patients. 25 As the incidence 
of melanoma continues to increase and the age at which it is diagnosed continues to 
decrease, more and younger patients will be referred to the oncology clinics. 26 
In the present study, more than half of the patients experienced no burden during the 
PET, more than 65% no burden during the CT and more than 80% no burden during 
the chest X-ray. Patients experienced significantly more discomfort during the PET scan 
compared to the CT scan (p=0.003). Patients who were more satisfied, experienced less 
burden during the diagnostic tests (univariate analysis). 
Patients in this study were very satisfied with various aspects concerning the diagnostic 
tests. Patients seem to be the most satisfied with the amount of information that was 
provided to them, the willingness and patience of the doctors to answer questions. A 
high score was reported when patients were satisfied with how quickly they were helped, 
despite the fact that a few patients mentioned that the time between the diagnostic 
tests and the operation was long. Patients were least satisfied with the amount of space 
that was given to them to make their own decisions. Mainly patients who scored low 
on this question felt that the doctor and patient had to make the decisions together. 
Additionally, we found a significant correlation between quality of life and decision­
maker: patients who left the decision entirely to the doctor or predominantly to the 
doctor reported a higher quality of life in the present study. 
Several studies have been performed to evaluate anxiety-related reactions associated 
with Magnetic Resonance Imaging (MRl).27-29 A Canadian review reported that anxiety­
related reactions occur in approximately 4% to 30% of the patients undergoing MRI, 
ranging from apprehension to severe reactions that interfered with the performance of 
the test. 3° Criteria for diagnosis and categorization of the reactions and identification of 
patients at risk are scarce, although management strategies such as patient education, 
drug therapy, and cognitive-behavioral intervention have been proposed. 31 A recent 
prospective study in patients at risk for colorectal cancer showed that patients preferred 
CT colonography above colonoscopy. However, this preference decreased over time, and 
outcome considerations gradually replaced temporary experiences of inconvenience. 3 2  
I t  is likely that future decisions will be based on the final opinion, since this opinion is  
formed after immediate experiences have tempered and when patients have returned to 
normal functioning. The authors assumed that experience and preference are preferably 
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measured after a certain time, as this may better reflect future behavior than if experience 
and preference are measured under stressful circumstances.33 In the present study, we 
chose a 2 to 6 week interval after surgery and found no association between time since 
operation to questionnaire and burden. However, it remains unknown when opinions 
change and which interval should be used to optimally measure patient preference. 
In the present study, most of the patients experienced discomfort, particularly during the 
PET scan. This is probably due to the fact that patients have to lay still for a longer period 
of time as during a CT scan. Future PET-CT scanners could correct this discomfort as they 
can scan a patient in less than 30 minutes, or even in 10 minutes if more FOG is injected . 
Furthermore, patients who felt they were not sufficiently informed about the procedure 
or were colt felt embarrassed and discomfort; burdens that probably could be avoided. 
Several limitations to the study should be noted. First, it is not possible to determine 
whether the non-responders were less satisfied or experienced more burdens from the 
diagnostic tests. Second, the questionnaires were only sent to a relatively small sample 
of patients who showed no distant metastases on PET and CT scans. It could be that 
patients who had distant metastases experienced more burden from the diagnostic tests; 
future studies should compare these two groups. However, to our knowledge this is the 
first study to investigate the patients' perceptions of the diagnostic tests FOG-PET, CT 
and chest X-ray, and, therefore, the results could be of great interest. The findings can 
not be representative for all melanoma patients, but they do highlight salient issues in an 
area where research has been lacking. 
In conclusion, although patients experience more discomfort during the PET scan, the 
overall levels of moderate to extreme embarrassment, discomfort and anxiety were low. 
The accuracy, costs and percentage of patients upstaged will probably be the most 
important outcomes to determine the additional value of FOG-PET and CT, but it is 
reassuring to know that the overall burden of these diagnostic tests is low. 
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ABSTRACT 
Purpose. Melanoma patients with potentially resectable lymph node metastases require 
accurate staging to prevent unnecessary surgery. FOG-PET is attractive for this since 
melanoma typically is FOG avid. The aim of this prospective multicenter study was to 
perform a head-to-head comparison of FOG-PET and CT in staging of melanoma patients 
with palpable lymph node metastases in terms of diagnostic accuracy and impact on 
treatment. 
Patients and Methods. All consecutive patients with palpable, proven lymph node 
metastases of melanoma between mid 2003 and 2007 were prospectively included. 
The number/site of distant metastases detected with FOG-PET and CT were recorded. 
Histology/cytology or 6 months follow-up were the reference standard. Intended and 
performed treatment was recorded. 
Results. In 32% of the 251 patients distant metastases were suspected by FOG-PET, 29% 
by CT (p=0.26) . In 27% upstaging was correct by FOG-PET and 24% with CT (p=0.18). 
FOG-PET detected more metastatic sites (133 vs. 112, p=0.03), significantly more bone 
and subcutaneous metastases. Treatment changed in 19% of patients; in 79% as result 
of both scans, 17% exclusively FOG-PET and 4% exclusively CT. In 34 patients (14%) 
FOG-PET had an additional value over spiral CT and in 23 patients (9%) CT had additional 
value over FOG-PET. 
Conclusion. As a result of FOG-PET and CT 27% of patients were upstaged and treatment 
changed in 1 out of 5 patients. FOG-PET and CT are equivalent in upstaging, however 
FOG-PET detected more metastatic sites, especially bone and subcutaneous. FOG-PET 




Melanoma causes more than 75% of all deaths related to skin cancer, and its incidence 
dramatically increased in Caucasian populations. 1 Predictions of melanoma incidence 
show an increase of 99% by 2015. 2 In patients with loco-regional metastases, the 
major objective in treatment planning is the earliest possible detection of metastases. 1 
However, melanoma has the well-known feature to spread to unusual sites and multiple 
distant metastases are usually contraindication for surgery. 3A Consequently, accurate 
staging is extremely important for clinical decision making to identify those patients who 
may benefit from surgery while avoiding unnecessary, potentially harmful surgery that 
does not improve survival.4·5 Furthermore, accurate staging is important to properly 
select patients for trials and patient counselling on prognosis. 5 Additionally, FDG-PET 
could be able to detect more metastases, which could be important if metastasectomy 
is considered. 
The diagnostic accuracy of imaging tools depends on the method of examination, 
technique, organ and size of the tumor.6 The primary strength of CT is its delineation 
of anatomic detail, however recent interest has focused on the usefulness of FDG­
PET.1 ,4 Melanomas typically are quite FDG-avid; and together with the erratic pattern 
of spread, the disease is candidate for screening distant metastases in high risk patients 
with whole body FDG-PET. Studies suggest that FDG-PET may indeed be more accurate 
to detect melanoma metastases, particularly in patients with regional spread (American 
Joint Committee on Cancer (AJCC) stage 111).4.7- 1 2  Whole-body PET does not provide 
the same degree of anatomical detail as CT or MRI, nevertheless its advantages include 
evaluation of the entire body, increased ability compared to conventional imaging to 
detect malignant tumours as result of an increased glucose metabolism and absence 
of CT contrast-related problems.7· 13-1 5 Furthermore, the level of FDG avidity may add a 
biological, potentially prognostic relevant dimension to this test result.1 6  Limitations of 
FDG-PET comprise its relative insensitivity to detect brain metastases and metastases �5 
mm as well as its reduced availability compared to CT.4•8 •9• 13 
Since patients with loco-regional metastases are at a clearly higher risk for systemic 
disease than patients with lower disease stages, imaging studies especially for this 
group are warranted.1 7 So far, most studies reported accuracies of FDG-PET for all 
stages of melanoma but do not comment on the ability of FDG-PET scanning to identify 
unsuspected disease or to change clinical management in especially stage Ill melanoma 
patients. 1 2  The aim of the present prospective multicenter study was to perform a head­
to-head comparison of FDG-PET and CT in the staging of melanoma patients with 
palpable lymph node metastases (AJCC stage Ill) in terms of diagnostic accuracy and 




All consecutive patients with palpable, histology or cytology proven lymph node 
metastases (not sentinel node staged) of melanoma referred to participating hospitals 
(July 2003-December 2007) for examination with FOG-PET were prospectively included 
in this study. Participating hospitals were University Medical Centre Groningen, Radboud 
University Nijmegen Medical Centre, VU University Medical Centre Amsterdam, St. 
Antonius Hospital Nieuwegein and Meander Medical Centre Amersfoort. All patients 
were considered candidates for regional lymph node dissection. Patients had to be at 
least 1 8  years and provide written informed consent. Exclusion criteria were patients 
with impalpable, tumour positive sentinel nodes; distant metastases on chest X-ray, 
diabetes mellitus or claustrophobia, and pregnant or lactating women. If patients were 
sentinel node staged at the time of the primary melanoma (only those patients in the 
latter period) sentinel node had been, consequently, always negative for the patients 
included in this study. The study was approved by the Medical Ethical Committees of all 
participating hospitals. 
PET protocol 
FOG-PET and CT were performed in random order. In Groningen, FOG was synthesized on 
site. 1 8  In all other hospitals, FOG was obtained from Covidien, Petten, The Netherlands. 
Prior to FOG-PET, patients were instructed to fast for at least 6 hours, and drink one litre 
of water. After intravenous injection of FOG (range 220-690 MBq), whole-body imaging 
was performed: two/three dimensional mode, emission scans 5 minutes/bed position, 
starting 60-90 minutes after injection FOG. Patients were usually scanned from head to 
feet. In Groningen, Amsterdam, Nijmegen (before 2005), a Siemens ECAT EXACT HR+ 
scanner (Siemens/CTI Inc., Knoxville, TN) was used and in Nieuwegein a Philips Allegro 
PET system (Philips Medical Systems, Eindhoven, the Netherlands) was used. In Nijmegen, 
after 2005, the FOG-PET in the combined PET/CT scanner (Siemens Biograph) was used 
(13 patients). In these 13 patients only the FOG-PET was considered, without the use of 
CT images (CT scan performed in referring hospital). In Amersfoort, a mobile scanner 
was used (Accel with LSO crystals, Siemens Medical Solutions Inc., Hoffman IL ,  USA). All 
image reconstructions were iterative (OSEM) with 8-16 subsets and 2-4 iterations; both 
attenuation corrected and non-corrected images were used. FOG-PET readings were 
performed by attending staff nuclear medicine physicians (blinded for results of CT). 
CT protocol 
Multi-slice CT neck, chest and abdomen was done with oral (800 ml) and intravenous 
administration of contrast agents using standard imaging protocols. Each patient 
underwent chest and abdominal CT scans. If presenting lymph node metastases were 
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located in the neck, a cervical CT was also performed. Image acquisitions were performed 
with multidetector spiral CT scanners with at least 4 detectors using standard protocols. 
Images were transported to a PACS system or computer display to be interpreted 
by the attending staff (blinded for results of FDG-PET). After FDG-PET and CT were 
performed, results of both scans were compared and patients underwent a regional 
lymph node dissection if both modalities were negative for distant metastases. If one 
or both were positive an attempt was undertaken to confirm the lesion (cytopathology, 
histopathology, other diagnostic modalities (bone scan, MRI) or at least 6 months follow­
up) and appropriate individualized treatment was administered after discussing the 
patient in the multidisciplinary oncology meeting. 
Data analysis 
The localisation and number of lesions suspect for distant metastases was noted and an 
attempt was made to confirm the lesion . .  The treatment plan was recorded and compared 
with intended treatment (lymph node dissection with curative intent). FDG-PET and CT 
scans were assessed by experienced local observers and recorded as positive or negative. 
If regional lymph node metastases were found other than the known lymph node 
metastases (e.g. lymph node metastases left axilla in a patient with known metastases 
right axilla) the scan was scored as "negative" for distant metastases, however a change 
in treatment was recorded (additional lymph node dissection). Lymph nodes beyond the 
regional lymph nodes {M1a) were scored as "positive". Upstaging was defined as change 
in stage from Ill to IV. Patients in whom the upstaging was correct were classified as 
"true upstaging". For statistical analysis the McNemar test for paired groups and the 
paired t-test were used.1 9  To compare false positive rates between hospitals, Fisher's 
exact test was used. Analysis concerning number of metastatic sites was based on 
presence of metastatic spread in each given organ, irrespective of the actual number of 
metastatic foci; the analysis True-Positive (TP), True-Negative {TN), False-Positive (FP) or 
False-Negative {FN) was patient-based. 
RESU LTS 
Patients 
Overall, 251 patients were included: 136 University Medical Centre Groningen, 42 Radboud 
University Nijmegen Medical Centre, 38 VU University Medical Centre Amsterdam, 24 
Antonius Hospital Nieuwegein and 11 Meander Medical Centre Amersfoort. Table 1 
shows the characteristics. 
79 
Table 1: Patient characteristics of the 2 5 1  patients. 
Characteristic Number Percentage 
Gender Male 1 52 60.6 
Female 99 39.4 
Agecategory <50 years 76 30 .3  
50-65 years 99 39.4 
>65 years 76 30 .3  
Localization Head & neck 29 1 1 .6 
Upper extremities 26 1 0 .4 
Trunk 93 37.0 
Lower extremities 88 35 .0 
Unknown primary 1 5  6 .0 
Clark level 1/ 1 1/ 1 1 1  84 33 .5  
IV/V 1 44 57.4 
Unknown primary 1 5  5 .9  
M issing* 8 3 .2  
Breslow thickness �1 .0 32 1 2 .8  
1 .0-2 .0  73  29.1  
�2.0 1 29 51 .4 
Unknown primary 1 5  5 .9 
Missing* 2 0 .8 
Ulceration Yes 53 2 1 . 1  
No  1 83 72 .9 
Unknown primary 1 5  6 .0  
Diagnosis lymph node metastases Synchronous 39 1 5 . 5  
Metachronous � 3  years 145 57.8 
Metachronous > 3 years 67 26.7 
Localization Neck 43 1 7. 1  
Axil la 94 37. 5  
I nguinal 1 14 45.4 
*8 patients missi ng: fol l icular structure, more than 1 3  years between pr imary and lymph nodes (3 patients, 
one a lso no Breslow thickness), incidence abroad (also no Breslow thickness), m�cosal melanoma (2 
patients) and primary melanoma was treated as benign lesion .  
Upstaging 
The median time interval between FDG-PET and CT was 5 days. In 32%(95%CI 26-37) 
the FDG-PET reading was positive for distant metastases, in 29%(95%CI 23-34) CT 
reading was positive (p=0. 262; Table 2). After correlation with cytology/histology and/ 
or six months follow-up, the scans results proved to be correct ("true upstaging")  in 
68/251 FDG-PET scans (27%(95%Cl22-33); 86% of FDG-PET positive patients) and in 
61/251 CT scans (24%(95%Cl19-30); 85% of CT positive patients; p=0.18). False positive 
rates for FDG-PET and CT were not statistically different between hospitals (p=0.1 3  and 
p=0.71, respectively). T he presenting lymph node metastases were identified at FDG-PET 
in 229/251 (91%) and CT in 231/251 (92%). Lymph node metastases not visualized by 
FDG-PET were statistically smaller than FDG-PET positive ones (mean size 3.6 (95%CI :  
3.3-3.9) cm versus 2 .4 (95%CI: 0.9-3.8) cm; p=0.03). In 11/251 (4.4%) patients lymph 
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Table 2: Number of patients upstaged with FDG-PET and CT and number of patients where the 
upstaging was correct based on pathology or follow-up. 
FDG-PET CT 
Patients upstaging 79 (32%) 72 (29%) p=0.26 
Patients true upstaging 68 (27%) 61 (24%) p=0.18 
Within the group of patients true upstaged 
Patients with solitary distant metastases 40 (59%) 37 (61%) p=0.58 
Patients with multiple distant metastases 28 (41%) 24 (39%) p=0.29 
Table 3: Number of distant metastatic sites detected with FDG-PET and CT with p-value for the d ifferences 
between the number of metastases detected. *one-sided test 
Region FDG-PET upstaging CT upstaging p-value 
Metastases True-Positive Metastases True-Positive 
Liver 21 19 22 20 0 .81 
Lung 38 33 46 41 0 .16 
Abdomen 20 15 18 1 3  0 .62 
Bone 27 26 10 10 <0.0001 
Subcutaneous 11 11 5 5 0 .03 
Other 16 16 11 11 0 .11 
Overall number of metastases* 133 112 0 .03 
120 100 0 .03 
node metastases were detected neither by CT nor FDG-PET. Overall, FDG-PET identified 
133 metastatic sites compared to 112 with CT (p=0.03) of which 120 TP with FDG-PET 
versus 1 00 TP with CT (p=0.03; Table 3). FDG-PET and CT had similar performance 
for detection of liver, lung and abdominal metastases (p=0.81, p=0.16 and p=0.62, 
respectively). However, FDG-PET detected significantly more bone metastases (27 sites) 
as compared to CT (10 sites, p<0.0001) and more subcutaneous metastases (p=0.03). 
Differences and similarities between PET and CT results 
With a median follow-up of 13.7 months most scans (n=155) were true-negative (TN) for 
distant metastases (Table 4). In 6 patients CT was false-positive with TN FDG-PET: 3 lung 
and 2 abdominal lesions could not be confirmed to be metastases and a suspected liver 
metastasis proved to be a haemangioma. In 68 patients FDG-PET was true-positive (TP), 
in 51 of them CT was also TP. In 10 patients FDG-PET scan proved to be false-negative 
comprising lung (n=S, confirmed during follow-up), liver (n=2), combined lung and 
abdominal metastases (n=2) and abdominal lymph node metastases (n=1). In 7 patients 
FDG-PET was FP with TN CT: suspected liver and lung metastases were not confirmed 
in follow-up, a single lung lesion was benign and a suspected metastasis in the ovary 
proved to be a cyst. Finally, in 4 patients FDG-PET and CT were FP for distant metastases: 
lung lesions and abdominal abnormalities remained unconfirmed during follow-up; in 1 
of these 4 patients the lesion was a verruca. 
8 1  
Table 4: Concordance and d isconcordance between FDG-PET and CT in the detection of distant metastases 
in melanoma patients with lymph node metastases. 
PET True-Negative 1 55 
PET True-Positive O 
PET False-Negative O 




1 0  
Lung (5) *( 1 )  
Liver (2) *(1 ) 
Lung and abdominal (2) 
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Sternal ( 1 )  




PET False-Positive 7 0 0 4 




Ovary ( 1 )  
Change in treatment 
As shown in Table 5, based on imaging and verification procedures, treatment plans 
were changed in 48 patients (1 9%; 9 5%Cl 1 4-24). In 36 patients (75%) from surgery 
to chemotherapy, 9 surg ical treatment changed, 1 received rad iotherapy and 2 refused 
further treatment. In all patients metastases were confi rmed in follow-up or other 
d iagnostic modal ities. In 79% of these 48 patients treatment changed as result of both 
scans,  1 7% exclusively FDG-PET and 4% solely CT. As a lso shown in  Table 5, FDG-PET 
had a n  added cl in ical va lue  over CT in 34/251  patients ( 14%;95%Cl9-1 8)); in 6 patients 
CT was fa lse-positive for d istant metastases and in 1 6  patients FDG-PET detected 
d istant metastases not seen on CT. In 1 2  patients (5%) with d istant metastases (seen 
on both FDG-PET and CT), FDG-PET dep icted more metastatic sites than CT. S ing le 
d istant metastasis were depicted in  42% and mu ltiple distant metastases in 46%. On 
the contrary, CT had an add itional va lue  over FDG-PET in 23  patients (9%; 95%Cl6-1 3); 
in 1 0  patients CT was TP, in  7 patients CT was TN and in 6 patients CT showed more 
metastatic sites. 
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Table 5: Change in intended treatment to performed treatment based on the results of the FDG-PET and CT 
scan and details of the lymph node dissection 
Change in treatment Patients (%) 
No change in treatment 203 (81%) 
Change in treatment 48 (19%) 
Change based on FDG-PET and/or CT 
FDG-PET and CT 38 (79%) 
Exclusively PET 8 ( 17%) 
Exclusively CT 2 (4%) 
Additional value FDG-PET 34 (14%) 
CT M1 and PET MO 6 (2%) 
CT MO and PET M1 16 (6%) 
More metastatic sites 12 (5%) 
Additional value CT 23 (9%) 
CT M1 and PET MO 10 (4%) 
CT MO and PET M1 7 (3%) 
More metastatic sites 6 (2%) 
Details 
Neck lymph node d issection 33 (16%), axilla 74 
(37%), groin 91 (45%), no d issection 5 (3%)* 
Removed nodes: median 14 (1 -48), Nodes 
positive: median 2 (1-24) 
Size (cm): median 3.0 (0-13.0) 
Extranodal growth: yes 23%, no 69%, 
unknown 8% 
Chemotherapy 36 (75%) 
Alteration in surgical treatment 9 (19%) 
No treatment or radiotherapy 3 (6%) 
PET TN & CT FP 
PETTP  & CT FN 
PET>CT & CT;t: 0 
CTTP & PET FN 
CT TN & PET FP  
CT>PET & PET;t: 0 
* Patients with no lymph node dissection: patient died before lymph node dissection, lymph node not 
found on PET or CT or patient refused. 
Besides the 48 patients (19%) in whom treatment changed as decribed above; there were 
203 patients (81%) in whom treatment did not change. In these patients single distant 
metastasis were depicted in 15% and multiple distant metastases in 3% (no metastases in 
82%). In 152/203 (75%) neither FDG-PET nor CT showed distant metastases. In 32/203 
patients (16%) planned lymph node dissection was performed although FDG-PET or CT 
led to upstaging. In the remaining 19/203 (9%) distant metastases were depicted with 
FDG-PET and CT, while patients still received a lymph node dissection; in 4 of these 19 
patients the scans turned out to be FP. 
DISCUSSION 
The sensitivity of FDG-PET for detection of melanoma metastases has been reported 
extensively, however most studies were retrospective and only a single study studied 
exclusively stage Ill. Besides, none have compared FDG-PET to multidetector CT in a 
large prospective cohort. Additionally, there are currently no standardized or universally 
agreed guidelines for imaging modalities in stage Ill melanoma patients. In the present 
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prospective multicenter study 27% of the melanoma patients with palpable lymph node 
metastases were upstaged to stage IV as result of the FDG-PET and 24% as result of 
the CT. Overall, FDG-PET depicted more metastatic sites than CT (p=0.03). In 1 out of 5 
patients treatment changed. In 34 patients (14%) FDG-PET had additional value over CT 
and in 23 (9%) CT had additional value over FDG-PET. 
Accurate staging of melanoma patients with palpable lymph node metastases is 
important to select for appropriate treatment; this requires highly accurate, preferable 
whole-body imaging tests. Tests should have a low number of false-negatives and be 
able to detect metastases at an early stage.6 However, high specificity, good tolerance, 
low costs and availability are also important.6 In the present study, CT had more false­
negative results (n=17) than PET (n=11 ). In 8% the known lymph node metastases were 
not identified suggesting that the melanoma was not FDG avid or metastases were too 
small to detect. 
Previous studies have shown that FDG-PET is most useful in stage Ill melanoma patients. 
Three studies assessed CT scan in patients with loco-regional metastasis: unexpected 
metastatic disease was found in 7%, 8% and 16%.20-22 However, the same studies 
reported false-positives in respectively 22%, 8% and 12%. In the present study a 
higher percentage of unexpected metastatic disease was found, probably as result of 
the technical development which has improved sensitivity. The number of true-positives 
(n=61) exceeded the number of false-positives (n=11 ). Sensitivity (TP/(T P+FN)*100%) to 
detect distant metastases for the CT scan was 78% (95%CI 69-87) and PET scan 86% 
(95%CI 78-94). To our knowledge only two studies have compared FDG-PET and CT in 
all stages of melanoma patients (none in exclusively stage Ill) ; both found FDG-PET to 
be superior in sensitivity and specificity.4· 1 3  Direct comparison of 53 patients showed an 
increased percentage of metastases detected with PET (81 %) versus CT (57%), but did 
not specify the results for stage 1 1 1  patients.1 3 The prospective study of Holder et al found 
a higher sensitivity and comparable specificity compared to CT, but again analysis did 
not specify for stage 1 1 1 .4 Tyler et al reported the only study that assessed the value of 
FDG-PET in only stage 1 1 1  melanoma patients; results showed a change in management 
in 15% of the 95  patients.1 2  The authors concluded that (as in the present study) the 
identification of metastatic disease did not always change the clinical management. In 
our study 27% of the patients were upstaged correctly and in 19% treatment did change. 
The number of liver metastases detected by FDG-PET and CT was similar and both 
had the same number of FP (n=2). CT did detect more lung metastases (although not 
significant), which is known from the literature. The superiority of CT to FDG-PET in 
detecting pulmonary involvement was not as high as reported in other studies. The 
number of abdominal metastases was also similar, although 5 metastases detected with 
CT were false-positive. The number of bone and subcutaneous metastases depicted with 
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FDG-PET was significantly more than CT. In none of the patients therapy did change 
as result of solely subcutaneous lesions. Ultrasound could be a good option to depict 
these subcutaneous lesions; however one would have to do an ultrasound survey of 
the entire body. On the other hand, ultrasound is an excellent technique to confirm 
subcutaneous FDG avid foci. Several bone metastases were seen in a second reading 
of CT, suggesting that bone structures were not routinely evaluated (enough) with CT. 
Overall, FDG-PET did detect statistically significant more metastases (p=0.03). This could 
be important in determining appropriate treatment; although there is no consensus, 
many surgeons pursue surgical excision of metastatic disease if only a few sites of disease 
are apparent. 23, 24 Resection of all metastatic sites, when possible, might effect survival 
in patients who have no evidence of disease after metastasectomy. Even 5-year survival 
rates of 40% might be achieved. 24 
Based on the results we recommend FDG-PET for clinical stage 111 melanoma patients; 
if distant metastases are suggested and surgery is considered, a complementary CT is 
indicated. When no metastases are detected with PET, an additional CT is not indicated. 
If PET or PET/CT is not available (for example, in the Netherlands 25% of the hospitals 
has a PET or PET/CT), multidetector CT is a good alternative. However, if metastasectomy 
is planned a complementary FDG-PET is preferred to exclude the presence of more 
metastases. The costs in the Netherlands for a "whole-body" FDG-PET scan is 1171 Euro 
as compared to 409 Euro for the chest CT and abdominal CT combined (Dutch Healthcare 
Insurance Board 2003). The results of most published FDG-PET studies are limited by 
pretest selection or posttest evaluation bias.1 3  In this prospective study we avoided this 
bias and also compared FDG-PET with CT. The recent introduction of combined PET/CT 
scanners obtains both anatomical and functional imaging in a single scanning session. 
2 3 A recent study showed a better diagnostic performance of PET/CT in the N- and 
M-staging; another study showed improvement in sensitivity, but not specificity. 25• 26 The 
benefit is not as great as for other tumours, which may be due to the high avidity of 
melanoma for FDG.2 5 However, the PET/CT scanner is not available in all hospitals and 
cost-effectiveness has to be studied. 
Our study allows exploration of three scenarios: 1. all patients undergo staging with 
a combined PET-CT scanner; then, 24% (61/251) would undergo an unnecessary PET 
scan (distant metastases showed with CT). In scenario 2 where patients would only 
receive a CT, distant metastases would be missed 16/251 (6%) and in 12/251 (5%) more 
metastases would be detected with FDG-PET. In scenario 3, only FDG-PET; 10/251 (4%) 
distant metastases would be missed. Taken together, our data suggest that FDG-PET/CT 
scanners, combining the best of both worlds, would be the preferred technique from an 
accuracy perspective. If FDG-PET(/CT) is not available, CT scan is indicated. In summary, 
27% of the melanoma patients with palpable lymph node metastases are upstaged 
with FDG/PET or CT (FDG-PET 27% versus 24% with CT (p=0.178)). FDG-PET was 
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significantly better in detecting bone and subcutaneous metastases, FDG-PET and CT 
were comparable in detecting liver, abdominal and lung metastases. Treatment changed 
in 1 out of 5 patients, mostly to chemotherapy as result of both scans. In 34 patients 
(14%) FDG-PET had an additional value above spiral CT and in 23 patients (9%) CT had 
an additional value over FDG-PET. In conclusion, FDG-PET and/or CT are indicated in the 
staging of melanoma patients with palpable lymph node metastases. 
Figure 1: FDG-PET scan of a patient with known lymph node metastases and unexpected metastasis spinal 
cord mid thorax, not seen on the CT scan. The bone metastasis was confirmed with MRI in follow-up. 
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ABSTRACT 
Purpose. FDG-PET/CT is an excellent tool to detect melanoma metastases and it also 
allows for quantification of FDG uptake using standardized uptake value (SUV). The aim 
of this study was to prospectively investigate the potential prognostic value of SUV for 
Disease Free Survival (DFS) and Disease Specific Survival (DSS) for melanoma patients 
Stage 1 1 1 B. 
Methods. From November 2003-March 2008, all consecutive patients were included in 
the present study. Inclusion criteria were: palpable, histology or cytology proven lymph 
node metastases of melanoma, referred to the University Medical Centre Groningen for 
examination with FDG-PET and CT. Patients without distant metastases were evaluated. 
Multivariable survival analysis was performed to determine whether SUV was associated 
with DFS and DSS (Cox Proportional Hazard analysis). 
Results. In 80 (65%) patients (without distant metastases) SUV could be measured. 
Overall 5-years DFS for patients with a low SUVmean was 41% (95%CI 26-56) and 24% 
for patients with a high SUVmean (95%CI 12-38; p=0.02). Overall 5-years DSS was 
48% (95%CI 31-62) and 30% (95%CI 17-45) for patients with a low or high SUVmean 
(p=0.04), respectively. In multivariable analysis SUVmean was associated with DFS (HR 
1.7; p=0.048), however not associated with DSS (H R 1.6; p=0.1). 
Conclusions. FDG uptake in the clinically overt nodal melanoma metastases is inversely 
associated with Disease Free Survival. Univariate analysis showed an association with DSS, 
however adjusted for potential confounders this association was no longer significant. 
When confirmed in larger studies, SUVmean could potentially be used (additional to the 




Melanoma is one of the tumours with the most rapidly increasing incidence rates, 
especially in Caucasian populations. Within a decade, its incidence in the Netherlands 
has risen by 63% up to 2 1 .7/1 00.000 (European Standardized Rate) versus 1 3 .3/1 00 .000 
in 1 998. 1 Standard treatment for patients with palpable lymph node metastases (AJCC 
Stage 111B) is a therapeutic lymph node dissection (TLND). However, these patients are 
at high risk to develop distant metastases. Established prognostic factors for Stage 111B 
melanoma patients are the number and size of metastatic nodes, and the presence of 
extranodal growth. 2•3 Identification of additional prognostic factors could lead to more 
individualized treatment and follow-up schemes. 
Whole-body 1 8F-FluoroDeoxyGlucose positron emission tomography (FDG-PET) is a 
sensitive screening tool in high risk melanoma patients, since melanomas are typically 
FDG-avid.4 The added value of FDG-PET over CT with respect to diagnostic accuracy and 
impact on management has been established in several studies.4-10 Besides improved 
detection of metastases, a standard clinical PET-CT scan offers the opportunity to quantify 
the level of glucose metabolism in tumours. Glucose metabolism, as assessed with FDG, 
is an epiphenomenon of cancer and seems to bear prognostic value.11-17 However, the 
case of FDG as a prognostic biomarker is not undisputed 1 8 , probably as a consequence 
of confounding and heterogeneity in both the clinical spectrum and PET technology. 
We published some preliminary data acquired in a retrospective setting suggesting an 
inverse relation between tumour FDG uptake in patients with stage Ill melanoma who 
are operated with curative intent.1 3  The present study aimed to prospectively validate 
these findings accounting for the abovementioned potential confounders. 
METHODS 
Patients 
From November 2003 until March 2008, all patients with palpable, histology or cytology 
proven lymph node metastases of melanoma referred to the University Medical Centre 
Groningen (UMCG) for examination with FDG-PET and CT were prospectively included in 
this study. Prior to study entry, all patients were considered candidates for a therapeutic 
lymph node dissection (TLND), and they took part in a large prospective multicenter study 
to assess the diagnostic performance of FDG-PET and multi slice CT.4 Inclusion criteria 
for the present study were: Stage 111 after FDG PET and abdominal-thoracic CT, candidate 
for TLND with curative intent, and scanned on the same FDG-PET scanner with identical 
patient preparation, acquisition and reconstruction protocols. Patients with diabetes were 
not included. The study was approved by the UMCG Medical Ethical Committee. Patients 
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were actively followed up until January 2012. Follow-up was uniform for all patients 
consisting of clinical evaluation of physical signs and symptoms at standard follow-up 
visits (every 3 months in the 1st year, every 4 months in the 2nd year, twice a year in the 
3rd to sth year and every year in the 6th-1 oth year); diagnostic tests (chest X-ray, CT or 
FOG-PET) were only indicated if distant metastases were suspected. 
FOG-PET and SUV 
FOG was synthesized on site according to Hamacher by an automated synthesis module. 1 9  
Prior to FOG-PET imaging, patients were instructed to fast for at least 6 hours and to 
drink one litre of water. After intravenous injection of FOG, whole-body imaging was 
performed in the two dimensional mode, using a Siemens ECAT EXACT HR+ scanner 
(Siemens/CTI Inc., Knoxville, TN), applying emission scans of 5 minutes per bed position, 
starting 90 minutes after the injection of FOG. Image reconstructions were iterative 
(OSEM) with 8 subsets and 2 iterations. The image matrix size was 128 and the voxel 
size was 5.0. All scans were corrected for decay, scatter, randoms, attenuation, and 
normalization. The post-reconstruction filter (Gaussian post-processing filter) was 5 mm, 
yielding an estimated spatial resolution (FWHM) of 7 mm. 
FOG uptake was calculated as SUV = radioactivity concentration tissue (Bq/cc) / (injected 
dose (Bq) / patient body weight (g)) . Three-dimensional volumes of interest (VOis) were 
placed semi-automatically around the lymph node metastasis with the highest FOG 
uptake (visual assessment) using dedicated software ( IDL-Viewer, Leuven) . The numerator 
of the SUV was chosen to measure either the mean counts within an isocontour to 
70% of the voxel with the highest counts, or the maximum itself, yielding SUVmean or 
SUVmax, respectively. 
Data analysis 
To explore the distribution of SUVmean and SUVmax a kernel density plot was used, 
which approximates the probability density of the variable; Kernel density plots have 
the advantage of being independent of the choice of origin, unlike histograms. The 
associations between SUVmean/SUVmax or the log-transformation (which gave the best 
fit) and patient characteristics were assessed by the Student's t-test or analysis of variance. 
Patients were divided in two groups (high and low SUV) based on the median value of 
the log(SUVmean) and log(SUVmax) for the survival analysis. This dichotomization led to 
the same patient categorization for SUVmax and SUVmean in 95% of the patients. Since 
repeatability of SUVmean is superior to that of SUVmax20• 2 1 , we show the results of the 
SUVmean measure in the analyses. 
Survival analysis was performed for DFS and DSS; differences in survival were assessed 
using the log-rank test. For DFS an event was recorded for any recurrence, for DSS 
an event was recorded in case of death due to melanoma metastases. Multivariable 
Cox proportional hazard analysis was performed to determine independent prognostic 
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factors. Multivariable models were created with age, gender, localization of the lymph 
nodes defined as cervical, axilla or groin, number of removed nodes during the lymph 
node dissection, number of lymph nodes positive with histopathology after the lymph 
node dissection, tumour size in the largest lymph node metastasis determined after the 
lymph node dissection with histopathology, extranodal growth defined as metastatic 
tumour which clearly extends (histologically) through the nodal capsule into the perinodal 
fatty tissue or tumour involvement in the hilar region with interruption of the smooth 
outline of the (presumed) capsule, Breslow thickness and ulceration of the primary 
melanoma and high or low SUVmean. The Proportional Hazard Assumption was tested 
for the multivariable models. All p-values were considered significant if p<0.05. 
RESU LTS 
A total number of 80 patients were included in the present study. There were no patients 
lost to follow-up. Table 1 shows the characteristics of this cohort. There were slightly 
more females; 41 (51.2%) as compared to 39 males (48.8%). Median age was 57.0 
(range 24.7-93.2) years. Lymph node metastases were located at the groin (55.0%), axilla 
( 32.5%) or cervical (12.5%). The median number of removed nodes was 16 (range 7-48) 
and the median number of positive nodes was 2 (range 1-19). The tumour size in the 
lymph node ranged from 0.5 to 7.0 cm with a median of 3.1 cm. In 25 patients (31.2%) 
of the patients extranodal growth was recorded. 
As shown in Figure 1, the SUV values were not normally distributed (no Gaussian 
distribution). A log-transformation of the SUVmean and SUVmax showed the best fit 
to assume a Gaussian distribution. The log-transformed SUVmean and SUVmax were 
not associated with gender (p=0. 3 and p=0.4), age (p=0.2 and p=0.1 ), localisation of 
the lymph nodes (p=0.2 for both), the number of removed nodes (p=0.4 for both), 
the number of positive nodes (p=0.1 for both) or extranodal growth (p=0.6 for both), 
respectively. SUV was however associated with tumour size of the melanoma metastasis 
in the lymph node (p<0.001). 
Survival 
During the follow-up (all patients: median 3.0 years, range:0. 3-8.2 years; patients without 
event: 5.5 (3.1-8.2) years), 55 patients (68.8%) developed a recurrence. Overall, 49 
patients (61. 3%) died as result of the recurrent disease and 6 patients with a recurrence 
were still alive at the end of the study. The median SUVmean (used for further analysis) 
was 6.49 ( IQR 4.5-10.9) and the median log(SUVmean) was 1.86. 
Disease Free Survival (5-years DFS) for patients with a low SUVmean was 40.9 (95%CI 
25.5-55.7) and 24.2% (95%CI 12.4-38.0) for patients with a high SUVmean (p=0.02), 
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Table 1: Patients and tumour characteristics of the 80 patients with palpable, histology or cytology, proven 
lymph node metastases of melanoma 
Characteristic N=80 N %/ range 
Gender Male 39 48 .8 
Female 41 51 . 2  
Age category <50 years 25 3 1 . 2  
50-65 years 32 40.0 
>65 years 23 28 .8 
Primary melanoma 
Localization of the primary melanoma Upper extremities 9 1 1 . 2 
Lower extremities 34 42. 5  
Trunk 29 36.3 
Head & neck 6 7. 5 
Unknown primary 2 2 . 5  
Breslow thickness (mm) �1 .0 1 0  1 2 . 5  
1 .0-2 .0 27 33.8 
�2.0 41 51 .2  
Unknown primary 2 2 . 5  
U lceration No 63 78.8 
Yes 1 5  1 8 .7 
Unknown primary 2 2 . 5  
Lymph node metastases 
Localization Cervical 1 0  1 2 . 5  
Axi l la 26 32 .5  
Groin 44 55.0 
Removed nodes Median (range) 1 6  7-48 
Positive nodes Median (range) 2 1 -1 9  
Tumorsize Median (range) 3 . 1  0 . 5-7.0 
Extranodal growth No 55 68.8 
Yes 25 3 1 . 2  
as shown in Figure 2 .  Webtable 1 shows the univariate and multivariable analysis of the 
DFS. SUVmean was associated '-'.Vith DFS with a Hazard Ratio (HR) of 1 .7 (95%CI 1 .0-3.0; 
p=0.048). Other variables associated with DFS in multivariable analysis were the number 
of positive nodes (HR 1 .1 (95%CI 1.0-1.2; p=0.02) and the presence of extra nodal growth 
(HR 3.4 (95%CI 1.4-4 . 2; p=0.003). 
Disease Specific Survival (5-years DSS) was 47.5% (95%CI 30.9-62.3) for patients with a 
low SUVmean and 30.3% (95%CI 16.7-45.0) for patients with a high SUVmean (p=0.02, 
Figure 2). Webtable 2 shows the univariate and multivariable analysis of the DSS. 
SUVmean was not associated with DSS in multivariable analysis (HR 1.6 (95%CI 0.9-2.9; 
p=0.1). Female gender was associated with a better DSS in multivariable analysis (HR 0.5 
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Figure 1: Distribution of the SUVmean and SUVmax value in comparison with the normal (Gaussian) 
distribution 
Table 2: Multivariable analyses of the Disease Free Survival (DFS) and Disease Specific Survival (DSS) for the 
patients with Stage I l l  melanoma. 
Variable Disease Free Survival** 
SUV* Low 
H igh 
1 (ref) 0.048 
1.74 {1.00-3.00) 
Disease Specific Survival*** 
1 (ref) 0 .1 
1 . 57 (0 .86-2.87) 
*Divided by the median of log(SUVmean)=1 .86, ** Adjusted for positive nodes and extra nodal growth (see 
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Figure 2: Kaplan Meier curve for the D isease Free Survival (DFS) and Disease Specific Survival (DSS) for 
patients with a high and low SUV. 
DISCUSSION 
The present prospective study endorses the prognostic value of SUV for DFS in 
melanoma patients stage IIIB that have been optimally staged with FDG-PET and CT. 
The SUV as a quantitative parameter of fluordeoxyglucose uptake has a long tradition 
in nuclear medicine.14  Although its value for predicting tumour response to therapy has 
become generally accepted, the clinical usefulness and applicability of SUV for prognostic 
purposes is still under discussion. 
As far as the authors are aware there are two other studies (from our group) that 
addressed the value of SUV in melanoma patients. 13· 2 2  The first study was a retrospective 
small study and found no significant association between SUVmean and survival (p=0.11 ); 
however, DFS was significantly decreased in patients with a high SUVmean (p=0_03). 13 
In the study of Kruijff et al no association of SUV with survival was recorded.22 There 
are however significant differences between the patients in both databases, especially in 
localization, the number of positive nodes (more in the present study) and the percentage 
of patients with extranodal growth (less in the present study). Besides, cut-off values in 
both studies are data-driven and differ. In the present prospective study we confirm the 
association found in the retrospective study 13; there was a significant decreased DFS for 
patients with a high SUVmean in the lymph node metastasis (p=0.048). An association 
of SUVmean with survival was not found. DSS was, however, associated with gender as 
described previously by De Vries et al . Compared to men, women had a superior survival 
even after adjusting for multiple confounding variables in 10538 melanoma patients. 23 
Probably other factors than stage at diagnosis and localization reduces mortality risk in 
female melanoma patients. The associations between extranodal growth and the number 
of nodes have been described before. 24 Some of the primary melanoma characteristics 
as the Breslow thickness and ulceration were not associated with survival for these 
patients with macrometastatic disease. Interestingly, a recent study of Balch et al showed 
similar results: in patients with nodal micrometastases multiple covariates independently 
predicted survival, including several primary melanoma features (thickness, mitotic rate, 
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ulceration, and anatomic site of the primary tumour). 25 In contrast, for patients with 
nodal macrometastases, primary melanoma characteristics did not predict survival. 
We present a single centre study with standardized PET procedures to obtain homogeneity 
at that level. Since the measured SUV is a function of many technical and biological 
factors, the absolute values are only generalisable if these are accounted for. A recent 
study of Westerterp et al reported differences in SUV quantification between institutes 
with different PET scanners. 26 Consequently, multi-centre trials need standardization of 
acquisition, reconstruction and data analysis. When the present study was initiated, there 
were no gu idelines how to harmonize the results of multicenter studies using different 
scanners, acquisition and reconstruction protocols. To date, provided that one follows 
the 2010 PET gu idelines for trials and clinical practice (19), this is no longer an obstacle, 
and hopefully the evidence on the potential of quantitative PET in oncology will mature 
rapidly. In the present study we used the median value of the log-transformed SUVmean 
for risk stratification. However, there is always change for bias if data-driven cut-off 
values are used. 27 To be a practical prognostic factor in routine practice, standardization 
of protocols and cut-off values for SUV should be agreed upon or the methodology to 
determine the optimal threshold for each centre should be established. 1 7 
As nowadays a FDG-PET scan as a staging procedure prior to treatment of metastatic 
melanoma in regional lymph nodes is performed, determination of SUV values would 
provide additional information at very little extra cost. In conclusion, in melanoma patients 
clinically Stage Ill, a high SUVmean was associated with decreased disease free survival. 
When confirmed in larger studies, SUVmean could potentially be used, additional to the 
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Supplementary webtable 1: Univariate and multivariable anal sis of the Disease Free Survival 
Variable Univariate analysis p- Multivariable p-
HR (95%CI) value analysis value 
HR (95%CI) 
Gender Male 1 (ref) 0 . 1  
Female 0.63 (0.37-1 .07) 
Age Continuous 0.99 (0.98-1 .0 1 )  0 .8  
Breslow thickness '.S:1 .0  1 (ref) 0 .9 
1 .0-2 . 0  0 . 9 1  (0.38-2 . 1 7) 
�2.0 1 .05 (0.46-2 .39) 
Unknown primary 0.69 (0.08-5.62) 
Ulceration primary No 1 (ref) 0 . 2  
Yes 1 . 51 (0 . 8 1 -2 .83) 
Nodes removed Continuous 0.98 (0.94-1 .02) 0 .3 
Nodes positive Continuous 1.11 (1.04-1.20) 0.003 1.09 (1.01-1.18) 0.02 
Localization Cervical 1 (ref) 0 .06 
Axi l la  4.1 7 (1 . 23-14 . 1 )  
Gro in 3 .96 ( 1 . 2 1 -1 2 .96) 
Extranodal growth No 1 (ref) <0.001 1 (ref) 0.003 
Yes 2.85 (1.66-4.90) 2.37 (1.35-4.15) 
Tumor size lymph node Continuous 1 . 1 3 (0.98-1 . 29) 0 . 1  
SUV* Low 1 (ref) 0.02 1 (ref) 0.048 
High 1.93 (1.13-3.30) 1.74 (1.00-3.00) 
Ref = reference, HR = Hazard Ratio. All significant variables in un ivariate analysis were entered into the 
multivariable ana lysis. 
Supplementary webtable 2: Univariate and multivariable anal sis of the Disease Specific Survival 
Variable Univariate analysis p- Multivariable p-
HR (95%CI) value analysis value 
HR (95%CI) 
Gender Male 1 (ref) 0.02 1 (ref) 0.009 
Fema le  0.50 (0.28-0.89) 0.46 (0.26-0.82) 
Age Continuous 1 .00 (0.99-1 .02) 0.7 
Breslow thickness '.S:1 .0 1 (ref) 0 .9 
1 .0-2 .0  0 .98  (0.36-2 .66) 
�2.0 1 .02 (0.39-2.65) 
Unknown pr imary 0.85 (0 . 1 0-7.24) 
Ulceration primary No 1 (ref) 0 .08 
Yes 1 .77 (0 .93-3 .35) 
Nodes removed Continuous 0.99 (0.95-1 .03) 0 .6 
Nodes positive Continuous 1.10 (1.02-1.18) 0.01 1 .08 (0.99-1 . 1 6) 0.06 
Localization Cervica l 1 (ref) 0 .06 
Axi l la 5.94 (1 . 36-25 .76) 
G roin 4.49 (1 .07-1 8 .87) 
Extranodal growth No 1 (ref) 0.02 1 (ref) 0 . 1  
Yes 2.00 (1.13-3.54) 1 . 63 (0.87-3 .07) 
Tumor size lymph node Continuous 1 .74 (0 .96-3 . 1 5) 0 .07 
SUV* Low 1 (ref) 0.04 1 (ref) 0 . 1  
H igh 1.82 (1.03-3.22) 1 . 57 (0 .86-2 . 87) 
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ABSTRACT 
Objective. The aim of this prospective study was to assess predictive value of FDG-PET 
and CT and analyze their cost-effectiveness in several diagnosis-treatment combinations. 
Background. The incidence of melanoma continues to rise. A proportion will present or 
recur with lymph node metastases (AJCC/UICC Stage Ill). To detect distant metastases, 
CT and/or FDG-PET are available; however, few studies have assessed their value and 
costs in Stage Ill. 
Methods. All consecutive melanoma patients with palpable, proven lymph node metastases 
(2003-2008) referred for examination with FDG-PET and CT were prospectively included. 
Sensitivity, specificity and accuracy were calculated as well as positive predictive value 
(PPV) and negative predictive value (NPV). In economic evaluation the costs of diagnostic 
work-up with and without FDG-PET and CT were compared. 
Results. Overall, 253 melanoma patients were included. FDG-PET showed a higher 
sensitivity than CT: 86.1% compared to 78.2%. Specificity was higher for CT (93.7%) 
compared to FDG-PET (93.1%). Overall, FDG-PET showed a higher PPV and NPV. Cost­
consequence analysis showed that adding CT (True-Posit ive upstaging in 61 patients) to 
diagnostic work-up decreased costs by 5 .5%, adding FDG-PET (True Positive upstaging 
in 68 patients) increased cost by 7.2% and adding both (True-Positive upstaging in 78 
patients) increased cost by 15 .1%. 
Conclusions. In this study, FDG-PET had higher sensitiv ity and predictive value, while CT 
had a higher specificity. Adding one of these diagnostic tools improved the staging of 
Stage Ill patients with less than 10% cost increase. A proposal for stage-specific use of 
imaging modalities for clinicians caring for melanoma patients is presented. 
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INTRODUCTION 
Cutaneous melanoma remains a challenge despite increased levels of awareness, 
education and targeted health policies, especially when metastases are present. In 
general, mortality rates due to melanoma continue to climb, though the mortality figures 
are several fold lower than incidence due to improved survival. 1 Despite the fact that 
most melanoma patients present with AJCC/UICC Stage I or II disease, a proportion 
present or recur with loco-regional metastases (Stage 111). Standard treatment is a 
therapeutic lymph node dissection (TLND) with curative intent, unless distant metastases 
are detected. However, melanoma often spreads to unusual sites and consequently, 
accurate staging is important for clinical decision-making. To detect distant metastases, 
several imaging modalities are available, including FDG-PET and CT. FDG-PET is a non­
invasive imaging modality which has gained increasing acceptance because melanoma 
cells have a higher rate of utilization of glucose than normal cells. 2 PET has an overall 
sensitivity of 74%-100% and specificity of 67%-100% for all stages of melanoma.2• 3 
FDG-PET has no demonstrated value in patients with Stage I or II melanoma. These 
patients are optimally staged with sentinel lymph node biopsy.4·5 However, FDG-PET 
does have significant value in Stage Ill melanoma patients because it can demonstrate 
distant metastases. A recent prospective study showed a change in treatment in 19% of 
Stage 111 patients after the use of FDG-PET. 6 When comparing FDG-PET and CT, CT shows 
a higher sensitivity in lung metastases (especially small lung metastases) and FDG-PET in 
abdominal, bone and subcutaneous metastases. 6 
There have been few specific studies in Stage Ill melanoma patients, and we are not 
aware of any previous studies assessing the costs and benefits of FDG-PET and CT, 
important considerations in these times of financial crisis. However, these are important 
matters that must be considered when generating guidelines for the use of diagnostics 
tests. At present there are no standardized or universally agreed guidelines. Therefore, 
the aims of this study were to assess the sensitivity, specificity and predictive value 
FDG-PET and CT and perform a comparison of the two modalities, and to study the costs 
and benefits of the two modalities. Finally, proposed guidelines for diagnostic tools in 
melanoma patients are presented. 
METHODS 
Patients 
Participating hospitals were the University Medical Center Groningen, Radboud 
University Nijmegen Medical Center, VU University Medical Center Amsterdam, St. 
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Antonius Hospital Nieuwegein and Meander Medical Center Amersfoort. All consecutive 
melanoma patients with palpable, histology- or cytology- proven lymph node metastases 
referred to the participating hospitals between July 2003 and July 2008 for examination 
with FDG-PET and CT were prospectively included in this study. All these patients were 
considered candidates for regional lymph node dissection. For inclusion in the study 
patients had to be at least 18 years old, provide written informed consent, have no 
distant metastases on chest X-ray, no diabetes mellitus or claustrophobia. Women who 
were pregnant or lactating were excluded. Patients with non-palpable, tumor positive 
sentinel nodes were also excluded. The study was approved by the Medical Ethical 
Committees of all participating hospitals. 
PET and CT protocols 
Protocols for this study have been described elsewhere.6 In short, FDG was synthesized 
on site or obtained from Covidien, Petten, the Netherlands. Prior to FDG-PET imaging, 
patients were instructed to fast for at least 6 hours and drink one liter of water. After 
intravenous injection of FDG, total-body imaging from feet to head was performed. All 
reconstructions were iterative and in all centers FDG-PET reading were done by attending 
staff nuclear physicians. The absence or presence of distant (lymph node) metastases 
was recorded. Multi-slice CT of the neck, chest and abdomen was done with oral and 
intravenous administration of contrast agents using standard imaging protocols. Imaging 
was performed with a multidetector spiral CT with at least 4 detectors using standard 
protocols. Images were read from a computer display. FDG-PET and CT were performed 
in random order according to hospital logistics. If one or both of the scans were positive 
for distant metastases, an attempt was undertaken to confirm the lesions and appropriate 
treatment was administered. 
Data analysis 
FDG-PET and CT abnormalities were assessed by experienced local observers and recorded 
as positive or negative. Scans were recorded as "negative" if there was no suspicion of 
distant metastases or if the lesions were considered likely to be due to inflammation or 
if there was nonspecific uptake. If the lesions were suspicious of distant metastases, the 
scan was scored as "positive". Scan results were compared with pathology/histology 
results or at least six months follow-up. T he FDG-PET scan was considered true-negative 
(T N) if no distant metastases were detected and patients remained without evidence 
of metastases. Scans were considered false-negative (FN) if no distant metastases were 
detected, however evidence of disease was found with other diagnostic tools or within 6 
months. Scans were considered true-positive (TP) if distant metastases were detected and 
this was confirmed by other diagnostic tools or follow-up. Finally, false-positive (FP) scans 
were defined as scans that were recorded as positive, but distant metastases remained 
unconfirmed by other diagnostic tests or during follow-up. Sensitivity was calculated as 
T P/(T P+FN)x100, specificity as TN/(T N+FP)x100, accuracy as TN+TP/(TN+TP+FN+FP)x100. 
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Positive Predictive Value was calculated as TP/(TP+FP)x100 and Negative Predictive Value 
as TN/(TN+FN)x100. 
In the economic evaluation the costs of the diagnostic work-up and subsequent treatment 
with and without FDG-PET and CT were compared. We focused on the costs of diagnostic 
strategies and therapeutic interventions where chemotherapy (DTIC) and radiotherapy 
were taken into account. Four scenarios were modeled: 1) without CT and FDG-PET 
(only chest X-ray and physical examination), 2) with only CT, 3) with only FDG-PET and 
4) with CT and FDG-PET. For the costs of the CT we combined the costs of the chest 
and abdominal CT. The evaluation was conducted from a hospital perspective. Direct 
medical costs associated with FDG-PET and CT, including costs of medical personnel, 
diagnostic equipment, and materials used were taken into account. Information on costs 
were gathered during the study; for FDG-PET and CT tariffs were used as issued in 2009 
by the Dutch Healthcare Insurance Board. Because in some patients treatment did not 
change while PET or CT was positive, an intention to treat as well as per protocol analyses 
were performed. In the "intention to treat" analyses the treatment that patients actually 
received was used. In the "per protocol" analyses the treatment what it should have 
been, based on the results of the FDG-PET and CT scans, was used. Patients could still 
receive surgery (completion lymph node dissection) with curative intent or if treatment 
changed they could receive chemotherapy (DTIC 6x), completion lymph node dissection 
with palliative intent, no treatment or in a single patient two lymph node dissections. On 
average, patients remained in the hospital 6 days after the operation. 
RESU LTS 
Overall, 253 melanoma patients with palpable, histology- or cytology- proven lymph node 
metastases were included in this study. More than half the patients were male (60.5%). 
Mean age was 56.9 (range 19-93) years. More than half the patients (n=136, 53.8%) were 
assessed at the University Medical Centre Groningen, 42 (16.6%) in Radboud University 
Nijmegen Medical Center, 38 (15.0%) at VU University Medical Center Amsterdam, 26 
( 10. 3%) at St. Antonius Hospital Nieuwegein and 11 (4. 3%) at Meander Medical Center 
Amersfoort. The primary melanoma was usually located on the trunk (37.2%) or the 
lower extremities (35.2%). Lymph node metastases were located in the groin in 116 
patients (45.8%), axilla (n=94; 37.2%) or neck (n=43; 17.0%). 
Table 2 shows the sensitivity, specificity and accuracy of FDG-PET and CT in detecting 
distant metastases. FDG-PET showed a higher sensitivity than CT: 86. 1% (95%CI 78.4-
93.7) compared to 78.2% (95%CI 69.0-87.4). Thus, the actual positives which were 
correctly identified was higher with FDG-PET than with CT; the number of TP were 68 
with FDG-PET and 61 with CT. The specificity, however, was higher with CT (93.7%; 
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Table 1: Patient characteristics 
Number % 
Sex 
Male 1 53 60. 5 
Female 1 00 39 .5  
Age 
< 50 years 78 30.8 
50-65 years 99 39 . 1  
>65 years 76 30 . 1  
Hospital 
UMCG 1 36 53 .8  
Radboud 42 1 6 .6  
VUMC 38 1 5 .0  
Nieuwegein 26 1 0 .3  
Amersfoort 1 1  4.3 
Location of primary tumor 
Upper extremities 26 1 0 .3  
Lower extremities 89 35 .2  
Trunk 94 37.2 
Head/neck 29 1 1 . 5 
Unknown primary 1 5  5 .9 
Breslow thickness of primary tumor 
::;1 .0 32 1 2 .7 
1 .0-2 .0 74 29.2 
�2.0 1 28 50.6 
Unknown 1 9* 7. 5 
U lceration of primary tumor 
No 200 79.1  
Yes 53 23.0 
Location of lymph nodes 
Neck 43 1 7.0 
Axi l la 94 37.2 
I nguinal 1 1 6 45.8 
*Breslow thickness unknown: incidence abroad, mucosal melanoma (n=2), incidence in 1 983 .  
Table 2 :  Sensitivity, specificity, positive and negative predictive va lues and accuracy of  FDG-PET and CT to 
detect distant melanoma metastases. 
Diagnostic Sensitivity Specificity Positive Negative Accuracy 
Predictive Predictive 
Value Value 
FDG-PET* 86.1  93 . 1  85.0 93 .6 91 .0 
(78 .4-93 .7) (89.3-96.9) (77. 2-92.8) (88.3-99.0) (87.4-94.5) 
CT* * 78 . 2  93 .7 84.7 90.6 89.0 
(69 .0-87.4) (90 . 1 -97.3) (76.4-93 .0) (83 .9-97.3) (85.1 -92 .8) 
*PET: tn 1 62, fn 1 1 ,  tp 68, fp 1 2  
**CT: tn 1 64, fn 1 7, t p  61 , fp 1 1  
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95%CI 90.1 -97.3) as compared to FDG-PET (93.1%; 95%CI 89.3-96.9). The proportion of 
patients where the scans were TN was slightly higher for CT than for FDG-PET ( 1 64 vs. 
1 62). Overall, accuracy was higher for FDG-PET scan than for CT: 91 .0% (95%CI 87.4-
94.5) compared to 89.0% (95%CI 85.1 -92.8). 
Table 3 shows the positive and negative predictive values of FDG-PET and CT for the 
different locations of distant melanoma metastases. Overall, FDG-PET showed higher 
PPV and NPV. CT showed a higher PPV and NPV values for liver and lung metastases. 
For abdominal metastases, FDG-PET showed a higher NPV (98.7% vs. 97.0%), however 
CT showed a higher PPV (72.2% vs. 71 .4%). For bone and subcutaneous metastases, 








Stage I or II with 
or without SLNB 
FOG-PET CT 
PPV 95%CI NPV 95%CI PPV 95%CI NPV 95%CI 
86.4% 72.0-1 00 97.0% 89.8-1 00 90.9% 78.9-1 00 97.8% 9 1 . 8-1 00 
86.8% 76.1 -97.6 9 1 .2% 82 . 1 -1 00 89. 1% 80. 1 -98. 1  94.7% 88 . 2-1 00 
7 1 .4% 52. 1 -90.8 98.7% 93 .9-1 00 72.2% 51 . 5-92 .9  97.0% 89.2-1 00 
96.3% 89.2-1 00 1 00% 1 00% 93 .0% 77.2-1 00 
1 00 1 00 1 00 98.0 85.7-1 00  
85.0% 77 .2-92.8 93.6% 88.3-99.0 84. 7% 76.4-93.0 90.6% 83.9-97.3 
Patient with melanoma (primary or recurrent) 
!Stage I l l  





Confirm with histology, 











Tailored treatment. PET if 
metastasectomy is  
considered 
Note: FDG-PET(/CT) means FDG-PET single or combined modality FDG-PET/CT 
Figure 1: Proposed guidel ine for the diagnostic tools in melanoma patients 
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Table 4: Cost-benefit ana lysis of the different d iagnostic scenarios for 253 patients (al l  costs are in 2009 
Euros). 
Scenario Costs n Costs n Costs n Costs 
No CT or FDG-PET Only CT 
PET 1 1 7 1  0 0 0 0 0 0 
CT 506 0 0 253 253 1 280 1 8  
1 280 1 8  
Upstag ing 7 2  
T P  61  
Intention to treat Per protocol 
Surgery with curative intent 876 253 2 2 1 628 2 1 4  1 87464 1 92 1 68 1 92 
Hospital stay (6days) 3798 253 9 60894 2 1 4  81 2772 1 92 7292 1 6  
Change in  treatment 0 39 61 
Chemotherapy 1 200 0 0 27 32400 49 58800 
Surgery with pal l iative intent 876 0 0 6 5256 6 5256 
Hospital stay (6 days) 3798 0 6 22788 6 22788 
Two lymph node dissections 1 752 0 0 1 1 752 1 1 752 
Hospital stay (6 days) 3798 0 0 1 3 798 1 3 798 
No treatm ent 0 0 0 3 0 3 0 
Unknown 0 0 2 0 2 0 
Costs 1 1 82522 1 1 94248 1 1 1 7820 
Costs per patient € 4 .674 € 4 .720 € 4.41 8 
(+1 .0%) (-5 . 5%) 
FOG-PET had a higher NPV than CT. The PPV for subcutaneous metastases was the same 
for FOG-PET and CT; however FDG-PET detected more subcutaneous metastases. 
Table 4 shows the costs analysis for the four scenarios. The first scenario was defined as 
the situation where no diagnostic tests were performed, the second with only CT, the 
third with only FDG-PET and fourth scenario with both FOG-PET and CT. The cost per 
patient when no diagnostic tests are performed was 4674 Euros; this included only the 
costs of surgery and the hospital stay. If only a CT was performed, the cost per patient 
increased with 1.0% in the present study (intention to treat analysis), but would decrease 
with 5.5% if treatment was according to the results of the CT scan. Adding only the 
FOG-PET scan increased the cost by 14.8%, however in the per protocol analysis cost 
increased by 7.2% . Finally, the cost would increase by 23.9% (intention to treat analysis) 
and 15.1% (per protocol) when adding both FOG-PET and CT. Costs for the diagnostic 
modality were higher with FOG-PET (1171 Euro) then CT (506 Euro), however costs for 
surgery were lower with FDG-PET as less patients received a therapeutic lymph node 
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n Costs n Costs n Costs n Costs 
Only PET CT & PET 
253 296263 253 296263 253 253 296263 
296263 
0 0 0 0 253 1280 1 8  253 1 280 1 8  
Upstaging 80 Upstag ing 95 
TP 68 TP 78 
Intention to treat Per protocol Intention to treat Per protocol 
2 1 1  1 84836 1 85 1 62060 205 1 79580 1 75 1 53300 
2 1 1  801 378 1 85 702630 205 778590 175  664650 
42 68 48 78 
27 32400 53 63600 33 39600 63 75600 
8 7008 8 7008 8 7008 8 7008 
8 30384 8 30384 8 30384 8 30384 
1 1 752 1 1 752 1 1 752 1 1 752 
1 3798 1 3798 1 3798 1 3798 
3 0 3 0 3 0 3 0 
3 0 3 0 3 0 3 0 
1 35781 9  1 267495 1464993 1 360773 
€ 5 .367 € 5 .0 1 0  € 5 .790 € 5 .379 
(+14.8%) (+7.2%) (+23 .9%) (+1 5 . 1%) 
dissection. Costs for chemotherapy were, however, higher in the scenario with FDG-PET 
as more patients received chemotherapy. 
Figure 1 proposes guidelines for the assessment of melanoma patients. For patients 
with melanoma Stage I and II disease, FDG-PET has no additional value. For melanoma 
patients with clinical Stage Ill disease, after full physical examination a chest X-ray should 
be performed. If lung metastases are apparent on chest X-ray, this finding should be 
confirmed with CT. If this is also positive, patients should be managed as Stage IV patients. 
If there is no suspicion of distant metastases on the chest X-ray, total-body FDG-PET or 
FDG-PET/CT should be performed. Patients should be scanned from head to feet. If the 
FDG-PET scan is negative for distant metastases, patients should receive a therapeutic 
regional lymph node dissection. If the PET scan is positive, confirmation should be 
obtained by CT, other diagnostic tests or histology/cytology. If confirmation is obtained, 
patients should be managed as Stage IV patients. If no confirmation is obtained, patients 
should be discussed by a multidisciplinary team to determine appropriate treatment. 
Sometimes it may be considered appropriate to perform a "palliative" lymph node 
109 
I 
dissection to control regional disease, and radiation treatment is sometimes an option to 
improve loco-regional control. If FDG-PET is not available, CT can be performed. If distant 
metastases are demonstrated and metastasectomy is considered, an additional FDG-PET 
should then be performed to exclude the presence of more metastases. For Stage IV 
melanoma FDG-PET/(CT) could be performed if the exact localization and number of 
metastatic sites need to be evaluated. 
DISCUSS I ON 
The development of metastases from melanoma is unpredictable in individual patients. 2•7•8 
Accurate staging is essential to determine appropriate treatment and possibly improve 
the prognosis. 2 The present study confirms the conclusions of earlier studies concerning 
the accuracy of FDG-PET in Stage 111 melanoma patients. Analysis of costs shows that 
adding FOG-PET and/or CT does not increase costs substantially, while increasing the 
number of upstaged patients who would otherwise undergo an unnecessary operation. 
As far as we are aware, this is the largest study so far reported in this selected group of 
patients. 
The sensitivity of FOG- PET is dependent on the size of the lesion, its anatomical location 
and its rate of FDG uptake per volume unit of tissue.9 The limited spatial resolution of 
FOG-PET means that the technology is unable to detect tumour deposits less than 3-5 mm 
in diameter.9 In the present study FOG-PET showed higher sensitivity and accuracy than 
CT: 86.1 % and 91.0% compared to 78.2% and 89.0% for CT. The specificity, however, 
was slightly higher for CT (93.7%) as compared to FOG-PET (93.1%). These numbers are 
similar to those reported in a recent review by Prichard et al, who found a sensitivity 
of 74%-100% and specificity of 67%-100%, however this was a combined value for al l 
stages of melanoma.1° Comparison of FOG-PET with CT and MRI in that study showed a 
higher sensitivity and specificity for PET in all regions of the body except the thorax. In the 
present study we also found a higher PPV and NPV for the detection of lung metastases 
with CT. Brady et al studied 1 16 patients of whom 72% had Stage Ill disease. 1 1 They 
found that PET scanning was more sensitive than CT in detecting occult disease (68% 
versus 48%), but both tests were highly specific (92% versus 95%). Our specificity figures 
were similar (93.1% and 93.7%), however the sensitivity was much higher (78.2%). The 
only other study that has exclusively considered Stage 111 is the one reported by Tyler et 
al. 1 2  They prospectively studied 95 patients with clinically evident Stage Ill melanoma. 
The FOG-PET identified 144 of 165 areas of melanoma; thus sensitivity was 87. 3%, which 
is comparable to the sensitivity we found (86. 1 %). The PPV of 85.0% in the present study 
was higher that the one they reported (78.6%). The specificity in their study was only 
43. 5%, while it was 93.1% in the present study. 
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The two imaging modalities had PPV and NPV results that varied according to tumor 
location. CT showed a higher PPV and NPV for liver and lung metastases. It is known 
from the literature that CT demonstrates lung metastases (which are often small) better 
than FDG-PET, however the difference found in the present study was not as large as 
previously reported (FDG-PET vs CT: PPV 86.8% vs 89.1% and NPV 91.2% vs 94.7%). 
For abdominal metastases, FDG-PET showed a higher N PV, however CT showed a higher 
PPV (72.2% vs. 71 .4%). For bone and skin metastases, FDG-PET had a higher NPV than 
CT (bone 100% versus 93.0%, skin 100% versus 98.0%). In retrospect however, several 
bone metastases were reported on a second reading of the CT, suggesting that the bone 
structures were not routinely evaluated carefully with CT. A recent retrospective study 
of 342 melanoma patients who were evaluated with FDG-PET/CT scans showed that 
the PPV of an isolated musculoskeletal FDG-avid site (single site lesion) ultimately being 
metastatic melanoma was only 31%, whereas the PPV of a musculoskeletal FDG-avid site 
found in addition to other FDG-avid sites (i.e. visceral or nodal) was 87%. 13 The PPV in 
subcutaneous metastases was the same for FDG-PET and CT, however FDG-PET detected 
more subcutaneous metastases. The localization of different metastases could be 
important in determining the most appropriate treatment. Some surgeons recommend 
the surgical excision of distant metastases if only one or a few sites are apparent. 1 4· 1 5  
This might prolong survival or even be curative for a small group of patients; 5-year 
survival rates of 40% have been reported. 1 5 Current evidence strongly suggests that 
PET-CT should be performed prior to such potentially curative surgery in patients with 
e.g. haematogenous metastases (including adrenal, solitary brain metastases, small 
bowel, and solitary pulmonary lesions). 
To be cost-effective, FDG-PET must be more diagnostically · accurate than existing 
modalities. FDG-PET findings must also improve patient management, and the benefit 
obtained must be worth any extra expenditure. 1 6  FDG-PET and CT were shown to 
upstage a large proportion of patients and less metastasis were missed with FDG-PET 
with or without CT. Costs for the diagnostics increased, however costs for surgical 
operations and hospital stay decreased. As shown in a previous study, FDG-PET and CT 
findings improved patient management. Valk et al also studied the cost-effectiveness of 
FDG-PET, in 45 patients who had undergone PET imaging for metastatic or recurrent 
melanoma.1 6  The PET resulted in a change in surgical treatment in 36% of the patients. 
When the costs of procedures contraindicated by PET findings was compared to the total 
costs of PET studies, the savings-to-cost ratio was greater than 2: 1 when PET was used as 
an additional procedure and approximately 4 :1 with elimination of CT scans of the chest 
and abdomen. 1 6  However, the study was limited by the fact that only major changes 
in surgical treatment were assessed and by it retrospective nature in a small cohort 
of patients. Attempting to scan the patient with a number of conventional diagnostic 
modalities is not cost-effective or practical, mainly because these studies have a lower 
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sensitivity and lesions outside the fields of study can be missed.1 7 The initial cost of 
establishing a scanner accounts for the majority of the expense. 
Recently, combined FDG-PET/CT scanners have been introduced. Mottaghy et al 
performed a retrospective study to evaluate the additional value of FDG-PET/CT 
in comparison with PET alone and with side-by-side PET and CT in 127 patients with 
melanoma.1 8  The number of lesions with an uncertain localisation was significantly 
reduced by PET/CT. PET, side-by-side PET and CT and PET/CT showed a sensitivity of 
86%, 89% and 91%, a specificity of 94%, 94% and 94%, a positive predictive value of 
96%, 96% and 96% and a negative predictive value of 80%, 83% and 87% in all stages 
of melanoma. 1 8  So, specificity and PPV were not improved by adding CT or by FDG-PET/ 
CT as compared to PET alone. The particular value of FDG-PET/CT is in improving the 
sensitivity and NPV. The benefit of FDG-PET/CT in patients with melanoma is not as 
great as that reported for other tumour entities, which may be due to the high avidity 
of melanoma for FDG. 1 8  As costs for combined PET/CT are not yet established in the 
Netherlands, we could not calculate these costs; in current Dutch practice, costs for both 
PET and CT scan are charged in case of a PET/CT scan that includes CT with intravenous 
contrast agents. 
Based on the results of the present and other studies we propose the routine use of 
FDG-PET or FDG-PET/CT for clinically Stage Ill melanoma patients; if FDG-PET or PET/ 
CT is not available, multidetector CT is a good alternative. Overall, melanoma patients 
with lymph node metastases are optimally staged with these diagnostic tools, which 
could facilitate tailored treatment. Since there are currently no standardized or universally 
agreed guidelines regarding the stage-specific use of imaging modalities available 
for clinicians caring for melanoma patients, we propose this guideline for the use of 
FDG-PET/CT in melanoma patients with clinical Stage Ill disease. 
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ABSTRACT 
Adjuvant radiation treatment following lymph node dissection in the melanoma patient 
has been suggested and investigated in an attempt to gain regional control and improve 
survival. In this review we discussed the treatment, the loco-regional control, disease-free 
and survival rates and complications. 
Historically melanoma has been thought of as a relatively radioresistant tumour. 
Nowadays, radiation delivered according to the hypofractionated schedule is the most 
used, although there are no data to confirm that this schedule improves the therapeutic 
impact. Almost all the reviewed studies were retrospective, which could have led to an 
underestimation of the true incidence of the treatment toxicity and morbidity. 
Adjuvant radiotherapy after lymph node dissection for metastases of melanoma seems 
to improve loco-regional control without improving overall survival. The available 
data indicate the need for improved regional control rates in patients with extranodal 
extension, multiple involved nodes (more than three) and patients with large involved 
nodes (larger than 3 cm). The complications seem manageable and consist mainly of 
fibrosis and edema. 
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INTRODUCTI ON 
Increased awareness and surveillance have resulted in earlier diagnosis of melanoma. 
Consequently, the melanoma patient is now diagnosed at an earlier stage of disease. 
( 1) Nevertheless, some melanoma patients still present or recur with loco-regional 
metastases (Stage Ill A.J .C.c.) . Surgical excision of the primary tumour and/or lymph 
node dissection remains the standard of care for these patients. 
Only 25-50% of the patients with regional lymph node metastases survive more than 
five years after a therapeutic lymph node dissection and 34-50% of the patients recur 
loco-regionally.(2-9) Most of these melanoma patients die as a consequence of distant 
metastases, usually in less than two years after lymph node dissection. Loco-regional 
recurrences are often difficult to treat and might be accompanied with a substantial 
morbidity, such as ulceration and disfigurement. Therefore, prevention of loco-regional 
failure could improve the quality of life, even if it does not increase the long-term 
survival. ( 10) 
Adjuvant radiation treatment to the dissected nodal basin has been suggested and 
investigated in an attempt to gain regional control after lymph node dissection . (11-19) 
However, the potential benefits of adjuvant radiation after therapeutic lymph node 
dissection for stage Ill melanoma patients must be weighed against the morbidity and 
side effects of radiation treatment. 
Although early retrospective data suggested less sensitivity of melanoma to radiation, it 
is now well documented that regardless of the fractionation schedule, melanoma cells 
are radioresponsive if adequate doses of radiation are delivered.(20-23) Despite this well 
documented radioresponsivity, routine irradiation is often avoided because there is still 
a belief that radiotherapy is ineffective for melanoma as well as an concern regarding 
short and long-term radiation induced morbidity.(24) Adjuvant radiotherapy for lymph 
node metastases is nowadays generally reserved for melanoma patients with a high 
risk for regional recurrence after therapeutic lymph node dissection. High-risk features 
include extranodal growth (ENG) pattern, large lymph nodes, the involvement of multiple 
pathological lymph nodes, clinically palpable adenopathy and the anatomical site of 
involved lymph nodes.(3-7;25;26) 
The relevant literature concerning the use of adjuvant radiotherapy after therapeutic 
lymph node dissection for stage Ill melanoma patients is reviewed. Different aspects 
of the treatment, the 5-year loco-regional, disease-free and survival rates and the 
complications of the radiation are discussed. 
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TREATM ENT 
There is a belief among radiation oncologists that larger fraction size with lower total 
dose, so called "hypofractionation", improves the therapeutic impact of radiation for 
melanoma. However, the optimal fractionation scheme for malignant melanoma remains 
controversial. Historically melanoma has been thought of as a relatively radioresistant 
tumour with a low a/f3 ratio, but several studies have shown that melanoma is 
radioresponsive. Besides that, the historical basis of this belief has been reviewed and the 
data justifying these opinions about melanoma and radiosensitivity is of extremely poor 
quality.(27) 
This historical belief led to treatment schedules using large fraction doses of radiation. 
(28-34) A prospective, randomised trial of the Radiation Therapy Oncology Group 
(RTOG) evaluated the effectiveness of high dose per fraction irradiation in the treatment 
of bulky melanoma. (22) One hundred twenty-six melanoma patients with measurable 
lesions were analysed: 63 patients received radiotherapy in large, infrequent fractions 
(4 x 8 Gy) and 64 patients received radiotherapy according to a conventional radiation 
fractionation scheme (20 x 2.5 Gy).The results show that response rates were similar 
for both arms of the study suggesting that melanoma does not responds favourably to 
large fractions. The problem in this trial lies, according to Trott, in the choice of doses 
that were compared(35) Whereas the one arm with 20 times 2.5 Gy gives a commonly 
used conventional treatment of proven effectiveness, the high fractional dose schedule 
of 4 times 8 Gy is consistent with an intermediate level of fractionation sensitivity, i.e., 
an a/f3 ratio of 7 Gy. Given the shallow slope of the dose response curve for malignant 
melanoma, an increase or decrease of the given dose of 4 times 8 Gy by 12-1 6% would 
go unrecognised in any trial. (34) Interestingly, the overall response to irradiation was 
good. Approximately 60% of the patients exhibited a favourable response to therapy; 
either partial remission (reduction greater than 50% in one cross-sectional division 
of the tumour) or complete remission, thus refuting the concept that melanoma is a 
radioresistant tumour. 
Another study, from the Department of Radiation and Medical Oncology in Ontario, 
confirms the conclusion that melanoma is not a radioresistant tumour.(36) Thirty-one 
patients were treated for residual melanoma after surgery (25 following lymph node 
dissection) and 23 patients with recurrent melanoma with 8 Gy per fraction on day 0, 
day 7, and day 21 . Eighty-two percent of the patients treated for microscopic residual 
disease were free of local recurrence for three years. Ten of the 1 8  patients were alive 
and free of disease for up to 44 months following radiation. Seven of the nine patients 
treated for gross residual tumour had no recurrence or progression of tumour within the 
irradiated volume, five of the nine achieved a complete remission and three were alive 
and free of disease at 1 0, 1 3  and 42 months, respectively. The results show that large 
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dose per fraction radiotherapy (8 Gy) is effective in the treatment of melanoma and 
produces a high response rate of patients with measurable disease. 
Studies from the M.D. Anderson Cancer Center reported that the use of a few large 
fractions of radiotherapy (6 Gy, twice a week, to a total of 30 Gy) was associated with a 
improved 2-year and 5 -year loco-regional control of 83% and 88%, respectively.(10;11) 
I n  conclusion, hypofractionated schedules of 30 Gy in 5 fractions in 2. 5 weeks and 33 Gy 
in 6 fractions in 2.5 weeks are believed to improve the therapeutic ratio for melanomas, 
although there is still continuing controversy with respect to the optimal schedule. 
( 34; 35) The hypofractionated schedules are the best documented in effectiveness and 
complications, but there is no evidence that the conventional schedules are not effective 
in melanoma treatment. 
LOCO-REGIONAL CONTROL, DISEASE-FREE 
SURVIVAL AND OVERALL SURVIVAL 
Nine studies investigated the effect of adjuvant radiotherapy after therapeutic lymph 
node dissection and were reviewed with respect to the 5-year loco-regional control (with 
and without radiotherapy), the disease-free and survival rates are presented in Table 1. 
Almost all the studies were retrospective, the predominant location was the neck and head 
region (7 studies) or axilla (2 studies). No studies with respect to only inguinal irradiation 
were found. In six studies the radiotherapy was delivered according to a hypofractionated 
schedule, one study used a variety of schedules and two studies delivered the radiation 
according to the conventional schedule of smaller fractions every day. 
The 5-year loco-regional control rate after irradiation ranged from 82% to 95%. 
( 11; 12;16; 17;19) Compared to a loco-regional control rate after surgery alone of 50% 
to 86%.(3-7; 17;25,26; 37; 38) Only three studies calculated a 5-year disease-free survival: 
46% with the hypofractionated schedule and 26% and 76% with the conventional 
schedules.(12;14;15) The 5-year survival rates ranged from 38% to 50% for melanoma 
patients after lymph node dissection and adjuvant radiotherapy delivered according 
to the hypofractionated schedule. The 5-year survival rate for patients with stage Ill 
melanoma after lymph node dissection ranges from 25% to 55%. Adjuvant radiotherapy 
does not produce a significant improvement in survival.(4;8;9; 39) 
The University of Texas M.D. Anderson Cancer Center (MDACC) divided the patients, with 
cutaneous melanoma of the head and neck, in their prospective study in three groups: 
one group (n=79) received elective irradiation after wide local excision of previously 
untreated lesions. A second group (n=32) received adjuvant irradiation after excision of 
primary lesions plus limited neck dissection, and a third group (n=63) received irradiation 
after neck dissection for nodal relapse. (11) 
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Table 1: 5-year loco-reg ional control, d isease-free and survival rates for the identified studies. 
Study Number of Prospective or Location 
patients retrospective 
Ang et al , 1 994(1 1 )  32* Prospective Head and neck 
O' Brien et al, 1 994( 1 7) 27 Retrospective Head and neck 
O' B rien et al, 1 997(1 6) 45 Retrospective Head and neck 
Burmeister et al, 1 995(40) 26 Retrospective Neck (42%), axi l la (46%) and inguinal  
(1 2%) 
Corry et al , 1 999(1 4) 42**  Retrospective Head/neck (50%), axi l la (29%) and 
groin/pelvis (2 1 %) 
Stevens et a l ,  2000(1 8) 1 39 Retrospective Neck and head (54%), axi l la (35%), 
g roin (8%) and multi ple (3%) 
Fuhrmann et al, 2001 ( 1 5) 58 Retrospective Head/neck ( 19%), trunk (37.9%), axi l la 
( 1 2 . 1 %) and inguinal (3 1 %) 
Strom and Ross, 1 995(1 9) 22  Retrospective Axi l la 
Bal la et al , 2002(1 2) 89 Retrospective Axi l la 
*Adjunctive irradiation after excision of primary lesions plus l imited neck d issection. * * Pa l liative group not 
included . #Disease-free and survival at 3 years (no variation in  the last 1 0  months). RT = radiotherapy. 
The 5-year actuarial local-regional control rate of 88% for the whole group of patients 
was higher than that of the historical group prior to the use of postoperative radiotherapy 
(50%).(25) The thickness of the primary lesion, presence of more than three positive 
nodes, and extracapsular extension did not influence the loco-regional control rate after 
radiotherapy. After reporting the results, patients with Stage I l l  disease or cervical lymph 
node recurrence without distant metastases received routinely adjuvant irradiation. In an 
update of 1 60 patients with cervical lymph node metastases from melanoma, reviewed 
retrospectively, adjuvant radiotherapy resulted in 1 0-year loco-regional control rate of 
94%.(24) 
In a later retrospective study of the MDACC to evaluate the outcome and treatment­
related toxicity for patients with axillary lymph node metastases from malignant 
melanoma treated with surgery and radiation, using a hypofractionated regimen resulted 
in an 87% 5-year axillary control rate, superior to the 50% local control achieved with 
surgery alone. (12;25) Another retrospective study of postoperative irradiation to the 
axilla for malignant melanoma showed a local control of 95% after 5 years in a small 
group of selected patients treated for subclinical disease. ( 1 9) In addition, a substantial 
number of these patients were long-term survivors. 
Several studies from Australia show good results with adjuvant radiotherapy. Burmeister 
concludes that there appears to be a definite role for adjuvant radiotherapy following 
lymph node dissection with regard to local control, without improving survival. (40) 
The study population from the Peter Maccallum Cancer Institute was divided into two 
categories: a palliative group and an adjuvant group. ( 14) Used radiation schedules were 
50 or 60 Gy in 25 or 30 fractions, 5 per week and they found an estimated 5-year 
overall survival of 33%. This could be due to the fact that 86% of the patients in the 
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Treatment 5-year loco-regional control 5-year disease- 5-year survival 
RT No RT free survival rate 
3 0  Gy, 5 fractions, 2 .5  weeks 93% 40% 
33 Gy, 6 fractions, 2 . 5  weeks 92% 67% 
33 Gy, 6 fractions, 3 weeks 82% 61 % 40% 
Variety of schedules 88% 4%# 26%# 
50 Gy, 25 fractions, 5 weeks and 80% 26% 33% 
60 Gy, 30 fractions, 6 weeks 
33 Gy, 6 fractions, 2 .5  weeks 38% 
5 0-65 Gy, 2 .0-3 .8  Gy per fraction 76% 22% 
30  Gy, 5 fractions, 2.5 weeks 95% 50% 
30 Gy, 5 fractions, 2.5 weeks 87% 46% 50% 
adjuvant group had negative prognostic factors (multiple nodes, extracapsular extension 
or recurrent nodal disease). Nevertheless, the 5-year loco-regional control was 80%. 
Three studies from the Sydney Melanoma Unit found a positive effect following 
postoperative radiotherapy.(16-1 8) Two studies of O'Brien of the head and neck 
documented an improved loco-regional control compared to surgery alone.(16;17) In the 
first study the patients who received radiotherapy had worse pathology than the patients 
who received no radiation therapy.( 17) Despite this greater potential for treatment failure, 
recurrence developed in only 2 irradiated necks (7%) compared to 12 nonirradiated 
necks (23%). By the Kaplan-Meier method, the neck control rate was 92% for irradiated 
patients compared with 67% for the nonirradiated group. These differences were not 
statistically significant, but the beneficial trend is clear. In another group of 45 patients, 
who received a lower dose of radiation, the same conclusion could be drawn.(16) The 
regional recurrence was 6.5% in the irradiated group, compared with 18.7% in the non­
irradiated group (p=0.055). The irradiated group, however, had more extensive nodal 
involvement than the non-irradiated group. Another retrospective study consisted of 139 
patients with proven regional lymph node metastases.(18) Proven recurrences within the 
radiation field occurred in 20 patients (11 %) after a median time of 6 months. 
Two studies do not justify the routine use of postoperative radiotherapy.(15;26) In a 
German study the overall survival curves were almost identical in the surgery alone 
group versus the surgery and adjuvant radiation group.(15) There were nine disease 
recurrences in the study group and 12 in the control group (not significant). Patients 
and controls were matched for the number of lymph nodes involved and for gender. 
However, prognostic factors of the primary tumours were not well balanced between 
both groups: the irradiated patients had a higher percentage of thicker primary tumours 
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and more head and neck melanomas compared to the controls. As the authors discussed, 
tumour thickness is a significant prognostic factor so the higher percentage of thicker 
melanomas in the irradiated group probably affected their results. An American study, 
with 217 patients (21 irradiated), documented an incidence of cervical recurrence of 
14% in patients who received adjuvant radiotherapy and 14% in those who did not, not 
justifying the routine use of radiotherapy.(26) 
RIS K  FACTORS 
Risk factors for melanoma stage Ill patients for disease recurrence after lymph node 
dissection, distant metastases of melanoma and, as a consequence, overall survival is 
presented in Table 2. 
Extranodal extension and multiple involved nodes were mentioned in almost all the 
studies. Adjuvant irradiation was recommended when extracapsular extension was 
noted histologically and different studies found the presence of extranodal extension a 
significant predictor of nodal basin failure. Multiple involved nodes were defined as 3 or 
more involved nodes. (3; 11; 12;40;41) Large involved lymph nodes were mentioned in 4 
studies, defined as nodes greater than 3 cm in size. (3; 12; 18; 36) Tumour spill at surgery 
was mentioned twice and minimal residual disease after surgery (i.e. involved surgical 
margins) once. Lesion thickness, mentioned in one study, strongly affected the 5-year 
survival rate of patients who received irradiation . (11) Disease recurrence after lymph 
node dissection appeared to be a negative prognostic factor for survival in 3 studies. 
These factors were all considerate to be indications for postoperative irradiation in 
patients with lymph node dissection. The available data indicate the need for improving 
regional control rates in patients with 1) extranodal extension, 2) multiple involved nodes 
(more than 3) or 3) large involved nodes (>3 cm). 
Table 2: Risk factors for recurrence or distant metastases. 
Study 
Johanson et al, 1 983(36) 
Ang et a l ,  1 994(1 1 )  
Ross e t  a l ,  1 994(41) 
Burmeister et a l ,  1 995(40) 
O'Brien et al ,  1 997( 1 6) 
Corry et al, 1 999(14) 
Lee et a l ,  2000(3) 
Shen et a l ,  2000(26) 
Stevens et a l ,  2000(1 8) 
Bal la et al, 2002(1 2) 
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COMPLICATIONS 
The complications of adjuvant radiotherapy after lymph node dissection are summarised 
in Table 3. Edema was mentioned in almost all the studies besides fibrosis and skin 
desquamation, which may be encountered after irradiation treatment. Edema is also 
a potential complication after lymph node dissection, however given the retrospective 
nature of the studies, it was not possible to categorise complications as specifically 
related to surgery or radiation. 
Complications of postoperative radiotherapy are in general manageable. Irradiation 
to the neck and head region is well tolerated although transient parotid swelling and 
mucositis are side effects frequently seen during treatment. (11) Neck fibrosis is a late side 
effect frequently seen after radiation therapy. With a median follow-up time of over 35 
months, late radiation complications were observed in only three patients. 
Arm edema is evaluated in 18-29% of the patients after adjuvant irradiation of the axilla. 
( 12; 19) Twelve cases were regarded as grade 1 (transient or asymptomatic), 13 were grade 
2 (requiring medical intervention) and 1 was grade 3 (requiring surgical intervention). 
A MDACC study of patients with an cervical lymph node dissection and radiotherapy 
also used this grading system: eighteen complications (11%) were asymptomatic findings 
noted at the time of follow-up physical examination (grade 1) and nine (5.6%) were 
regarded as grade 2: symptomatic finding requiring any form of medical therapy. There 
were no grade 3 (requiring surgery) complications.(24) 
There is no study reporting the morbidity of exclusively inguinal irradiation after 
superficial or deep lymph node dissection. However, the Canadian study of Johanson et 
al has the most patients with inguinal lymph node dissection included and report femoral 
neuropathy and chronic abdominal pain as complications of high dose inguinal irradiation 
after lymph node dissection.(36) The other studies concluded that the complications 
were acceptable, that there were no high-grade late toxicity symptoms and only a few 
patients with minimal and self-limited complications.(13; 14; 18; 36;40;42) 
DISCUSSION AND CONCLUSIONS 
Adjuvant radiotherapy after lymph node dissection for metastases of melanoma may 
improve loco-regional control without improving overall survival. The most important 
indications for adjuvant radiotherapy after lymph node dissection are 1) extranodal 
disease, 2) multiple involved nodes or 3) large involved nodes. The complications seem 
manageable and consist mainly of fibrosis and edema. 
Melanomas have traditionally been regarded as extremely radioresistant tumours. The 
origin of this dogma is unclear, but it has been repeated in standard texts for several 
years.(10) Currently, the radiotherapy seems to improve the local control of melanoma 
patients compared to patients with only a lymph node dissection. Adjuvant radiotherapy 
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Table 3: Complications of adjuvant radiotherapy after lymph node dissection . 
Study Dose Location Early complication 
(percentage of patients) 
Ang et al, 1 994( 1 1 )  5 x 6Gy Head and neck Transient parotid swel l ing 
(unknown), Moist skin 
desquamation and confluent 
mucositis (<5%), Wound 
i nfection (0.6%) 
Morris et al, 2000(42) 5 X 6Gy Neck (64%), axi l la (22%), groin Acute parot id itis (5%), 
(7%) and subcutaneous (7%) Mild erythema (36%), 
Desquamation (5%) 
Stevens et al, 2000(1 8) 5 X 6Gy Neck (55%), axilla (34%), inguinalMoist skin desquamation and 
(8%) and multip le (3%) patchy mucositis (0.7%) ---------- --- ----
Balla et al , 2002(1 2) 
Bal la et al, 2003(24) 
Strom and Ross, 1995(1 9) 
Johanson et al, 1983(36) 
5 X 6Gy Ax i 1 1  a 
5 x 6Gr_ Cervical 
5 X 6Gy Axilla 
3 x 8Gy Groin (34%), axilla (55%) 
and head/neck ( 1 1 %) 
Burmeister et al, 2002(13) 20 x 2.4Gy Head and neck (32%), axi l la 
(43%) and inguinal (25%) 
Corry et al, 1 999(1 4) 25 x 2Gy Head/neck (50%), axilla 
(29%) and groin/pelvis (21%) 
Burmeister et al, 1 995(40)* Variety Axil la (46%) , neck (42%) 
and inguinal (1 2%) 
* Complications of patients with adjuvant treatment. 
Moderate erythema, dry 
desquamation with occasional 
patchy moist react ion 
(unknown) 
Acute toxicity: skin reaction 
(2.4%) 
should not cause a high morbidity in long treatment schedules to the patient who might 
not have a long disease-free period. 
Surgery is the primary treatment for localised and loco-regional melanoma.(23) 
Unfortunately, a significant proportion of patients will develop recurrences after proper 
surgical procedures. 
Karakousis et al reported a regional recurrence rate of 49% following regional nodal 
dissection in a group of patients where 60% had multiple involved nodes.(43) Byers 
reported a 46% regional failure rate in patients who had a neck dissection for nodal 
metastasis from head and neck melanoma and Balch reported a 50% nodal failure rate 
in patients after lymph node dissection.(25;44) The loco-regional control rates of 82% 
to 95% for radiotherapy after lymph node dissection, found in the reviewed studies, is 
an improvement to surgery alone. Unfortunately, there are no prospective randomised 
studies defining the definitive role of adjuvant irradiation after a proper so-called curative 
lymph node dissection and the retrospective studies did not always include enough 
patients to perform a proper statistical analysis. 
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Late complication 
Neck fibrosis, M i ld hearing impairment, Transient exposure external auditory canal 
carti lage ( 1 . 7%) 
Xerostomia (5%), Edema local (2%), Fibrosis (2%), Telangectasias (2%), Upper extremity 
weakness (2%) 
Edema (7%), Uni lateral fibrosis, ipsi lateral mastoiditis and hearing impairment (0.7%), 
Severe pain in the jaw ( 1 .4%) 
Arm edema (29.2%) 
Asymptomatic compl ication (1 1 %), Compli-cations requiring medical treatment(S.6%) 
Arm edema ( 17.9%) 
Branchial radiculopathy, femora l neuropathy, chronic abdominal pain (5%) 
Lymphoedema (30%), F ibrosis of subcutaneous tissue (28%), S l ight and patch atrophy 
(23%), Asymptomatic reduced bone density and mild joint stiffness (7.2%), Mild 
paraesthesia (4%), Necrosis of subcutaneous tissue (2%), U lceration of the skin (0.7%), 
Severe induration and loss of subcutaneous tissue ( 1 . 3%) 
Lymphedema (8%), Skin u lcer (0.9%), Fibrosis (4 .4%). 
Edema of limb (1 5%), Skin changes ( 1 2%), Edema of breast (8%), Fibrosis (4%) 
Recurrence after lymph node dissection is associated with poorer survival.(45) The 
5-year overall survival rate of 38% to 50% with adjuvant radiotherapy after lymph 
node dissection is not a significant improvement to surgery. Adjuvant radiotherapy 
should prevent recurrences in melanoma patients and thereby prolong the survival, or 
if it does not improve survival, to improve the quality of life by loco-regional control. A 
randomised, prospective study should be conducted to establish the beneficial influence 
on the loco-regional control and answer the question about the unclear beneficial effect 
on overall survival. Based on the results, radiotherapy could be imbedded in evidence­
based guidelines for melanoma therapy in various melanoma patients. 
Adjuvant radiotherapy is nowadays generally reserved for patients with pathologic 
features indicating a high risk for regional recurrence after surgery alone.{12;24) Failure 
rates ranging from 30% to 50% have been reported when these high risk features are 
present(3-7;24-26) Extranodal extension and multiple or enlarged involved nodes were in 
this review identified as the major three risk factors. Three studies demonstrated clearly 
that extranodal disease is the most important risk factor for loco-regional recurrence. 
{3;4;26) The number of involved lymph nodes (more than 3) is also a predictor for 
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loco-regional recurrences after lymph node dissection.(4;46) Although less frequently 
reported, lymph node size (> 3 cm) is also associated with regional recurrence. (3) 
The role of radiation therapy after lymph node dissection has been the subject in a 
limited number of mainly retrospective studies with a low level of evidence (level 2b). 
Given the retrospective nature of the reviewed studies, it is very likely that there was an 
underestimation of the true incidence of the treatment toxicity and morbidity. 
To evaluate the use of adjuvant radiotherapy and the complications of this treatment, 
randomised prospective studies with patients who had lymph node dissection and 
adjuvant radiation therapy compared to patients with only lymph node dissection have 
to be undertaken. However, designing and successfully conducting such trials pose 
many challenges. "The Plenary Session Discussion from the Fifty-Third Annual Cancer 
Symposium of the Society of Surgical Oncology" highlighted several obstacles to 
conducting such trials, which include defining and measuring the end point of regional 
relapse after lymph node dissection, regulating multiple prognostic and therapeutic 
variables, the significance of competing relapses, and salvage potential with further 
surgery.(47) 
We believe that adjuvant radiotherapy has a positive influence on loco-regional control, 
but the influence on survival is still unclear. A recent, retrospective, study of mucosal 
melanomas of the head and neck region confirms this conclusion; the addition of 
radiotherapy tended to decrease local failure (p=0.13), but did not significantly improve 
survival (p=0.73). (48) 
It's unclear why the role of adjuvant radiation is so limited investigated. Based on this 
study, we recommend adjuvant radiotherapy, after lymph node dissection, in the group 
of patients with extranodal extension, large or multiple involved nodes. 
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C h a p t e r 
Future perspectives 

FUTU RE  PERSPECT IVES 
Data on melanoma from the majority of countries have shown a rising incidence of 
melanoma during the last two decades, which remains to increase in many countries. 1 
Different patterns are emerging in relation to sex and age, in some countries the incidence 
seems to level off or even decreases in younger females; however, the incidence continues 
to increase in most countries for elderly males. 1 A large proportion of these patients are 
diagnosed with thin melanomas; however a substantial part will present or recur with 
regional disease (lymph node metastases). 
In those patients that present with regional lymph node metastases, clinical decision 
making requires accurate staging with FDG-PET and CT, as described in this thesis. 
Changes in the treatment of distant melanoma metastases and adjuvant treatment for 
stage I l l  melanoma patients wil l  change the impact of staging modalities. This chapter 
will discuss ongoing research and future perspectives in melanoma research. 
D iagnostic tools 
FOG-PET for the identification of sentinel nodes 
The average sensitivity of FDG-PET for subclinical nodal disease in stage I and II melanoma 
is very low (14%-17%), whereas sentinel node biopsy reaches a high sensitivity (86%-
94%). Recent studies confirmed that FDG-PET has no place in the initial work-up of 
patients without any clinical evidence of regional lymph node metastases. 2 The low yield 
in nodal staging is explained by the size of tumor deposits (30 mm) within non-enlarged, 
clinically normal lymph nodes which size is too small to be identified with FDG-PET. 
Ultrasound 
There is one available meta-analysis of ultrasound in melanoma; Bafounta et al performed 
a meta-analysis of the published studies comparing ultrasound with palpation for the 
detection of lymph node invasion in patients with stage 1-111 melanoma.3 ,4 Sensitivity 
for ultrasound ranges from 33. 3%-99.1% and for palpation from 3.2%-85.4% whereas 
specificity ranged from 96.8%-99.7% and 63.2%-99.7%, respectively.3 There were some 
limitations in the analysis, but overall, the systematic review provides level Illa evidence 
that ultrasound has higher discriminatory power than palpation to detect regional 
lymph node metastases from melanoma.4 Additionally, if a sentinel lymph node appears 
abnormal on ultrasound and if this is confirmed by cytology, the patient may proceed to 
therapeutic lymph node dissection directly and be spared a diagnostic surgical procedure, 
e.g. a sentinel lymph node biopsy.4 
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Combined FOG-PET/CT scanner 
Although FDG-PET and CT are often considered as staging procedure for stage Ill 
melanoma, the combination of the two in one modality has also been studied. There are 
few studies that compare the use of FDG-PET alone as single modality with the combined 
PET/CT scanner.5-8 Two studies found that FDG-PET/CT resulted in a significant increase 
in accuracy of 5% and 12%.6•7 The first study6 used a high-resolution 3D LSO PET and 
a 1 6  row multi-slice CT, the second7 a combination of a dual-detector helical CT and 
a high-resolution PET scanner. Both of these studies noted in particular, an increase in 
the sensitivity of FDG-PET/CT in the detection of pulmonary metastases compared with 
FDG-PET alone. This increase in sensitivity results from the fact that small pulmonary 
metastases may not be demonstrated by FDG-PET, but can still be successfully detected 
by CT. 6•7 One study did not detect any significant change in accuracy. 8 Whether the CT 
component of FDG-PET/CT can replace a dedicated thoracic CT remains to be seen, as 
it has been shown that 37% of small pulmonary nodules seen on a dedicated thoracic 
CT will not be detected by the CT component of some of the FDG-PET/CT because of 
the different respiratory phases of the two studies.4 However, there is still discussion 
whether adding a diagnostic thoracic CT always provides additional clinical value. 
As nowadays a FDG-PET or FDG-PET/CT scan as a staging procedure prior to treatment 
of metastatic melanoma in regional lymph nodes is performed, determination of 
SUV values would provide additional information at very little extra cost. A study of 
Westerterp et al reported differences in SUV quantification between institutes with 
different PET scanners.9 Consequently, multi-centre trials will need standardization of 
acquisition, reconstruction and data analysis. To date, provided that one follows the 2010 
PET guidelines for trials and clinical practice 1 ° ,  this is no longer an obstacle, and hopefully 
the evidence on the potential of quantitative PET in oncology will mature rapidly. 
MRI 
Contrast-enhanced MRI is the most accurate imaging technique for the assessment of 
cerebral metastases, and has been shown to be superior to contrast-enhanced CT. 1 1  
FDG-PET has been shown to be inferior to CT and to MRI for the detection of cerebral 
metastases because of the high physiologic metabolic activity of the brain and limitations 
of size resolution for FDG-PET. 1 2 • 1 3  A recent retrospective study of 100 patients 
recommended that cerebral MRI should only be performed in patients with stage IV 
disease or in patients where the detection of cerebral metastases would alter patient 
management, but further research to confirm these findings is needed.14 
There is now rapidly emerging interest in whole-body MRI for cancer staging and recent 
advances in MRI technology enable whole-body imaging in less than one hour.4·1 5  
Besides, the first combined whole-body PET/MRI scanners are now in place in the US 
and some parts of Europe. Pfannenberg et al compared whole-body MRI and FDG-PET/ 
CT in 64 patients.6 FDG-PET/CT was found to be significantly more accurate for nodal 
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and cutaneous, subcutaneous and pulmonary distant metastases staging (86.7% versus 
78.8%); whole-body MRI was superior for the detection of liver and cerebral metastases. 
However, tolerability of MRI could be an issue, as some patients were unable to complete 
the MRI for reasons including metallic implants and claustrophobia and cost-effectiveness 
has not been studied.6 Whether this will replace the whole-body FDG-PET(/CT) remains 
to be seen. 
Guidelines 
At this moment there are no specific guidelines for the staging of clinically stage 111 
(palpable lymph node metastases) melanoma. In the last chapter of this thesis we 
proposed a guideline for the use of FDG-PET, CT or the combined FDG-PET/CT scanner. 
For melanoma patients clinically stage Ill, FDG-PET certainly had additional value in 
patients with no suspicion for distant metastases on the chest X-ray. Patients should be 
scanned from head to feet to detect all possible metastases. If the PET scan is positive, 
confirmation should be attained by CT, other diagnostic tools or histology/cytology. If 
confirmation is obtained, patients should be included in trials for stage IV melanoma 
patients. If no confirmation is obtained, patients should be discussed by a multidisciplinary 
team to administer tailored treatment. Occasionally there might be an indication in stag.e 
IV patients for a so called palliative lymph node dissection to control regional disease and 
even radiation treatment is sometimes required. 
If FDG-PET is not available, CT can be performed. However, if distant metastases are 
depicted on CT and metastasectomy is considered, an additional FDG-PET should be 
performed to exclude the presence of more metastases. For stage IV melanoma FDG-PET/ 
(CT) could be performed if exact localization and number of metastatic sites have to be 
evaluated, for example to select patients for metastasectomy or clinical trials. Hopefully, 
these guidelines will be used in the clinical practice in the coming years. 
Laboratory investigations as diagnostic or staging tool 
Besides diagnostic modalities, laboratory investigations could also assist in patient 
selecting for specific treatment. LDH and S100 have been found more valuable than any 
other blood serum markers. LDH has been widely accepted as a prognostic marker in 
stage IV melanoma patients and was reported to be suitable to detect liver metastases, 
although its increased concentration is not very specific for that kind of metastases. S100 
was found to be positively correlated with the invasiveness of melanoma and has been 
shown to correlate with clinical staging, the extent of metastatic spread and disease 
progression.16•17 How these markers can be used in staging melanoma patients requires 
more research. 
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Adjuvant therapy stage I l l  melanoma patients 
Adjuvant radiotherapy 
Adjuvant radiotherapy is an option for patients with large or multiple lymph node 
metastases, or extranodal disease, as also described in this thesis. The first results from 
the only completed randomized study on effect of radiotherapy on regional recurrence, 
survival, morbidity and quality of life, presented at ASCO 2009, showed that adjuvant 
radiotherapy improved regional control but had no effect on survival.1 8  However, median 
survival observation time was still short (2.6 years for Disease Specific Survival and 3.9 
years for Overall Survival). 
Adjuvant chemotherapy 
There have been very few meaningful trials addressing adjuvantchemotherapy in melanoma 
as most (if not all) trials have been underpowered.1 9 To date, no adjuvant therapy has 
resulted in improved overall survival. In considering the role of adjuvant chemotherapy 
in melanoma, it is worthwhile to be aware of the progress made in other tumor types 
(for example breast, colon, gastric cancer) where the role of adjuvant chemotherapy has 
been established. Calculations have indicated that the maximum improvement in survival 
is likely to be in the range of 30%. 1 9 To detect a 30% improvement with 80% power, 
an adj�vant trial would need about 570 patients.1 9 The only study that reached that 
size was by Veronesi et al where 761 patients were randomized in 4 arms: wide local 
excision and excisional regional lymphadenectomy alone, surgery plus chemotherapy 
with dacarbazine, surgery plus immunotherapy with bacille Calmette-Guerin vaccine and 
surgery plus chemotherapy combined with immunotherapy. The study demonstrated no 
significant difference in survival at 3 years; however mean follow-up was only 41 months. 
Adjuvant immunotherapy 
The effect of interferon alpha (IFN-alpha2) given alone or in combination has been widely 
explored in clinical trials over the past 30 years. 20 Despite the number of adjuvant studies 
that have been conducted, controversy remains in the oncology community regarding 
the role of this treatment. Recently, a meta-analysis including 14 RCTs with in total 8122 
patients, of which 4362 patients were allocated to the IFN-a arm was performed. 2 1  
IFN-a treatment was associated with a statistically significant improvement in DFS in 10 
of the 17 comparisons (HR for disease recurrence=0.82 (95%CI 0.77-0.87; p< 0.001) 
and improved OS in four of the 14 comparisons (HR for death=0.89 (95%CI 0.83-0.96; 
p=0.002). No optimal IFN-alpha dose and/or treatment duration or a subset of patients 
more responsive to adjuvant therapy was identified using subgroup analysis and meta­
regression. 2 1 Future efforts could aim at tailored therapy based upon the knowledge of 
the unique features of melanoma and the immune system of each patient. 20 
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Adjuvant vaccine therapy 
Heat-shock proteins (HSPs) are a group of proteins whose expression is increased 
when the cells are exposed to elevated temperatures or other stressful cond it ions.  22 
Tumor-derived HSP-peptide complexes (HSPPCs) can be used for vaccination aga inst 
mal ignancies. I n  particular, HSPPC-96 complex, ca lled Vitespen (formerly Oncophage) 
is a HSPs-based vaccine made from ind ividual patients' tumors with a promis ing role 
in  cancer management. The vaccine has a lso been studied in  Phase 111 cl in ica l  trials in 
melanoma, showing an excellent safety profi le with essentia l ly no toxicity and cou ld  be a 
novel therapeutic approach . 22 
Therap ies for stage IV melanoma 
Surgical resection 
Surg ica l resection of melanoma d istant metastases is sti l l the only curative treatment for 
stage IV d isease, and recurrent stage IV d isease, but can only be performed if there a re 
a few resectable d istant metastases. A recent study from Ol l i la et al showed a su rviva l 
benefit with a 5-years surviva l of 40% by metastasectomy i n  selected patients . 23 Resu lts 
from the Canvaxin study reported at the Society of Surg ica l Oncology in 201 1 confirmed 
the va lue of surgery in stage IV melanoma patients . 
Chemotherapy 
Melanoma is considered a chemotherapy-resistant tumor, but in fact several 
chemotherapeutic agent show sing le-agent activity at the level of 1 0% to 1 5%, s imi lar  to 
the efficacy of the chemotherapy used against some other tumor types . 24 Dacarbazine 
(DT IC) remains the standard chemotherapy treatment of metastatic melanoma a lthough 
it is not known if  there is a smal l  overa l l  su rviva l benefit associated with treatment. 
Combination chemotherapy reg imens can induce objective responses in a h igher 
proportion of patients than DTIC  a lone. 24 Neither of the 2 trials that looked at overa ll 
surviva l was able to detect a benefit in median overal l  surviva l, but neither was powered to 
detect a d ifference of less than 50%. I t  remains possible that combination chemotherapy 
can improve survival by a smal ler marg in . 24 However, larger stud ies would be needed to 
detect these smal ler benefits . Therefore, a lthough cu rrent combination chemotherapy 
reg imens might be associated with a smal l  improvement in overa l l  surviva l, it seems 
un l ikely that the melanoma community wil l  be able to conduct a trial large enough to 
test this hypothesis . 
However, the smal l cohort of respond ing patients cou ld be stud ied to understand  why 
they respond to treatment. 24 There are currently some genetic tools that a l low us to 
genotype tumors (or patients) before therapy and then see which genetic changes 
correlate with response to treatment. 24 This approach is being used with so-ca l led 
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"targeted therapy" agents and is beginning to be used for chemotherapy in other tumor 
types.24 Instead of considering the small proportion of melanoma patients who respond 
to treatment as statistical aberrations, they should be viewed as consistent but low 
frequency events worthy of study that could give us clues leading to improved therapy.24 
lmmunotherapy 
lpilimumab is an antibody targeting CTLA-4, a protein with an established role in 
suppressing the immune system. Already at ASCO 2010 25 and later in the year published 
26 lpilimumab, with or without a gp1 00 peptide va�cine, as compared to gp100 alone, 
improved overall survival in patients with previously treated metastatic melanoma. This 
makes lpilimumab the first ever treatment to show superiority in a large randomized 
trail . Patients on the two ipilimumab arms experienced a median survival of 1 O months 
versus 6.4 months in the cancer vaccine arm. Adverse events, however, can be severe 
and long-lasting, but most are reversible with appropriate treatment. Moreover, a recent 
study published in 201127, showed that ipilimumab (10 mg per kilogram) in combination 
with dacarbazine, as compared to dacarbazine plus placebo, improved overall survival in 
patients with previously untreated metastatic disease. 
Melanoma genetics 
Since the identification of the BRAF mutation in melanoma in 2002 research currently 
focuses on the development of BRAF mutation inhibitors as a therapeutic target in 
disseminated melanoma. BRAF(V600E/K) is a frequent mutationally active tumor-specific 
kinase in melanomas that is currently targeted for therapy by the specific inhibitor 
PLX4032 (Vemurafenib). 28 The results of a recent study suggest that the drug can confer 
an advantage to BRAF(WT) primary and metastatic tumor cells in vivo and provide markers 
to monitor clinical responses.28 Another abstract presented at ASCO 2010 confirms 
that the BRAF inhibitor PLX4720 induces apoptosis in human melanoma with mutated 
BRAF at concentrations achievable in vivo.29 Melanoma lines with mutated CDK4 or 
EGRF receptors had lower cell viability. Apoptosis was correlated with the induction of 
the proapoptotic Bim, particularly Bim short and may be a useful biomarker to assess 
apoptotic responses and guide drug doses and combinations in the clinic. 29 Worldwide 
phase Ill trials are ongoing to investigate the value of so-called BRAF-inhibitors in the 
treatment of metastatic melanoma . A recently published study3° showed an improved 
overall and progression-free survival with vemurafenib in comparison to dacarbazine in 
patients with previously untreated melanoma with the BRAF V600E mutation. 
Metastatic melanoma remains one of the most difficult cancers to treat. Given the rising 
incidence of melanoma and the paucity of effective treatments, there is much hope 
and excitement in recent genetic and molecular insights for therapeutic advantage.31 
We have learned much from the successes and failures of targeted therapies and 
studies are beginning to lead to survival benefits in advanced melanoma. The genetic 
1 40 
pathways and alterations are now better defined in the most common forms of 
cutaneous melanoma.3 1  Another challenge will be to arrive at a molecular classification 
of melanoma based on genetic and epigenetic signatures.31 Currently, Breslow depth, 
ulceration status and mitotic rate remain the most widely accepted prognostic factors.32 
There are no commercially available laboratory tests that accurately predict which early 
stage tumors have a higher likelihood of progression and therefore a worse prognosis. 
Thus, identification of molecular signatures of melanoma progression would represent 
a major step toward accurate survival counseling and may aid in the identification and 
administration of previously unknown therapeutic targets. The coming years should 
be aimed at finding new therapies for patients with melanoma metastases, now that 
interferon and vaccination do not seem to work, with research to systemic treatment still 
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Chapter 1 General introduction 
Melanoma causes more than 75% of all deaths related to skin cancer, and its incidence 
dramatically increased in Caucasian populations over the last years. Melanoma has the 
well-known feature to spread to unusual sites and multiple distant metastases are usually 
a contraindication for surgery. Consequently, accurate staging is extremely important for 
clinical decision making to identify those patients who may benefit from surgery while 
avoiding unnecessary, potentially harmful surgery that does not improve survival and 
finally inform patients with respect to prognosis. Melanomas typically are quite FDG-avid; 
and together with the erratic pattern of spread, the patient is candidate for screening for 
distant metastases in high-risk primary melanoma with whole body FDG-PET. 
Chapter 2 The use of FDG-PET in melanoma patients 
The aim of Chapter 2 was to discuss the value of FDG-PET and combined FDG-PET/ 
CT in staging and follow-up of melanoma patients. Review of literature shows that the 
presence or absence of regional lymph node metastases is an important prognostic factor 
for patients with melanoma and the recent development of Sentinel Lymph Node Biopsy 
(SLNB) offers a highly sensitive staging method. FDG-PET has shown a limited sensitivity to 
detect microscopic lymph node metastases in this selected group of patients with stage I 
and II melanoma which can be explained as sizes of tumor deposits within non-enlarged, 
i.e. clinically normal lymph nodes are too small (30 mm) to be identified with FDG-PET. 
However, for the detection of distant metastases, FDG-PET is frequently used. Although 
there is no consensus, some surgeons pursue surgical excision of metastatic disease if 
only one or a few sites of disease are apparent. Precise identification of the location 
and number of metastatic lesions could therefore be important for surgical planning. 
There is an apparent paradox that even though patients with metastatic melanoma 
generally have a poor prognosis (the 5-years survival varies between 3-1 6%); there is 
still need for more accurate staging. Firstly, to identify those patients who may benefit 
from a surgical procedure, while avoiding these potentially harmful surgical procedures 
for patients with multiple distant metastases. Secondly, accurate staging is important 
to improve the efficiency of clinical trials, for example patients with a limited number of 
distant metastases; especially with the recent successful trials in patients with metastatic 
melanoma. Thirdly, to provide patients with detailed information about their prognosis. 
Taken the published literature together and reasoning that PET/CT is the current standard 
in PET imaging, there may be a case for the combined PET/CT in the setting of metastatic 
melanoma. However, further research is needed as the benefit seems to be less than 
reported for other tumor entities, which may be due to the high avidity of melanoma for 
FDG, so that many of the metastases are detected with FDG-PET and the additional CT 
does not increase the sensitivity. 
147 
Chapter 3 Impact of FOG-PET on surgical management 
Several studies have shown adequate sensitivity and specificity of FDG-PET for the 
detection of melanoma metastases. However, only few have addressed the impact on 
treatment. The aim of the study described in Chapter 3 was to study the impact on 
treatment of FDG-PET in melanoma patients in three Dutch university medical centres. 
For this study the medical records of 257 patients with all stages of melanoma were 
reviewed. The indications for FDG-PET and findings were recorded and treatment plans 
before and after FDG-PET were analysed to evaluate changes in disease management. 
Unexpected findings of suspected (pre)malignant tumours other than melanoma were 
also recorded. The results showed that most scans were requested for staging (overall 
71 . 2%), mainly to detect distant metastases in Stage Ill melanoma patients. Overall 56 
patients (21 .8%) were upstaged as a result of the FDG-PET scan . I n  44 patients ( 1 7. 1%) 
treatment changed, usually from surgery to systemic treatment in stage Il l patients. In 
4. 3% of the patients unexpected, mainly colorectal, tumours were detected. So, already 
in this study FDG-PET was the most valuable in patients with stage I l l melanoma to detect 
distant metastases and to identify those patients who are candidates for surgery and/ 
or systemic treatment. In 37% of the stage Ill patients, surgical treatment changed as a 
result of the FDG-PET scan. The study also showed that unexpected FDG-PET findings 
should not be disregarded, as (pre)malignant clinical relevant, tumours may be identified. 
Chapter 4 Prognostic value of SUV 
Identification of additional prognostic factors may allow the development of individualized 
strategies. The study in Chapter 4 describes the potential role of the Standard Uptake 
Value (SUV) in predicting disease-free and overall survival in melanoma patients with 
lymph node metastases. For the study all melanoma patients with palpable lymph 
node metastases who where referred to the University Medical Centre Groningen for 
a FDG-PET scan were eligible. The SUV in the lymph node metastasis was calculated. 
Differences in overall survival and disease-free rate were assessed (log-rank test). 
Univariate and multivariable analysis (Cox proportional hazard model) were performed 
to determine independent prognostic factors. In this retrospective study of 38 patients 
no statistical difference in survival for patients with a high or low SUVmean was found 
(p=0.1 1 ). Ulceration of the primary melanoma (p=0.02) was an independent predictor 
of survival. However, a significant difference was found in multivariable analysis of the 
disease-free survival (p=0.009), besides adjuvant radiation (p=0.001 ) and localization of 
the primary melanoma (p=0.01 7). We concluded that if the results are confirmed by 
prospective research, adjuvant (radiation) treatment should be considered for patients 
with high FDG uptake in melanoma lymph node metastases. 
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Chapter 5 Perception of burden by the melanoma patients 
Melanoma patients with lymph node metastases have to deal with diagnostic tests 
to exclude the presence of distant metastases; results of the tests could have major 
implications for their prognosis and treatment. There are, however, few studies concerning 
the patients' psychological issues and perception of diagnostic tests. The aim of the study 
presented in Chapter 5 was to describe the burden of diagnostic tests (X-ray, CT and PET) 
experienced by melanoma patients with lymph node metastases. For this study patients 
were asked to complete a questionnaire concerning satisfaction and burden experienced 
during the diagnostic tests. The levels of embarrassment, discomfort and anxiety for the 
different tests, as well as total scores for each burden were calculated. Logistic regression 
was used to examine factors associated with the degree of experienced burden. Overall, 
59 of the 68 patients completed the questionnaire: the response rate was 87%. The 
overall scores on satisfaction and Quality of Life were high. More than half of the 
patients experienced no burden during FDG-PET, 65% no burden during CT and 80% no 
burden during chest X-ray. Patients experienced significantly more discomfort during the 
FDG-PET scan than during the CT (p=0.003). Less burden was experienced (in univariate 
analysis) by patients who were more satisfied. So, we concluded that overall experienced 
burden by patients is low and should therefore not interfere with primary choice for a 
diagnostic test based on accuracy, costs and percentage of patients upstaged. However, 
attention should be paid to explain the procedure and answer questions of the patients 
to reduce burden. 
Chapter 6 Prospective comparison of FOG-PET and CT 
As mentioned before, melanoma patients with potentially resectable lymph node 
metastases require accurate staging (among others) to prevent unnecessary surgery. 
FDG-PET is an attractive imaging modality since melanoma typically is FDG avid. The aim 
of the prospective multicenter study described in Chapter 6 was to perform a head-to­
head comparison of FDG-PET and multislice spiral CT in staging of melanoma patients 
with palpable lymph node metastases in terms of diagnostic accuracy and impact on 
treatment. For this study all consecutive patients with palpable, proven lymph node 
metastases of melanoma between mid 2003 and 2007 were prospectively included. 
The number/site of distant metastases detected with FDG-PET and CT were recorded. 
Histology/cytology or 6 months follow-up were the reference standard. Intended and 
performed treatment was recorded. Results showed that in 32% of the 251 patients 
distant metastases were suspected by FDG-PET, 29% by CT (p=0.26). In 27% upstaging 
was correct by FDG-PET and 24% with CT (p=0.18). FDG-PET detected more metastatic 
sites (133 versus 112, p=0.03). Especially more bone and subcutaneous metastases were 
detected by FDG-PET. Treatment changed in 19% of patients; in 79% as result of both 
scans, 17% exclusively FDG-PET driven and 4% exclusively CT driven. In 34 patients (14%) 
FDG-PET had an additional value over spiral CT and in 23 patients (9%) CT had additional 
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value over FOG-PET. In conclusion, FOG-PET and CT are equivalent in upstaging, however 
FOG-PET detected more metastatic sites, especially in bone and subcutaneous. Thus 
based on this study, FOG-PET and/or CT are indicated in the staging of melanoma 
patients with palpable lymph node metastases. 
Chapter 7 The value of SUV measured in a prospective study 
As already mentioned in Chapter 4, the uptake of FOG in the lymph node metastasis 
could be of prognostic value. However, the prognostic value was only seen in this 
retrospective study. Therefore, aim of the study presented in Chapter 7 was to perform 
a prospective analysis to determine whether SUV is of prognostic value (Disease Free 
Survival (DFS) and Disease Specific Survival (DSS)) for melanoma patients with palpable 
lymph node metastases (Stage I I IB). From November 2003-March 2008, all consecutive 
patients with palpable, histology or cytology proven lymph node metastases of melanoma 
referred to the University Medical Centre Groningen for examination with FOG-PET were 
prospectively included and followed up for at least 2 years. The SUVmean and SUVmax 
in the lymph node metastasis were calculated for patients who showed no distant 
metastases. Multivariable survival analysis was performed to determine whether SUV 
was associated with DFS and DSS (Cox Proportional Hazard analysis). For this study, 1 36 
patients were eligible; in 89 patients no distant metastases were shown with FDG-PET or 
CT. High SUV values were present in elderly patients (p=0.02) and in patients with large 
tumor size (p<0.001 ). Patients with low SUVmean had a 3-years DFS of 68. 3% compared 
to 40.9% for patients with a high SUVmean (HR 2.4; p=0.01 ) .  In multivariate analysis 
SUVmean was also associated with DFS (HR 2. 3; p=0.03). Besides, DSS for patients 
with a high SUV was also decreased, even after adjustment for several confounders (HR 
2.6; p=0.04). So, the SUV in the lymph node metastasis is associated with Disease Free 
Survival and Disease Specific Survival for melanoma patients clinically Stage Ill and it 
could potentially be used, additional to other prognostic factors, to decide for adjuvant 
systemic treatment. 
Chapter 8 Costs of adding FOG-PET and CT to the diagnostic work-up 
The aim of the study described in Chapter 8 was to assess the predictive value of FDG-PET 
and multislice spiral CT in the detection of distant metastases and to analyze their costs. 
All consecutive melanoma patients with palpable, histology- or cytology- proven lymph 
node metastases referred to participating hospitals between July 2003 and January 
2008 for examination with FOG-PET and CT were prospectively included in this study. 
Sensitivity, specificity and accuracy of distant metastasis detection were calculated for 
FOG-PET and CT. For the different locations of distant metastases positive predictive value 
(PPV) and negative predictive value (NPV) were calculated. In the economic evaluation 
the costs of diagnostic work-up with and without FOG-PET and CT were compared. 
Overall, 253 melanoma patients with palpable lymph node metastases were included 
in this study. FDG-PET showed a higher sensitivity than CT: 86. 1% (95%CI 78.4-93.7) 
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compared to 78.2% (69.0-87.4). The specificity, however, was higher for CT (93.7%; 
95%CI 90.1-97. 3) as compared to FDG-PET (93.1%; 95%CI 89.3-96.9). Overall, FDG-PET 
showed a higher PPV and NPV to detect distant metastases. Cost-consequence analysis 
showed that adding CT decreased cost by 5 . 5%, adding FDG-PET increased cost by 7.2% 
and adding both increased cost by 15.1 %. In conclusion, adding these diagnostic tools 
improved the staging of Stage Ill patients with minimal cost increase. A proposal for 
the stage-specific use of imaging modalities available for clinicians caring for melanoma 
patients is presented in this chapter. 
Chapter 9 Radiation therapy following lymph node dissection 
Historically melanoma has been thought of as a relatively radiation resistant tumour. 
Nowadays, radiation delivered according to a hypofractionated schedule is the most 
used, although there are no data to confirm that this schedule improves the therapeutic 
impact. In the review presented in Chapter 9 the treatment, loco-regional control, disease­
free and survival rates and complications are discussed. Almost all the reviewed studies 
were retrospective, which could have led to an underestimation of the true incidence 
of the treatment toxicity and morbidity. Adjuvant radiotherapy after lymph node 
dissection for metastases of melanoma seems to improve loco-regional control without 
improving overall survival. The available data indicate the need for improved regional 
control rates in patients with extranodal extension, multiple involved nodes (more than 
three) and patients with large involved nodes (larger than 3 cm). The complications seem 
manageable and consist mainly of fibrosis and edema. 
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Chapter 
Sa menvatt i ng  

Samenvatting 
Hoofdstuk 1 lnleiding 
Het melanoom veroorzaakt meer dan 75% van de sterfte gerelateerd aan huidkanker en 
de incidentie is sterk gestegen in Westerse populaties. Een van de karakteristieken van het 
melanoom is dat het metastaseert naar diverse, onvoorspelbare lokalisaties; daarnaast is 
de diagnose van multiple metastasen op afstand vaak een contra-indicatie voor chirurgie. 
Als gevolg daarvan is een accurate stadiering van de patient van wezenlijk belang voor 
het beleid om die patienten te identificeren die mogelijk overlevingsvoordeel hebben 
van de operatie terwijl deze wordt vermeden in patienten waarbij de overleving niet zal 
verbeteren door de operatie. Daarnaast is het van belang de patient te informeren over 
zijn of haar prognose. Het melanoom is goed te detecteren door de hoge opname van 
FDG; samen met het grillige patroon van metastasen op afstand maakt dat FDG-PET een 
goede modaliteit is om patienten met een melanoom te screenen voor metastasen. 
Hoofdstuk 2 Het gebruik van FOG-PET voor melanoom patienten 
In hoofdstuk 2 wordt de waarde van FDG-PET en de gecombineerde FDG-PET/CT 
scanner in de stadiering en follow-up van melanoom patienten besproken. Een review 
van de literatuur laat zien dat de aanwezigheid van kliermetastasen een belangrijke 
prognostische factor is en dat de recente ontwikkeling van de schildwachtklierprocedure 
(sentinel node procedure) een erg sensitieve methode voor stadiering is. FDG-PET heeft 
maar een beperkte sensitiviteit om microscopisch kliermetastasen te detecteren in deze 
groep van stadium I en II patienten. Dit kan verklaard warden door de grootte van de 
micrometastasen in de niet vergrootte, ofwel klinisch normale, klieren welke te klein zijn 
om door de FDG-PET ge·,dentificeerd te warden. Echter, voor de detectie van metastasen 
op afstand wordt de FDG-PET frequent gebruikt. Ondanks het feit dat er geen 
consensus is over dit onderwerp, zijn er toch chirurgen die streven naar een chirurgische 
verwijdering van de afstandsmetastasen indien er maar een of enkele aanwezig zijn. 
Exacte identificatie van de lokalisatie en het aantal metastasen kan dan belangrijk zijn 
voor de chirurgische planning. Er is daarom een schijnbare paradox dat een accurate 
stadiering nodig is terwijl patienten met gemetastaseerd melanoom een slechte prognose 
hebben (5-jaars overleving van 3-1 6%). Meerdere redenen liggen ten grondslag aan deze 
wens tot stadiering: ten eerste om de patienten te identificeren die mogelijk voordeel 
hebben van de klierdissectie, terwijl deze procedure wordt vermeden bij patienten met 
multiple metastasen op afstand waar het geen overlevingswinst oplevert. Ten tweede 
kan accurate stadiering belangrijk zijn voor de inclusie in klinische trials. Ten derde in dit 
van belang om de patient gedetailleerd te infomeren over zijn of haar prognose. 
Aangezien de huidige standaard in PET beeldvorming de combinatie camera's zijn van 
PET met een CT scanner en de literatuur tot nu toe aangeeft dat met deze modaliteit 
ook een accurate stadiering kan warden verricht, is er een rol weg gelegd voor deze 
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gecombineerde scanner. Echter, er is nog verder onderzoek nodig voor welke patienten 
deze gecombineerde modaliteit toegevoegde waarde heeft aangezien veel metastasen 
reeds gedetecteerd kunnen worden met de FDG-PET en de additionele CT de sensitiviteit 
niet verhoogd. 
Hoofdstuk 3 Effect van FOG-PET op het chirurgisch behande/plan 
Er zijn maar weinig studies die naast de sensitiviteit en specificiteit van FDG-PET naar 
het effect van de resultaten van de scan op het beleid hebben gekeken. Het doel van 
hoofdstuk 3 was het bestuderen van het effect van de resultaten van FDG-PET op de 
behandeling van melanoom patienten in drie universitair medische centra. Voor de studie 
werden de medische statussen van 257 patienten bekeken. De indicatie voor de FDG-PET 
en de bevindingen op de scan werden genoteerd naast de behandelplannen voor en 
na de FDG-PET om een verandering in de behandeling op te sporen. Onverwachte 
bevindingen van (pre)maligne tumoren anders dan het melanoom werden ook genoteerd. 
De resultaten laten zien dat de meeste scans werden aangevraagd voor de stadiering van 
de melanoom patienten (71.2%), voornamelijk om metastasen op afstand te detecteren 
bij stadium Ill patienten. Er was sprake van 'upstaging' naar een hoger stadium bij 56 
patienten (21.8%). In 44 patienten (17.1%) veranderde de behandeling, meestal van 
chirurgie naar systemische behandeling in stadium Ill patienten. In 4.3% van de patienten 
werden onverwachte, meestal colorectale, tumoren gedetecteerd. Concluderend was in 
deze studie al te zien dat FDG-PET het meest waardevol is in stadium Ill melanoom 
patienten om metastasen op afstand te detecteren en patienten te identificeren die 
kandidaten zijn voor chirurgie of systemische behandeling. In 37% van de stadium Ill 
patienten veranderde de chirurgische behandeling as gevolg van de FDG-PET scan. De 
studie liet oak zien dat onverwachte FDG-PET bevindingen verder onderzocht moeten 
worden omdat er sprake kan zijn van (pre)maligne klinisch relevante tumoren. 
Hoofdstuk 4 Prognostische waarde van SUV 
ldentificatie van additionele prognostische factoren kan bijdragen aan de ontwikkeling 
van geYndividualiseerde strategieen. De studie in hoofdstuk 4 beschrijft de potentiele 
rol van de 'Standard Uptake Value (SUV)' in de ziektevrije en algemene overleving in 
melanoom patienten met lymfekliermetastasen. Voor de studie zijn alle melanoom 
patienten met palpabele lymfekliermetastasen die werden verwezen naar het UMCG 
voor een FDG-PET geYncludeerd. De SUV in de lymfekliermetastase werd berekend. 
Verschillen in algemene en ziektevrije overleving tussen patienten met een !age SUV 
en hoge SUV werden berekend. Univariate en multivariate Cox proportional hazard 
model analyses werden uitgevoerd om onafhankelijke prognostische factoren te 
identificeren. In deze retrospectieve studie van 38 patienten werden geen statistisch 
significante verschillen in overleving voor patienten met een hoge of !age SUV gevonden 
(p=0. 11). Ulceratie van de primaire tumor was wel een onafhankelijke prognostische 
factor voor overleving (p=0.02). Er werd wel een significant verschil gevonden in de 
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m ultivariate ana lyse van de ziektevrije overleving tussen patienten met een lage of hoge 
SUV (p=0.009), naast adjuvante rad iotherapie (p=0.001 )  en lokal isatie van het pr imair 
melanoom (p=0.0 17) .  Als deze resu ltaten warden bevestigd door prospectief onderzoek 
kan mogel ij k  adjuvante behandel ing warden overwogen voor patienten met een hoge 
SUV in  de lymfekl iermetastasen .  
Hoofdstuk 5 Perceptie van de be/asting voor de melanoom patienten 
Patienten met lymfekl iermetastasen van het melanoom moeten een aanta l d iagnostische 
testen ondergaan om de aanwezigheid van metastasen op afstand u it te s lu iten .  De 
resu ltaten van de testen kun nen g rate impl icaties hebben voor  de prognose en 
de behandel ing van deze patienten .  Er zijn tot op heden maar enkele stud ies over 
de psycholog ische factoren die een rol spelen en de perceptie van de patienten met 
betrekking tot deze diagnostische testen .  Het doel van de studie in hoofdstuk 5 was 
dan oak het beschrijven van de belasting van de diagnostische testen (thoraxfoto, CT en 
PET scan) zoa ls ervaren door de melanoom patienten met lymfekl iermetastasen .  Voor 
deze studie werd gevraagd aan de patienten om een vragenl ijst met betrekking tot de 
satisfactie en de ervaren belasting in  te vu l len .  De mate waarin patienten zich opgelaten, 
oncomfortabel en angstig voelden, werd genoteerd en tota le scores voor de ervaren 
belasting werden berekend.  Logistische regressie ana lyses werd gebru ikt om factoren te 
onderzoeken d ie samen hingen met de mate van ervaren belasting .  Van de 68 patienten 
d ie werden benaderd, stuurden 59 (87%) de ingevulde vragenl ijst terug . De scores voor 
satisfactie en kwal iteit van leven waren over het a lgemeen hoog . Meer dan de helft van 
de  patienten gaf aan dat de FDG-PET n iet belastend was, 65% voor de CT en 80% voor 
de thoraxfoto. Patienten rapporteerden wel vaker meer ongemak tijdens de FDG-PET 
scan dan tijdens de CT (p=0.003). Patienten die meer tevreden waren rapporteerden 
m inder belasting tijdens de diagnostische testen .  Concluderend is de ervaren belasting 
d oor de patienten laag en het zou daarom n iet moeten i nterfereren met de prima ire 
keuze voor een d iagnostische test op basis van accu ratesse, kosten en het percentage 
patienten dat ju ist wordt gestad ieerd . E r  moet echter wel aandacht warden geschonken 
aan het u itleggen van de procedure en het beantwoorden van mogel ijke vragen van de 
patient om de belasting tot een min imum te reduceren .  
Hoofdstuk 6 Prospectief vergelijk FOG-PET en CT 
B ij melanoom patienten met potentieel resectabele lymfekliermetastasen is het 
n oodzakel ijk  om accurate stadier ing u it te voeren om onnodige chirurgie te voorkomen, 
zoals eerder in  hoofdstuk 2 beschreven . FDG-PET is bij  u itstek geschikt h iervoor 
omdat het melanoom in  hoge mate de FDG opneemt. H et doel van de prospectieve 
mu lticenter studie beschrevenen in hoofdstuk 6 was het zij aan zij vergel ijken van 
FDG-PET en mu ltisl ice spiraal CT i n  de stad iering van melanoom patienten met pa lpa bele 
lymfekl iermetastasen in termen van diagnostische accuratesse en invloed op behandel ing .  
Voor deze studie werden al le opeenvolgende patienten met pa lpabele, bewezen 
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lymfekl iermetastasen tussen 2003 en 2008 prospectief geincludeerd .  Het aantal en de 
lokal isatie van de metastasen op afstand gedetecteerd met PET en CT werd genoteerd . 
H istolog ie, cytologie of ten minste 6 maanden fol low-up gold a ls referentie standaard .  
De voorgenomen en  uitgevoerde behandel ing werden genoteerd . Resu ltaten l ieten zien 
dat in  32% van de 25 1  patienten lokal isaties werden gedetecteerd die verdacht waren 
voor metastasen op afstand door de FDG-PET en in  29% door de CT (p=0. 26). In 27% 
bleek de upstag ing (van stadium I l l  naar IV) bij FDG-PET terecht te zijn en in  24% met 
de CT (p=0. 1 8) .  FDG-PET detecteerde meer lokal isaties met metastasen ( 1 33 versus 1 1 2, 
p=0.03) waaronder s ign ificant meer bot en subcutane metastasen.  De behandel ing 
veranderde in 1 9% van de patienten; in 79% a ls  gevolg van beide scans, in  1 7% a ls  
gevolg van de F DG-PET en in 4% als gevolg van de CT. I n  34 patienten ( 1 4%) had de 
FDG-PET een additionele waarde naast de CT en in 23 patienten (9%) had de CT een 
additionele waarde naast de FDG-PET. Samenvattend zijn de FDG-PET en CT equiva lent 
in het u pstagen van patienten met pa lpabele lymfekl iermetastasen, maar detecteerde de 
FDG-PET meer lokal isaties met metastasen,  voornamel ijk bit en subcutane metastasen.  
FDG-PET en/of CT zij n  ge'i'ndiceerd in de stad iering van melanoom patienten met 
palpabele lymfekl iermetastasen . 
Hoofdstuk 7 De waarde van SUV gemeten in een prospectieve studie 
Zoals a l  beschreven i n  hoofdstuk 4 kan de opname van FDG i n  de lymfekl ier van 
prognostische waarde zijn voor de melanoom patient. Het doel van de studie in hoofdstuk 
7 was het bestuderen van de mogelijke prognostische waarde van de SUV (standard ized 
uptake va lue) voor  de ziektevrije en ziektespecifieke overleving van melanoom patienten 
met pa lpabele lymfekl iermetastasen .  Van 2003-2008 werden a l le  opeenvolgende 
patienten met palpabele bewezen lymfekl iermetastasen van het melanoom verwezen 
naar het U n ivers ita i r  Med isch Centrum Groningen prospectief geincludeerd en gevolgd 
voor tenminste 2 jaar. De SUVmean en de SUVmax in  de lymfekl iermetastase werden 
berekend voor de patienten zonder metastasen op afstand .  M u ltivariate su rviva l  
ana lyse werd gebru ikt om onafhankel ijke prognostische factoren te bepa len . I n  deze 
studie konden 89 van de 1 36 van de U M CG patienten warden geincludeerd . Hoge SUV 
waarden werden gemeten in oudere patienten (p=0.02) en in  patienten met een g rote 
tumor in de lymfeklier (p<0.00 1 ) .  Patienten met een lage SUV waarde hadden een 3-jaars 
ziektevrije overleving van 68 .3% in vergel ijk ing met 40.9% voor de patienten met een 
hoge SUV waarde (H R 2 .3; p=0.03). Daarnaast was de ziektespecifieke overleving voor 
patienten met een hoge SUV ook lager, ook na correctie voor potentiele confouders (HR 
2 .6; p= 0.04) . Concluderend i s  de SUV in de lymfekl iermetastase sign ificant geassocieerd 
met de ziektevrije en ziektespecifieke overleving bij melanoom patienten met kl i n isch 
stad ium I l l  melanoom.  De SUV kan mogel ijk, naast andere prognostische factoren,  
worden gebru ikt in  de beslissing voor adjuvante systemische therap ie.  
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Hoofdstuk 8 Kosten voor het toevoegen van FOG-PET en CT aan het 
diagnostische traject 
Het doel van de studie beschreven in hoofdstuk 8 was om de voorspellende waarde 
van de FDG-PET en multislice spiraal CT te beschrijven voor de detectie van metastasen 
op afstand en het berekenen van de kosten voor het toevoegen van deze modaliteiten. 
Voor deze studie werden alle opeenvolgende melanoom patienten met palpabele 
bewezen lymfekliermetastasen in de participerende ziekenhuizen tussen juli 2003 en 
januari 2008 verwezen voor FDG-PET en CT prospectief ge'i'ncludeerd. De sensitiviteit, 
specificiteit en accuratesse met betrekking tot de detectie van metastasen op afstand 
van de FDG-PET en CT werden berekend. Daarnaast werd voor de verschillende mogelijke 
lokalisaties van de metastasen op afstand de positief en negatief voorspellende waarde 
berekend. In de economische evaluatie werden de kosten van het diagnostisch traject 
en behandeling berekend zonder en met FDG-PET en/of CT. FDG-PET had, in de 253 
patienten geincludeerd in deze studie, een hogere sensitiviteit dan CT: 86. 1 (95%BIV 
78.4-93.7) versus 78.2% (95%BIV 69.0-87.4). De specificiteit was echter hoger voor de 
CT (93.7%; 95%BIV 90.1 -97.3) in vergelijking met de FDG-PET (93. 1 %; 95%BIV 89. 3-
96.9). In het algemeen had de FDG-PET een hogere positief en negatief voorspellende 
waarde voor de detectie van metastasen op afstand. De kostenanalyse liet zien dat 
het toevoegen van alleen een CT de kosten met 5.5% verlaagde, het toevoegen van 
alleen de FDG-PET de kosten met 7.2% verhoogde en dat het toevoegen van beide 
modaliteiten de kosten met 1 5. 1% verhoogde. Samengevat geeft het toevoegen van 
deze modaliteiten een verbetering van de stadiering van klinisch stadium Ill melanoom 
patienten met een geringe kostenverhoging. Tevens wordt in dit hoofdstuk een voorstel 
gepresenteerd voor een stadiumspecifieke richtlijn met betrekking tot het gebruik van 
diagnostische modaliteiten. 
Hoofdstuk 9 Radiotherapie na therapeutische lymfek/ierdissectie 
Historisch gezien werd het melanoom gezien als relatief ongevoelig voor radiotherapie. 
Echter radiotherapie volgens een hypofractioneringsschema wordt wel veel toegepast, 
terwijl er ten tijde van het schrijven van hoofdstuk 9 geen data was om de therapeutische 
waarde hiervan te bevestigen. De review beschreven in hoofdstuk 9 bediscussieerd 
de behandeling, de regionale controle en de (ziektevrije) overleving. Bijna alle studies 
ge'i'ncludeerd in de review waren retrospectief, dat kan leiden tot een onderschatting 
van de incidentie van de toxiciteit van de behandeling en de morbiditeit. Adjuvante 
radiotherapie na lymfeklierdissectie voor metastasen van het melanoom lijkt de regionale 
controle te verbeteren zonder de algemene overleving te verbeteren. De beschikbare 
data geven aan dat patienten met extranodale groei van de kliermetastasen, met multiple 
positieve klieren (meer dan 3) en patienten met grote positieve klieren (grater dan 3 cm) 
de meeste winst kunnen behalen met adjuvante radiotherapie. De complicaties lijken 
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met een groat aantal vakken van de studierichting Voeding en Gezondheid kon zij de 
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Samenvatti ng van het onderzoek 
Achtergrond 
Bij ongeveer veertig procent van de patienten met een melanoom zal gedurende de ziekte 
metastasering naar de lymfeklieren optreden .  Met behulp van conventionele stadiering 
door middel van computer tomografie van longen en/of buik, zal bij ongeveer twintig 
percent van de patienten met een klinisch locoregionaal gemetastaseerd melanoom 
(stadium Ill) metastasering op afstand warden vastgesteld. Het optimaliseren van de 
stadiering met behulp van een non-invasieve methode is wenselijk, daar patienten die 
nu een in opzet curatieve chirurgische behandeling voor de kliermetastasen ondergaan, 
slechts een vijfjaarsoverleving hebben van 40-50%. Anders gezegd, ten tijde van de 
chirurgische behandeling waren reeds metastasen op afstand aanwezig. Er is behoefte 
aan een betere non-invasieve stadiering bij het klinisch locoregionaal gemetastaseerd 
melanoom. Positron Emissie Tomografie (PET) met 18F-fluoro-2deoxyglucose (FDG) heeft 
de potentie patienten met klinisch vastgestelde kliermetastasen van een melanoom beter 
te stadieren. De waarde van de nieuwe spiraal computer tomografie (spiraal CT) in de 
stadiering van patienten met kliermetastasen is nag niet onderzocht. 
Doe/stelling 
Vaststellen van de plaats van 'whole body' positron emIssIe tomografie (PET) en 
'whole body' spiraal computer tomografie (spiraal CT) bij de stadiering van het klinisch 
locoregionaal gemetastaseerd melanoom (stadium 111 ). 
Onderzoeksvraag 
Hoe groat is het percentage verandering van het klinisch stadium 111 melanoom, de 
zogenaamde 'upstaging', met behulp van 'whole body' FDG-PET en 'whole body' spiraal 
CT ten opzichte van de standaard rontgen foto van de longen (X-Thorax)? 
Wat is de sensitiviteit en specificiteit voor het detecteren van afstandsmetastasen van 
'whole body' FDG-PET en 'whole body' spiraal-CT bij de stadiering van klinisch stadium 
Ill melanoom? 
In welk percentage van de patienten warden extra metastasen gevonden met 'whole 
body' FDG-PET in vergelijking met 'whole body' spiraal-CT en andersom? 
Wat is de invloed van de 'optimalisering' van de stadiering via het toevoegen van 'whole­
body' FDG-PET en / of 'whole-body' spiraal CT op de (chirurgische) behandeling? 
Welke toepassing voor de stadiering van stadium Ill melanoom is het meest kosten 
effectief? 'Whole body' FDG-PET of spiraal-CT? of is er een indicatie voor beide 
onderzoeken, te samen of aanvullend? D.w.z. positieve PET dan gerichte CT, of positieve 
CT dan vervolgens PET. Wat is de kosteneffectiviteit van de 'whole-body' FDG-PET en 
'whole-body' spiraal CT? 
Studieopzet 
Alie patienten die zich presenteren met een klinisch locoregionaal gemetastaseerd 
melanoom (stadium Ill) en die in aanmerking komen voor een in opzet curatieve 
chirurgische verwijdering van de aangedane lymfeklieren komen voor het onderzoek in 
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aanmerking. In een prospectieve studie wardt de waarde van 'whole-body' FDG-PET 
en 'whole-body' spiraal CT in de stadiering van locoregionaal gemetastaseerd 
melanoom onderzocht. Zowel bij een positieve FDG-PET als een positieve spiraal CT zal 
warden gepoogd cytologische en/of histopathologische bevestiging van de gevonden 
afwijking(en) te verkrijgen. De definitieve uitslag van het biopt wordt gescoord als 
positief of negatief t.b.v. vaststellen van de voarspellende waarde. Op basis van de 
FDG-PET en spiraal CT bevindingen zal vervolgens aan iedere patient een individueel 
behandelingsadvies warden gegeven. 
Studiepopu/atie 
Patienten met een klinisch locoregionaal gemetastaseerd melanoom (stadium 111), dat 
cytologisch en/of histopathologische is bevestigd, en die in aanmerking komen voor een 
in opzet curatieve chirurgische verwijdering van de aangedane lymfeklieren komen voor 
het onderzoek in aanmerking. Consecutief warden 1 65 patienten gerekruteerd uit de 
I KN regio, IKA regio en IKO regio. Uitgesloten zijn patienten < 1 8  jaar, patienten die een 
schildwachtklierbiopsie hebben ondergaan en waar kliermetastasering is vastgesteld, en 
patienten met reeds aangetoonde haematogene of intransit metastasering. 
Uitkomstmaten 
Aantal patienten bij wie FDG-PET metastasen kan aantonen. 
Aantal patienten bij wie spiraal-CT metastasen kan aantonen. 
Aantal patienten dat als gevolg van de FDG-PET dan wel de CT geen lymfeklierdissectie 
zal ondergaan. 
Kosten effectiviteit van de implementatie van 'whole-body' FDG-PET en 'whole-body' 
spiraal CT bij de stadiering van het klinisch locoregionaal gemetastaseerde melanoom. 
Statistiek 
Met als uitgangspunt dat de FDG-PET in 35% van de gevallen positief is, waarvan oak de 
spiraal-CT in 25 % positief is, wordt er dus in 35% biopten genomen. Stel bij de PET is 
20% juist-positief en bij de spiraal-CT 1 5%. 




















Bij de vraag of er verschil is in specificiteit tussen PET en spiraal-CT, gaat het om de tumor 
positieven. De te gebruiken toets is dan McNemar. Tweezijdig getoetst, op niveau p=0.05 
met 85% power zijn dan 33 positieve biopten nodig, ofwel 33/0.2= 1 65 patienten 
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Economische eva/uatie 
Kosten verbonden aan de stadiering van patienten met een klinisch locoregionaal 
gemetastaseerd melanoom zullen vergeleken warden met de kosten van stadiering met 
een 'whole-body' FDG-PET en een 'whole-body'spiraal CT. De kosten effectiviteit wordt 
bepaald door het aantal correct gestadieerde patienten en de daarmee gepaard gaande 
kosten in het huidige totale traject te vergelijken met die in het voorgestelde plan. Het 
huidige disseminatie onderzoek bij melanoom stadium Ill omvat een X-thorax, en een 
bepaling van het LDH in het bloed. 
Achterg rond en doelstel l ingen van het 
onderzoek 
Vaststellen van de plaats van 'whole body' positron emissie tomografie (PET) en 
'whole body' spiraal computer tomografie (spiraal CT) bij de stadiering van het klinisch 
locoregionaal gemetastaseerd melanoom (stadium I ll) . 
2. 1 Behandeling van het me!anoom 
De incidentie van het melanoom neemt in Nederland jaarlijks nog steeds toe en 
bedraagt nu 14  per 1 00.000 per jaar.( 1 )  Ongeveer 9% van de patienten betreft 
stadium Ill (lymfekliermetastasering), 84% stadium I en I I  en 7% stadium IV. (2) 
Ongeveer 30% van de stadium I en II patienten krijgt een recidief met locoregionale 
metastasen. De leeftijd gecorreleerde sterfte ten gevolge van het melanoom blijft 
daarentegen onveranderd. ( 1 ) Dit komt doordat melanomen meer en meer in een vroeg 
stadium warden gediagnosticeerd. De prognose van het melanoom wordt bepaald 
door de klinische manifestatie van het melanoom (ulceratie, bloeding, lymfeklieren, 
anatomische lokalisatie), de histologische kenmerken (dikte van het melanoom, aantal 
mitosen, ulceratie/bloeding, aanwezigheid van 'tumor infiltrating lymphocytes', aantal 
pathologische klieren). (2) Het metastaseringsgedrag van het melanoom is voor de 
individuele patient met een melanoom niet te voorspellen. De prognose is gerelateerd 
aan het stadium van de ziekte.(3) 
De primaire behandeling van het melanoom is chirurgie. Op basis van prospectieve 
onderzoeken zijn de chirurgische resectie marges gedefinieerd.(4) Zonodig wordt het 
ontstane huiddefect bedekt met een vrij huidtransplantaat. Na chirurgische verwijdering 
is er een risico op lokale recidivering, intransitmetastasering, locoregionale metastasering 
en/of afstandsmetastesering. Er is geen plaats voor electieve klierdissecties bij stadium 
I melanoom.(4) Adjuvante hypertherme regionale perfusie vermindert niet de kans op 
het optreden op een locale recidivering, intransitmetastasering en/of locoregionale 
metastasering.(5) De schildwachtklierbiopsie bij het stadium I melanoom is een 
stadierende ingreep, zolang de resultaten van prospectieve onderzoeken nog niet hebben 
aangetoond dat klierdissectie na een positieve schildwachtklierbiopsie een verbetering 
geeft van de ziektevrije en/of totale overleving.(6) 
Er is geen indicatie voor het routinematig verrichten van disseminatie onderzoek 
met behulp van CT en/of botscans bij asymptomatische patienten met een primaire 
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melanoom (stadium I), daar de 'detectie rate' zeer laag is . Slechts ongeveer eenderde van 
de patienten met een stadium I melanoom ontwikkelt een recidief, en vaak gaat het dan 
om een lokaal en/of locoregionaal recidief. Met behulp van de schildwachtklierbiopsie bij 
stadium I melanomen > 1 .5 mm wordt bij ongeveer 20% van de patienten lymfogene 
metastasering gevonden.(7) Het stadierend onderzoek bij een klinisch stadium I 
melanoom omvat alleen een rontgenfoto van de longen (X-thorax) en eventueel bepaling 
van het LDH in het bloed. 
Wanneer er sprake is van een klinisch locoregionaal gemetastaseerd melanoom 
(stadium Ill) is er indicatie voor het cytologische/histologisch vaststellen van 
lymfekliermetastasering. Het metastaseringspatroon van het melanoom is allereerst naar 
de regionale lymfeklieren, en vervolgens de longen, lever, en andere organen. Voordat 
een in opzet curatieve klierdissectie wordt uitgevoerd is het noodzakelijk metastasering 
op afstand uit te sluiten. Vijftig tot zestig percent van deze patienten zal immers na de 
klierdissectie een recidief ontwikkelen, hetgeen wijst op occulte metastasering ten tijde 
van de klierdissectie. Het huidige disseminatie onderzoek bij melanoom stadium Ill omvat 
een X-thorax, en een bepaling van het LDH in het bloed. Bij een sterk verhoogd LDH kan 
er indicatie zijn voor het verrichten van een echografie van de lever. Op klinische gronden 
is er soms een indicatie voor een CT scan van de regionale klierstations of longen, of 
MRI van de hersenen. Op indicatie wordt botscintigrafie verricht ter uitsluiting van 
metastasering naar het skelet bij symptomatische patienten. Wanneer geen metastasen 
op afstand worden aangetoond vindt een in opzet curatieve klierdissectie plaats. Met 
deze chirurgische behandeling wordt slechts een 5-jaarsoverleving van maximaal 50% 
bereikt. (3) 
Is er sprake van metastasering op afstand, dan wordt besloten tot een palliatieve 
behandeling. Hoewel bij metastasering op afstand de patient een chirurgische ingreep 
en de daarbij behorende morbiditeit en kosten bespaard kan blijven, kan er daarentegen 
soms een indicatie tot palliatieve chirurgische resectie van de lymfeklieren en/of 
ge·1soleerde afstandsmetasen bestaan.(8) Andere vormen van palliatieve behandeling 
zijn radiotherapie, chemotherapie, immunotherapie, en/of vaccinatie therapie. De 
systeembehandeling wordt bij voorkeur in onderzoeksverband uitgevoerd, daar er geen 
standaard behandeling bij het melanoom is voor gemetastaseerde ziekte. 
2.2 Stadiering van het /ocoregionaa/ gemetastaseerd melanoom 
2.2. 1 Computer tomografie 
Er is weinig literatuur met betrekking tot de waarde van computer tomografie bij de 
stadiering van het locoregionaal gemetastaseerde melanoom. Drie studies uit MD 
Anderson, MSKCC en Ann Arbor bij symptomatische stadium Ill melanoom patienten 
vonden slechts bij respectievelijk 7%, 4% en 1 4% metastasen op afstand, en een ' false 
positive rate' van respectievelijk 8.4%, 22%, en 12%.(9, 1 0,1 1 )  In de MSKCC studie wordt 
de indruk gewekt, dat er is mogelijk een relatie tussen het aangedane lymfeklierstation 
en het metastaseringspatroon op afstand, terwijl dit in de Ann Arbor studie niet wordt 
bevestigd. (1 0, 1 1 )  Bij CT scan van de longen worden vaker metastasen gevonden bij 
patienten met halskliermetastasen, terwijl bij een CT scan van de buik vaker metastasen 
worden gevonden bij patienten met lieskliermetastasen. ( 1 0) De studies toonden een 
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'lage detectie rate' in het vaststellen van afstands metastasering en een niet onaanzienlijk 
percentage fout positieve onderzoeken. Daarnaast werd het oncologisch beleid slechts 
bij 7% van de patienten veranderd op basis van de uitkomsten van de CT scan. (10) 
Op basis van deze retrospectieve onderzoeken uit de tachtiger en begin negentiger 
jaren lijkt het routinematige gebruik van computer tomografie van buik, longen, voor 
het vaststellen van metastasering op afstand niet gerechtvaardigd. Hierbij dient echter 
wel opgemerkt te warden dat deze onderzoeken werden uitgevoerd met de 'oude CT 
apparatuur', er in het algemeen geen 'whole-body' CT werd verricht en de onderzoeken 
niet met de huidige ons ter beschikking staande gevoelige 'whole-body' spiraal CT 
plaatsvond. 
2.2.2  Positron Emissie Tomografie 
PET met 18F-fluorodeoxyglucose (FDG), FDG-PET, geeft een indruk over de metabole 
activiteit in een metastase. 'Whole body PET' geeft niet hetzelfde anatomische inzicht als 
een CT of MRI, maar wel een volledig 'anatomisch' overzicht, en in tegenstelling tot CT 
of MRI hoeft geen gebruik gemaakt te warden van contrastmiddelen. De ervaring met 
FDG-PET bij de stadiering van het locoregionaal gemetastaseerd melanoom is beperkt, 
maar mogelijk een waardevolle onderzoek methode gezien de hoge mate van sensitiviteit 
en specificiteit, met name bij het locoregionaal gemetastaseerde melanoom (stadium 
1 11). De sensitiviteit van FDG-PET in het vaststellen van metastasering is gerelateerd aan 
het 'tumor volume' in de metastase. PET kan zeer waarschijnlijk metastasen vanaf 5 
mm detecteren. FDG-PET heeft de potentie om meer metastasen aan te tonen dan 
conventioneel onderzoek, hoewel het vaststellen van hersen, lever, en/of skeletmetastasen 
mogelijk lager is dan van conventioneel CT, MRI, en/of skeletscintigrafie.(12-22) 
FDG-PET heeft het potentieel in zich om een belangrijke diagnostische techniek te warden 
bij het vaststellen van de uitgebreidheid van lymfogene metastasering, binnen en buiten 
het locoregionale klierstation, en metastasering op afstand bij het klinisch locoregionaal 
gemetastaseerde melanoom (stadium Ill) .  Daarentegen is er geen plaats voor PET in de 
stadiering van het klinisch stadium I melanoom. Bij de stadiering van het klinisch stadium 
I melanoom is de schildwachtklierbiopsie superieur aan PET.(23-25) 
2.3.3 Voorlopige resu/taten 
2.3.3. 1 Positron emissie tomografie 
Vanuit het UMCVU is een systematisch literatuuronderzoek gedaan naar de plaats van 
FDG-PET in de diagnostiek en behandeling van het melanoom.  Uit dit uitstekende review 
van de literatuur blijkt dat de 'pooled sensitivity en de 'pooled specificity' van FDG-PET 
in het vaststellen van melanoom metastasen respectievelijk 0.79 (95% Cl, 0.66-0.93) 
en 0.86 (95% Cl, 0.78-0.95) bedraagt. De 'pooled DOR' bedraagt 33.1 (95% Cl, 21.9-
54.0) en suggereert een hoge diagnostische acutaresse, met name voor haematogene 
metastasering (DOR 34.6) en minder voor lymfogene metastasering (DOR 19.5) . (26) 
In de stadiering van kl inisch stadium Ill melanoom, kan de sensitiviteit en specificiteit 
van CT en PET verschillend zijn voor de diverse regio's in het lichaam.(16) Opgemerkt 
dient te warden dat voor de meeste PET studies er sprake is van een 'pre- en posttest 
selection bias', waardoor de sensitiviteit misschien te hoog en de specificiteit te laag 
wordt ingeschat. Juiste klinische informatie bij de PET aanvraag en terugkoppeling van 
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de PET naar de aanvrager kan de 'predictive value' van een positieve PET scan verbeteren 
van 78.6% tot ongeveer 90.6%! (20) 
Met behulp van FDG-PET is een verandering in het stadium van de ziekte, zogenaamde 
'upstaging' te veronderstellen varierend van 16-28%.(19,20) Deze 'upstaging' kan van 
invloed zijn op het chirurgische/oncologische beleid. Waarschijnlijk zal oncologisch 
behandelingsplan op basis van het FDG-PET onderzoek het bij een op de zes patienten 
veranderen.(22) Volgens Valk et al. zou FDG-PET t.o.v. CT bij klinisch stadium 111 melanoom 
kosteneffectief zijn met een zogenaamde 'savings cost ratio' van 4: 1.(27) 
2.3.3.2 Computertomografie versus positron emissie tomografie 
In vier prospectieve onderzoeken waarin PET en CT in de stadiering werden vergeleken 
was PET superieur t.o.v. CT, en werden niet verwachtte metastasen gevonden in 7%, 
8%, 16% en 15%, echter de fout-positieve bevindingen waren 22%, 8%, 12%, en 
9%.(16,17,20,22) In alle vier de studies is de FDG-PET niet werkelijk vergeleken met CT, 
daar er wel een 'whole-body PET' werd vervaardigd, maar slechts een beperkte CT werd 
uitgevoerd. De vier studies tonen aan dat FDG-PET zeer gevoelig is voor het aantonen 
van de regionale kliermetastasen en daarnaast bij regionale kliermetatstasering elders 
metastasen aantoont. PET scans dienen wel geevalueerd te warden aan de hand van 
een goede klinische voorgeschiedenis en recente anamnese en lichamelijk onderzoek, 
teneinde het aantal fout-positieve uitkomsten te verminderen. (20) 
Hoewel het hier 'recente data' betreft heeft het CT onderzoek niet plaatsgevonden 
met 'spiraal CT', cq 'whole-body' CT. Derhalve dienen de gepubliceerde data als 
relatief 'onbetrouwbaar' beschouwd te warden. In geen van de publicaties wordt 
antwoord gegeven op de vraag of stadiering van het melanoom stadium Ill met PET 
of CT, of beide dient te geschieden, behoudens door Tyler et al. die meent dat beide 
onderzoekstechnieken complementair en niet-competatief zijn.(20) 
2.4 Samenvatting 
Er is behoefte aan het optimaliseren van de preoperatieve stadiering van het klinisch 
locoregionaal gemetastaseerd melanoom (stadium Ill), ten einde de meest optimale 
'oncologische behandeling' te kunnen uitvoeren, d.w.z. chirurgie, radiotherapie, 
chemotherapie, immunotherapie, vaccinatietherapie of een combinatie van deze 
behandelingen. Momenteel staan ons twee onderzoeken ter beschikking, 'whole­
body' FDG-PET, en spiraal CT, die beide geen standaard onderzoek zijn bij stadium 
I ll melanoom. Welk onderzoekstechniek is nu het meest specifiek in het aantonen cq 
uitsluiten van metastasering op afstand? Is dit FDG-PET, de nieuwe generatie spiraal-CTs 
of een combinatie van beide onderzoeken? 
3 .0 Stud ie design 
1 .  Hoe groot is  het percentage verandering van het klinisch stadium 111 melanoom, de 
zogenaamde 'upstaging', met behulp van 'whole body' FDG-PET en 'whole body' 
spiraal CT ten opzichte van de standaard rontgen foto van de longen (X-Thorax)? 
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2. Wat is de sensitiviteit en specificiteit voor het detecteren van afstandsmetastasen 
van 'whole body' FDG-PET en 'whole body' spiraal-CT bij de stadiering van klinisch 
stadium Ill melanoom? 
3. In welk percentage van de patienten worden extra metastasen gevonden met 'whole 
body' FDG-PET in vergelijking met 'whole body' spiraal-CT en andersom? 
4. Wat is de invloed van de 'optimalisering' van de stadiering via het toevoegen 
van 'whole-body' FDG-PET en / of 'whole-body' spiraal CT op de (chirurgische) 
behandeling? 
5. Welke toepassing voor de stadiering van stadium Ill melanoom is het meest kosten 
effectief? 'Whole body' FDG-PET of spiraal-CT?  of is er een indicatie voor beide 
onderzoeken, te samen of aanvullend? D.w.z. positieve PET dan gerichte CT, of 
positieve CT dan vervolgens PET. Wat is de kosteneffectiviteit van de 'whole-body' 
FDG-PET en 'whole-body' spiraal CT? 
3.2 Studie design 
Dit is een prospectieve niet gerandomiseerde studie die de waarde van 'whole­
body' FDG-PET en 'whole-body' spiraal CT onderzoekt bij het klinisch locoregionaal 
gemetastaseerde melanoom (stadium I l l). Patienten met cytologisch of histologisch 
vastgestelde lymfekliermetastasering van een melanoom zullen een 'whole-body' 
FDG-PET en 'whole-body' spiraal CT ondergaan. Hierbij zal het aantal metastasen buiten 
het regionaal aangedane klierstation warden vastgesteld en, indien mogelijk, cytologisch 
of histologisch worden bevestigd. Tevens geldt er een follow-up van 6 maanden . Op 
deze wijze kan de specificiteit en sensitiviteit van zowel 'whole-body' FDG-PET als 
'whole-body' spiraal CT warden vastgesteld; in het onderzoek wordt dus het volgende 
met elkaar vergeleken :  "conventionele diagnostiek + 'whole-body' FDG-PET" en 
"conventionele diagnostiek + 'whole-body' CT". Op basis van het stadierende onderzoek 
zal vervolgens een individueel behandelingsplan warden opgesteld dat kan bestaan uit 
chirurgie, radiotherapie, chemotherapie, of een combinatie van deze drie behandelingen. 
De flow diagram van de studie is bijgevoegd in bijlage 1. 
De kosten verbonden aan de stadiering van patienten met een klinisch locoregionaal 
gemetastaseerd melanoom zullen vergeleken warden met de kosten van stadiering met 
een 'whole-body' FDG-PET en een 'whole-body'spiraal CT. De kosten effectiviteit wordt 
bepaald door het aantal correct gestadieerde patienten en de daarmee gepaard gaande 
kosten in het huidige diagnostische traject te vergelijken met die in het voorgestelde plan . 
3.3 Onderzoeken 
Patienten die gediagnosticeerd zijn met een klinisch locoregionaal gemetastaseerd 
melanoom ondergaan een cytologische en/of histologische biopsie van de lymfeklier 
om de metastasering cytologisch/histopathologisch te bevestigen. Patienten bij wie 
vervolgens bij klinisch lichamelijk onderzoek of bij conventionele rontgen foto van de 
longen metastasering op afstand wordt vastgesteld komen niet in aanmerkingen voor 
participatie in dit onderzoek. 
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3.3. 1 Positron emissie tomografie 
1 8F-fluorodeoxyglucose voor het FDG-PET scan protocol wordt in het AZG geproduceerd 
volgens de methode van Hamacher et al (30) of wordt commercieel verkregen. 
Radiochemische zuiverheid is > 95%. Alleen de volledige ring PET scanners warden 
gebruikt zoals de Siemens ECAT HR+ machine (AZG, VUMC) of de Siemens Exact 
scanner (UMCN). Na een nachtelijke of >6 uur vastperiode warden de patienten 
intraveneus ge·1njecteerd met 4 MBq / kg lichaamsgewicht voor 3D en 2D acquisities 
(allebei toegestaan). Patienten krijgen 500-1 500 ml water te drinken. Het interval tussen 
de FDG injectie en de PET scan is 60-90 min. Op indicatie mag furosemide, diazepam en 
bedrust warden gegeven. Patienten warden gescand vanaf het midden van het femur 
tot de schedel. De emissie scanduur is 5 minuten per bedpositie, transmissie afbeelding 
3 minuten. Alie reconstructies zijn iteratief (OSEM) met 8-1 6 subsets en 2-4 'iterations'. 
3.3. 1. 1 Vers/ag/egging en verificatie FOG-PET 
De FDG-PET scans zullen warden ge'i'nterpreteerd door twee ervaren nucleaire 
geneeskundigen die geblindeerd zijn voor de uitslag van de CT-scan en de informatie 
van de PA, indien die al verricht is. Seide zullen aangeven (voor elke mogelijke plaats 
van een metastase) of er een af- of aanwezigheid is van een PET positieve laesie. Bij niet 
gelijke beoordeling moet er een consensus warden bereikt. Als FDG-PET een indicatie 
geeft voor metastasen moet er, indien mogelijk, cytologische /histologische bevestiging 
warden verkregen. 
3.3.2 Computer tomografie 
Multisclice spiraal CT scans zullen warden vervaardigd om metastasering op afstand 
uit te sluiten . Deze CT scan zullen vervaardigd warden met intraveneus contrast en 
oraal contrast van de thorax en abdomen (en eventueel hals) voor het vast stellen van 
lymfogene en/of haematogene metastasering naar de lymfeklieren, longen, lever en 
andere weefsels en organen. 
CT van thorax en abdomen en bij localisatie van het melanoom in het gebied van hoofd 
en hals ook een CT van de hals. Het onderzoek wordt uitgevoerd met een multidetector 
spiraal CT, tenminste met vier detectoren. De patient moet 800 ml oraal contrast drinken 
voor het CT onderzoek. Eerst een blanco bovenbuik (lever). Vervolgens CT Thorax 
met intraveneus contrast, 1 00 cc., 2.5 cc/sec., scandelay 30 sec. Collimatie 1 , 5  mm. 
Reconstructie 3mm. om 1 ,5  mm. 
Daarna gehele buik t/m liezen (CT Abdomen). De start 90 seconden na contrast 
toediening. Collimatie 1 ,5  mm. Reconstructie 3mm. om 1 ,5  mm. 
lndien ook hals: CT Hals met intraveneus contrast 75 cc. met 2,5 cc/sec. Scandelay 30 
sec, scannen van caudaal naar craniaal. Collimatie 0, 75 mm. Reconstructie 3mm. om de 
3 mm. 
De beelden warden getransporteerd naar een PACS systeem en/of een werkstation om 
te warden bestudeerd. Het onderzoek zal verricht warden vanaf de computerbeelden en 
niet vanaf zogenaamde 'foto's'. Alie spiraal CT scans dienen in het onderzoeksinstituut 
te warden vervaardigd, tenzij de spiraal CT van een ander ziekenhuis voldoet aan de 
specificaties zoals vastgelegd in het onderzoeksprotocol. 
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3.3.2. 1 vers/ag/egging en verificatie CT scans 
De spiraal CT scans zullen warden ge·1nterpreteerd door twee ervaren radiologen die 
geblindeerd zijn voor de uitslag van de FDG-PET scans en voor de informatie van de PA, 
indien die al is uitgevoerd. Beide zullen aangeven (voor elke mogelijke plaats van een 
metastase) of er een af- of aanwezigheid is van een CT positieve laesie Bij niet gelijke 
beoordeling moet er een consensus warden bereikt. Als CT een indicatie geeft voor 
metastasen moet er, indien mogelijk, cytologische /histologische bevestiging warden 
verkregen. 
3.4 Behande/ing 
De behandeling van de patienten met het klinisch locoregionaal gemetastaseerde 
melanoom is een regionale klierdissectie van het aangedane klierstation. Het doel van dit 
onderzoek is de stadiering van het klinische locoregionaal gemetastaseerde melanoom 
te optimaliseren. Op basis van de bij dit onderzoek wel of niet vastgestelde metastasen 
op afstand zal voor iedere patient een individueel behandelingsplan warden opgesteld. 
De uiteindelijk uit te voeren behandeling wordt bepaald door de specialist(en). 
3.5 Eindpunten van de studie 
Vaststellen van het percentage metastasen met FDG-PET. 
Vaststellen van het percentage metastasen met spiraal CT. 
Vaststellen van het percentage verandering m.b.t. het wel of niet opereren 
Kosten-effectiviteit van FOG-PET, spiraal CT en de combinatie van beide in het vaststellen 
van metastasen op afstand. 
4 .0  Patienten selectie 
4. 1 lnc/usie criteria 
Cytologisch of histologisch bewezen lymfekliermetastase van een melanoom 
Leeftijd minimaal 18 jaar 
Toestemming van de patient voor deelname aan het onderzoek 
Zes uur nuchter kunnen blijven (gecontroleerde diabetes) 
In staat zijn een PET en een CT scan te ondergaan 
4.2 Exc!usie criteria 
Klinisch vastgestelde haematogene metastasen of intransitmetastasering 





4.3 Toestemming patient 
De patient krijgt mondeling en schriftelijk informatie (informatie folder) over het 
onderzoek. Er wordt schriftelijke toestemming van de patient tot deelname aan het 
onderzoek gevraagd. Zie Addendum 
5 . 0  Data management 
5. 1 Registratie van patienten 
Zodra de diagnose regionaal gemetastaseerd melanoom is bevestigd kan de patient 
nadat een informed consent is ondertekend aangemeld warden voar de studie. 
Prof. Dr. H .  J .  Hoekstra 
Chirurgische Oncologie 
Academisch Ziekenhuis Groningen 
Postbus 30.001 
9700 RB Groningen 
Telefoon 050-361231 7 
Fax 050-3614873 
Email s.stalman@chir.azg.nl 
Contact persoon onderzoek: 




5.2. Data verzameling 
De data zullen op zogenaamde case record forms (CRFs) warden verzameld. Bij 
participatie in het onderzoek zal de volgende informatie warden vastgelegd: 
- Naam van het ziekenhuis 
- Naam van de chirurg 
- Naam van de patient of code (initialen), geboarte datum en geslacht 
- Controle van de in / exclusie criteria 
- Controle van informed consent 
- Na registratie in het onderzoek zal bij het onderzoek slechts nog gebruik gemaakt 
warden van een registratie nummer. ledere patient zal een eigen nummer krijgen 
opdat de privacy van de patient is gewaarborgd. 
Medische vragen en opmerkingen m.b.t. het onderzoek kunnen gericht warden aan de 
studie coordinatoren E. Bastiaannet of Prof. Dr. H . .  J. Hoekstra, Chirurgische Oncologie, 
Academisch Ziekenhuis Groningen, telefoon 050-3612317, fax 050-3614873, of email 
e.bastiaannet@chir.azg.nl of h.j .hoekstra@chir.azg.nl 
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5.3 Formulieren en procedure data verzameling 
5.3. 1 Patienten registratieformulier 
Het patienten registratie formulier omvat de data die noodzakelijk zijn om de patient te 
registreren voor de studie, de inclusie en exclusie criteria te controleren, de diagnose en 
stadium van de ziekte vast te stellen, en informed consent te registreren. 
5.3.2 Patienten onderzoeksformulier 
Op het patienten onderzoeksformul ier warden de bevindingen van de FDG-PET en spiraal 
CT genoteerd, evenals de cytologische / histopathologische uitslag van de bij FDG-PET 
en/of CT gevonden afwijkingen. 
6 . 0  Statistiek 
PET scans en 'whole body' spiraal-CT scans warden gedefinieerd als positief of negatief. 
Positieve scans worden verder gecategoriseerd in positief maar niet suggestief voor 
metastasen, of positief en suggestief voor metastasen. De PET en CT afwijkingen 
worden gevalideerd met behulp van de histologie als referentietest. Hierbij wordt voor 
elke positieve PET of CT, waar mogelijk, een biopt genomen ongeacht of de radioloog 
of nucleair geneeskundige de scan erg verdacht of minder verdacht voor metastasen 
beoordeelt. 
Met als uitgangspunt dat de FDG-PET in 35% van de gevallen positief is, waarvan oak de 
spiraal-CT in 25 % positief is, wordt er dus in 35% biopten genomen. Stel bij de PET is 
20% juist-positief en bij de spiraal-CT 1 5%. 




















Bij de vraag of er verschil is in specificiteit tussen PET en spiraal-CT, gaat het om de tumor 
positieven. De te gebruiken toets is dan McNemar. Tweezijdig getoetst, op niveau p=0.05 
met 85% power zijn dan 33 positieve biopten nodig, ofwel 33/0.2= 165 patienten 
7.0 Economische evaluatie  
De economische evaluatie wordt gericht op het vergelijken van de kosten van 
diagnostiek enerzijds en de kosten van ondoelmatige therapie anderzijds. De kosten 
warden gerelateerd aan de gevonden waarde voor het percentage upstaging en aan de 
sensitiviteit en specificiteit. De evaluatie wordt beperkt tot de direct medische kosten. De 
werkelijke kosten van diagnostiek middels FDG-PET en CT zullen worden vastgesteld en 
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vergeleken met de kosten van het veronderstelde therapeutische traject, b.v. de kosten 
van operatieve resectie inclusief klierdissectie, in de situatie zonder PET en CT. Data zullen 
worden vastgelegd in case record forms. 
8 .0  Deelnemende ziekenhu izen 
Algemene coordinator Prof. Dr. H. J. Hoekstra 
- Academisch ziekenhuis Groningen (AZG) 
Coordinator: Prof. Dr. H.J. Hoekstra 
- Universitair Medisch Centrum Nijmegen (UMCN), St. Radboud 
Coordinator: Prof. Dr. Th. Wobbes 
- Universitair Medisch Centrum VU 
Coordinator: Prof. Dr. S. Meijer 
9 .0  Eth ische aspecten 
Patienten die in aanmerking komen voor de studie zullen gevraagd worden in het 
onderzoek te participeren. De onderzoeker zal het doel van de studie uitleggen, waarna 
schriftelijke toestemming tot deelname aan het onderzoek wordt verkregen. 
De verantwoordelijke onderzoekers hebben zich er van verzekerd dat het onderzoek in 
overeenstemming is met de 'Declaration of Helsinki'. Het staat de patient vrij zich ten alle 
tijden zonder opgave van redenen uit het onderzoek terug te trekken, zonder dat dit een 
andere behandeling in de wegstaat. 
9. 1 Declaration of Helsinki 
De onderzoekers verzekeren dat het onderzoek is ontworpen in volledige overeen­
stemming met de uitgangspunten van de 'Declaration of Helsinki' en de wetten en regels 
zoals die in Nederland voor klinisch onderzoek gelden. 
9.2 Informed consent 
Nadat is vastgesteld dat een patient voldoet aan de inclusie criteria voor het onderzoek, 
moet het centrum de patient een 'informed consent' laten onderteken om in het 
onderzoek te kunnen participeren. Patienten die in aanmerking komen voor het 
onderzoek zal het doel van het onderzoek uitgelegd warden en dat de patient zijn of 
haar toestemming voor het onderzoek moet geven in overeenstemming met de daartoe 
geldende richtlijnen. Voor een weloverwogen beslissing heeft de patient zeven dagen 
bedenktijd. Het staat de patient vrij zich ten al le tijden uit het onderzoek terug te trekken 
zonder opgaaf van reden, zonder dat dit van invloed zal zijn op de behandeling. Patient 
kan zich terugtrekken d.m.v een mondeling of schriftelijk verzoek bij de onderzoekers. 
Verzekering 
ledere proefpersoon die deelneemt aan bovengenoemde studie is verzekerd 
overeenkomstig de Wet medisch wetenschappelijk onderzoek met mensen. De wijze 
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waarop de verzekering vorm is gegeven, zal staan vermeld in de schriftelijke informatie 
voor proefpersonen. 
9.3 Anonimiteit 
De identiteit van de patient zal strikt anoniem zijn en niet geopenbaard warden. Slecht 
de op naam gestelde verslagen van de FDG-PET , CT en eventuele uitslagen van cytologie 
/ histologie warden toegevoegd aan het medische dossier. De overige data t.b.v dit 
onderzoek zullen opgeslagen warden volgens de daartoe gestelde richtlijnen van het 
Ministerie van Gezondheid en de regels van 'good clinical practice' ( ICH-GCP, richtlijn 
17 januari 1997). De anonimiteit van patient zal gewaarborgd zijn door gebruik te 
maken van een patienten identificatie nummer, dat correspondeert met de data van de 
computerbestanden. De data uit dit onderzoek zijn op verzoek toegankelijk voor controle 
door de deelnemende onderzoekers, de medische ethische commissies en geregistreerde 
autoriteiten. 
1 0  B ijwerkingen / ns 1co's 
PET scans warden gemaakt een uur na i.v. injectie van 4 MBq / kg lichaamsgewicht van 
F-18-FDG. Gebaseerd op een radioactiviteit van 0.01 9 mSV/MBq en een gewicht van 
60 kg dan is de totale lichaamsdosis equivalent aan 4,5 mSv per PET onderzoek. De 
stralenbelasting van de 'whole-body' CT is 16 tot 20 mSV. De totale stralenbelasting 
waaraan de deelnemende proefpersonen warden blootgesteld is 20.5 tot 24.5 mSV. 
Wij menen dat deze dosis, die de gebruikelijke grens van 5 mSV te boven gaat, in dit 
geval gerechtvaardigd kan warden door het belang van het onderzoek (toekomstige 
mogelijk betere stadiering, mogelijk minder CT nodig). Het risico op secundaire primaire 
maligniteit bedraagt dan 1 ,0/350.000 persoonsjaren voor leukemie en 3,4/350.000 
persoonsjaren voor solide tumoren. 
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PATI ENTEN I N FORMATI E EN TOESTEM M I NGSFO RM U L I ER 
Optimalisering stadiering locoregionaal gemetastaseerd melanoom; 'positron emissie 
tomografie (PET), whole-body' computertomografie (CT) of beide onderzoeken? 
Geachte mevrouw, meneer 
Bij u is helaas uitzaaiing van een melanoom naar de lymfeklieren vastgesteld. Om u de 
meest adequate behandeling voor te kunnen stellen, is het vaststellen van de uitbreiding 
van de uitzaaiingen naar andere plaatsen belangrijk. Het standaard onderzoek omvat 
een rontgenfoto van de longen en de bepaling van het enzym LDH in het bloed. De 
behandeling van uitzaaiingen naar de lymfeklier is een chirurgische verwijdering van de 
regionale lymfeklieren. Helaas ontwikkelt ongeveer de helft van de patienten na deze 
operatie toch nog uitzaaiingen. De operatie is voor hen dus niet genezend geweest. Bij 
ongeveer twintig percent van de patienten zijn waarschijnlijk reeds uitzaaiingen buiten het 
regionale klierstation aanwezig op het moment van operatie. Er zijn nu twee onderzoek 
beschikbaar, die mogelijk in een vroeg stadium reeds uitzaaiingen buiten het klierstation 
kunnen vaststellen. Vervolgens kan dan individueel warden bekeken welke behandeling 
de beste behandeling is. Dit kan dan zijn chirurgie, radiotherapie, chemotherapie, of een 
combinatie behandeling. Het uiteindelijke doel van behandeling is u zo goed mogelijk te 
behandelen waarbij de kwaliteit van leven centraal staat. 
Doe/ van het onderzoek 
Met twee nieuwe technieken, positron emissie tomografie (PET) en spiraal computer 
tomografie (spiraal CT) zouden aanwezige uitzaaiingen buiten de lymfeklier kunnen 
warden vastgesteld. 
PET is een onderzoeksmethode die het mogelijk maakt om activiteit van kankercellen 
in het lichaam zichtbaar te maken en te meten . Dit geschiedt met een kleine 
hoeveelheid van een radioactief gemaakte stof (in uw geval suiker; het FDG oftewel 
1 8-F-Fuorodeoxyglucose) dat wordt ingespoten. Kankercellen hebben een verhoogde 
stofwisseling en toegenomen celdeling. Voor de groei gebruiken deze cellen de normaal 
in de voeding voorkomende stoffen, als eiwitten, vetten en suikers. Deze bouwstenen 
kunnen we radioactief markeren. Met een PET camera kunnen we de plaats met een 
verhoogde radioactiviteit in kaart brengen .  Op deze wijze kunnen eventuele uitzaaiingen 
in het lichaam opgespoord warden. Onderzoeken bij patienten met een naar de 
lymfeklieren uitgezaaid melanoom hebben inderdaad aangetoond dat met FDG-PET 
stadiering mogelijk is, maar het is nog onvoldoende onderzocht. 
Computer tomografie (CT) is een reeds, meer dan vijfentwintig jaar, bestaande vorm van 
radiodiagnostiek. De CT is in het verleden gebruikt om patienten met uitzaaiingen naar 
een lymfeklier beter te stadieren. De techniek had echter te veel beperkingen en derhalve 
is dit geen standaard onderzoek geworden .  Recent hebben wij de beschikking gekregen 
over de spiraal computer tomografie (CT). Dit is een zeer geavanceerde vorm van reeds 
langer bestaande computer tomografie. Met deze vorm van onderzoek kunnen patienten 
met een naar de lymfeklieren uitgezaaid melanoom misschien wel beter gestadieerd 
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warden. De waarde van spiraal CT bij het naar de lymfeklieren uitgezaaid melanoom is 
nag niet systematisch onderzocht. 
Vraagstelling bij dit onderzoek 
Met dit onderzoek zouden wij de volgende vragen willen beantwoorden: 
1 Hoe vaak warden elders in het lichaam uitzaaiingen gevonden met FOG-PET? 
2 Hoe vaak warden elders in het lichaam uitzaaiingen gevonden met spiraal CT? 
3 Hoe vaak be'i'nvloedt het vinden van uitzaaiingen elders in het lichaam de behandeling? 
4 Welke vorm van onderzoek is het meest kosten-effectief? 
Verzoek tot dee/name 
U wordt gevraagd mee te werken aan dit onderzoek, waarbij geprobeerd wordt met 
behulp van een PET scan en een licht radioactieve stof (FOG) en een CT scan eventuele 
uitzaaiingen elders in het lichaam aan te tonen cq uit te sluiten. Natuurlijk heeft u tijd 
nodig om erover na te denken of u aan deze studie wilt meewerken. Tevens moet u in 
de gelegenheid krijgen er met anderen over te kunnen praten. Om een goed overwogen 
besluit te kunnen nemen heeft u een bedenktijd van minstens zeven dagen. Zadra u de 
toestemming voor dit onderzoek heeft gegeven zullen de afspraken voor het PET en CT 
onderzoek warden gemaakt en ontvangt u hierover bericht. 
Het onderzoek 
lndien u toestemming heeft gegeven tot deelname aan beide onderzoeken ontvangt u 
een oproep van het PET centrum en een oproep van de Radiodiagnostiek. De onderzoeken 
kunnen helaas niet op een dag warden uitgevoerd. 
PET Onderzoek 
Tot het onderzoek op het PET centrum neemt u vanaf 12 uur 'nachts van die dag 
geen voedsel meer tot u. Water, thee of koffie zonder suiker mag u drinken. Het is 
wel toegestaan uw gebruikelijke medicatie in te nemen. Na aankomst in het PET 
centrum krijgt u een infuus in een ader om een licht radioactieve stof, FOG, een 
soort suiker gemakkelijk toe te dienen en regelmatig wat bloed (ongeveer 2 spuitjes; 
maximaal 70 ml) af te kunnen nemen voor de metingen voor dit onderzoek. U gaat 
vervolgens onder een cirkelvormige PET-camera. Voor een goed onderzoek is het 
van belang dat u tijdens het onderzoek stil blijft liggen. 
PET maakt gebruik van radioactief gemerkte stoffen. In dit onderzoek gaat het om 
suiker. De hoeveelheid toegediende radioactieve straling (370 megaBecquerel) per 
verrichtte FOG-PET geeft een stralenbelasting van ongeveer 2.5 milliSivert (mSv). 
De natuurlijke achtergrondstraling in Nederland bedraagt 1.5 mSv. De Wereld 
Gezondheid Organisatie hanteert in het kader van medische experimenten een norm 
van maximaal 5 mSv/jr voor gezonde vrijwilligers. Voor medische behandeling mag 
en moeten vaak hogere stralingsdoses warden gebruikt zoals bij dit onderzoek. 
Spiraa/ CT 
Tijdens het maken van een CT-scan draait de rontgenbuis om u heen en wordt 
de tafel, waarop u ligt, verplaatst. Een computer maakt van de door het lichaam 
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gezonden straling een rontgenfoto. De stralenbelasting komt overeen met 16-20 
milliSivert (mSv). Het CT-apparaat ziet eruit als een korte tunnel. Hierin moet u zo 
stil mogelijk blijven liggen. Voor het onderzoek moet u een contrastmiddel innemen, 
Telebrix. U krijgt dit toegestuurd. U begint hiermee een dag voor het onderzoek in 
de ochtend. U lost de inhoud van het flesje Telebrix op in 800 ml water of ranja. 
Bij iedere maaltijd drinkt u hiervan 200 ml, de laatste 200 ml op de ochtend van 
onderzoek. Een half uur voor het onderzoek krijgt u nogmaals een hoeveelheid 
van deze oplossing te drinken op de CT-afdeling. De radioloog of de laborant geeft 
een injectie met contrastvloeistof in een bloedvat in de arm. Het naaldje wordt 
vastgeplakt en blijft enige tijd in het bloedvat zitten. 
Terugtrekken en registratie en privacy 
Deelnemen aan dit onderzoek is geheel vrijblijvend. U bent geheel vrij te besluiten 
niet mee te doen. Als u meedoet kunt u op elk moment uw mening herzien en alsnog 
besluiten af te zien van verdere deelname aan het onderzoek. Welke keuze u ook maakt, 
dit zal geen enkele invloed hebben op uw verdere behandeling; u zal dan ook altijd een 
optimale behandeling blijven krijgen. De verhouding met uw behandelend arts zal niet 
verstoord raken. lndien u besluit af te zien van verder deelname aan dit wetenschappelijk 
onderzoek, kunt u dit op elk moment mondeling dan wel schriftelijk kenbaar maken aan 
uw behandelend arts of onderzoekers. 
De informatie van de FDG-PET en CT die tijdens dit onderzoek wordt verkregen zal aan uw 
medisch dossier warden toegevoegd, daar de uitslagen bij de medische besluitvorming 
tot de meest optimale behandeling warden betrokken. 
Verzekering 
Dit wetenschappelijk onderzoek valt mede onder verantwoordelijkheid van de 
opdrachtgever, het Academisch Ziekenhuis Groningen. De opdrachtgever heeft een 
verzekering afgesloten voor eventuele schade die u zou kunnen lijden als gevolg van 
deelname aan dit wetenschappelijk onderzoek. 
Het bedrag waarvoor de verzekering is afgesloten is maximaal euro 9.075.604 voor de 
totale schade die zich per verzekeringsjaar bij proefpersonen heeft geopenbaard bij alle 
onderzoek dat het Academisch Ziekenhuis Groningen wordt verricht, maximaal euro 
6.806.704 per onderzoek en maximaal euro 453.780 per proefpersoon. 
Van de dekking door de verzekering is uitgesloten: 
- schade waarvan (nagenoeg) zeker was dat deze zich bij de proefpersoon zou 
voordoen 
- schade die zich bij nakomelingen openbaart als gevolg van een nadelige inwerking 
van het onderzoek op het genetische materiaal van de proefpersoon 
- schade door de aantasting van de gezondheid van de proefpersoon die zich ook 
geopenbaard zou hebben wanneer de proefpersoon niet aan dit onderzoek had 
deelgenomen. 
- schade veroorzaakt door het niet (volledig) opvolgen van instructies betreffende het 
onderzoek. 
De verzekering is afgesloten bij Centramed b.a., Postbus 93601, 2509 AR Den Haag. 
203 
lndien u schade heeft geleden of het vermoeden daarvan heeft, dient u zich direct met 
Prof. Dr. H .  J. Hoekstra (lid van het onderzoeksteam) telefoonnummer 050-361231 7 in 
verbinding te stellen en zijn aanwijzingen op te volgen. Ook dient u in zo'n geval contact 
op te nemen met de juridisch stafmedewerker van het Academisch Ziekenhuis Groningen 
bereikbaar via telefoonnummer 050-3614304. 
Bij wie kan ik terecht met vragen? 
Mocht u vragen hebben over dit onderzoek, dan kunt u zich gerust wenden tot de 
volgende onafhankelijke, dwz niet direct bij het onderzoek betrokken, contact pers(o) 
on(en) voor de afdeling Chirurgi�: 
Prof. Dr. Th. Wiggers, chirurg, Chirurgische Oncologie, tel. 050-361231 7 
Dr. J. de Vries, chirurg, Chirurgische Oncologie, tel. 050-361231 7 
Voor overige informatie kunt u ook terecht bij de volgende contactpersonen van de bij 
dit onderzoek betrokken afdelingen: 
Drs. K. Meijer, nurse-practitionar, Chirurgische Oncologie, tel. 050-361 6161 zoemer 77279 
Dr. A.M.J .  Paans, klinisch fysicus, PET-centrum, tel. 050-361 331 1 
Drs. F. Bongaerdts, radioloog, Radiologie, tel. 050-361 61 61 
Of bij een van de volgende onderzoekers: 
Prof. Dr. H . J .  Hoekstra, chirurg-oncoloog, Chirurgische Oncologie, tel. 050-361231 
Dr. P. L. Jager, nucleair geneeskundige, PET-centrum, tel. 050-361228232 
Dr. E.J. van de Jagt, radioloog, Radiologie, tel . 050-361 61 61 
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TO ESTEM M I N G TOT D EELNAM E AAN 
WETEN SCHAPPEL I J K O N DERZO EK 
Optimalisering stadiering locoregionaal gemetastaseerd melanoom; 




Ondergetekende verklaart het volgende: 
lk heb uitvoerig mondeling en schriftelijke informatie ontvangen inzake de opzet, doel 
en eventuele risico's of ongemakken van bovengenoemd onderzoek en heb dit volledig 
begrepen. 
I k heb voldoende gelegenheid gehad tot nadenken, overleg en het stellen van vragen 
aan de onderzoekers(s). 
lk stem geheel vrijwillig in met deelname aan bovengenoemd onderzoek, zolang ik deze 
toestemming niet herroep. 
lk kan mij op ieder moment uit het onderzoek terugtrekken zonder dat dit enig nadelig 
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